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Summary. Laura Watson. Wolfson College. 
Characterisation of human metabolism in physiological and pathophysiological states. 
The aim of this thesis was to describe the relationships between energy expenditure and body 
composition in healthy adults and children and in patients with metabolic disorders. In a 
healthy population resting energy expenditure (REE) is highly influenced by body composition, 
specifically lean mass (LM). Prediction equations can therefore accurately predict REE from 
body composition in healthy individuals. However, application of these equations to clinical 
patients, in whom metabolism is disordered, risks miscalculation of energy metabolism due 
to their dissociation between body composition and energy expenditure. Therefore new 
prediction equations were derived based on precise body composition measurements in 
healthy adults and children. Then, in patients with metabolic disorders, differences between 
their measured and equation-predicted REE and LM were presented as standardised Z scores.  
REE in healthy adults was predicted by the coefficients: age, fat mass and fat-free mass. LM in 
healthy adults was predicted by the coefficients: bone mineral content and height2 in men; 
and by fat and height2 in women. In healthy children, REE was predicted using gender specific 
models: by fat and LM in boys; and by solely LM in girls. REE and LM were then measured in 
adult and paediatric patients with metabolic disorders (Lipodystrophy, Thyrotoxicosis and 
Resistance to Thyroid Hormone β or α), and Z scores were calculated to highlight their 
deviations from the healthy populations. 
In adults, thyrotoxicosis patients displayed the highest REE Z scores (5.8), followed by 
lipodystrophy (2.9) and RTHβ cases (1.8), with RTHα demonstrating the lowest REE Z scores (-
2.3). For LM, lipodystrophy patients exhibited with the highest Z scores (4.2), followed by 
RTHα patients (2.1), with RTHβ patients showing normal LM Z scores (-0.2) and thyrotoxicosis 
patients presenting with the lowest LM Z scores (-1.2). In the paediatric patients, RTHβ 
patients demonstrated REE Z scores similar to healthy controls (males; -0.15, females; 0.15), 
but RTHα patients displayed lower REE Z scores (male; -0.82, female; -2.2) compared to RTHβ 
patients and healthy controls.  
These studies highlight the disassociation between REE and body composition in patients with 
metabolic disorders. The application of a prediction equation for REE to calculate Z scores 
between measured and predicted values allows quantification of the differences between 
patients with metabolic disorders and healthy populations, and is a new and important 
concept.   
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1. General Introduction. 
 
1.1. Measurement of body composition 
 Body composition describes approximately 60-80% of the variability in resting energy 
expenditure (REE), with the majority of the contribution from lean or fat-free mass (FFM (lean 
plus bone mass)) and a much smaller, but significant, contribution from fat mass. Dual-energy 
X-ray absorptiometry (DXA) is the method used throughout this thesis to explore both whole 
body and regional fat, lean and bone mass.  
Throughout the history of DXA, developments in science and technology have 
facilitated advances in bone density and body composition measurement instruments. Single-
photon technology was first introduced in 1963, using a single gamma ray radionuclide source 
with the ability to image peripheral skeleton sites [1]. Dual-photon technology was later 
developed, making it possible to scan the axial skeleton using the transmission of gamma rays 
of two different energies. However, both of these instruments had limitations: the use of 
radionuclides that decayed quickly, long scanning times and poor resolution [2 3]. As the 
technology advanced further, these instruments were replaced with single and dual-energy X-
ray absorptiometry (SXA, DXA). Both instruments used a low dose X-ray tube instead of a 
radionuclide source, had shorter scanning times, and benefited from higher resolution and 
thus improved precision. Because SXA uses only a single X-ray beam, it is necessary to correct 
for soft tissue by laying the site of interest in a water bath. DXA was introduced in 1987 and 
has become the “gold standard” for clinical bone density measurements.  The use of X-ray 
beams of two energies enables distinction of soft tissue and bone without the need for a water 
bath [4 5]. The abilities of the latest DXAs to accurately assess both whole body and regional 
soft tissue, fat and lean mass, as well as bone mineral density, has encouraged the utilisation 
of DXA within body composition research. Based on the successful use of DXA in research studies, 
this technology is now migrating into clinical practice.  
1.1.1 DXA precision 
Precision within this thesis is defined as the repeatability of measurements, with % 
Coefficient of Variance (%CV) and Least Significant Change (LSC) reported. Instrument 
precision is important not only for ensuring confidence in the data acquired but also for 
avoiding misinterpretation of changes in measurements over time. The precision of an 
instrument is usually established upon installation through repeated measurements in vitro, 
using a phantom, or in vivo, on participants. The International Society of Clinical Densitometry 
2 
 
(ISCD) has oversight of most policies and procedures issued by DXA manufacturers. In their 
guidelines, they suggest 30 repeated scans or 15 triplicated scans on the new instrument to 
explore its repeatability [6 7]. A least significant change (LSC) value is calculated from repeated 
measures on each region and site scanned twice; this represents the difference in 
measurements between two scans before a true biological change can be assumed [8].  
1.1.2. DXA accuracy 
In addition to repeated measurements on each scanner for establishment of precision, 
measurements should also be performed against different instruments to determine their 
accuracy. Instrument accuracy is ascertained by comparing the measurements on one 
instrument to the same measurements collected by another appropriate technique. This 
scenario typically occurs when new instruments are released by the same or a competing 
manufacturer. Determining the accuracy of a new instrument is essential before it can be used 
clinically for patients requiring repeated measures over a period of time and also in research 
spanning longitudinally where an unavoidable change in instrument occurs in the middle of 
data collection. Verifying the accuracy of a new instrument against the existing instrument will 
highlight any differences or biases between them and allow existing data to be corrected for 
any differences by the derivation and application of cross-calibration equations [7].  
Exploring the accuracy of a DXA instrument compared to highly regarded reference 
methods, such as magnetic resonance imaging (MRI), positron emission tomography–
computed tomography (PETCT) or a four-component (4-C) model, can further contribute to 
the understanding of the DXA instrument’s accuracy. The 4-C model incorporates 
measurements of bone mineral density by DXA, total body mass and body volume by air 
displacement plethymography (ADP) and total body water by deuterium dilution. This 
approach can be used to assess whole body fat or lean mass. The benefit of this approach for 
whole body composition is the inclusion of total body water, which is assumed to be constant 
at 73% in two-component models (e.g. DXA and ADP). Previous studies have demonstrated 
differences in body composition measurements between DXA and 4-C models: Tylavsky et al 
[9] compared fat-free mass (FFM) and fat mass measured by  the Hologic QDR4500A DXA to 
measurements obtained using a 4-C model (Lohman 4-C model [10] and Going 4-C model 
[11]). Their findings demonstrated that DXA overestimated FFM and underestimated fat mass 
compared to 4-C (Lohman) derived measures. In contrast, using a more recent DXA 
instrument, Gately et al [12] demonstrated significant differences in body fat percentage 
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between DXA (Prodigy) and 4-C (Lohman) with DXA overestimating fat percentage in 
overweight and obese children. A similar study of obese children by Wells et al [13] also 
demonstrated that DXA (Prodigy) significantly overestimated fat mass and underestimated 
lean mass compared to a 4-C model. The relationship between 4-C and the latest DXA model 
from GE healthcare, the iDXA, is yet to be explored in children and adults. 
Cross-calibration is performed by applying regression equations that describe the difference 
between two instruments or software versions and have been described extensively in the 
literature for various models of DXA [14-31]. This permits comparison of data from multiple 
DXA instruments, thus allowing the adoption of new DXA technology in research and clinical 
settings without negatively impacting the data generated over time. 
1.2. Predicting resting energy expenditure and body composition in adults and children 
Total daily energy expenditure (TDEE) is divided into three components: resting energy 
expenditure (REE), the minimum amount of energy needed to maintain normal function; diet-
induced thermogenesis (DIT), the amount of energy used to process recently ingested food; 
and physical activity energy expenditure (PAEE), energy expended by physical movement [32]. 
REE constitutes 60-80% of TDEE in healthy adults and is most commonly used as an indirect 
estimate of TDEE, in combination with a physical activity score (PAL) and daily energy intake 
requirements. REE is often referred to as basal metabolic rate (BMR), but the terms can only 
be used interchangeably if the conditions of measurement are the same, i.e. at complete rest 
upon waking. REE can be measured by indirect calorimetry, but it is commonly predicted by 
multiple regression equations that are applicable to the population being studied [33-35].  
1.2.1. Predicting REE in adults and children 
Regression equations for the prediction of REE are common throughout the literature. 
They are used in clinical settings for estimating energy requirements within dietetics or 
establishing whether an individual’s REE is normal compared to the prediction, which may give 
insight into a disease state.  
The most common prediction equations for adults and children are the WHO Schofield 
equations [33], Oxford equations by Henry [34], Harris and Benedict [35], Mifflin [36], Owen 
[37] and Molnar [38]. These equations are based on simple anthropometric measurements 
(age, height, gender and weight), making them easy to apply in most settings and populations. 
As with any form of methodology, it is essential to recognise how the equations were derived, 
the population on which they were based and the accuracy of the variables within them. 
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Starting with the WHO requisitioned equations by Schofield [33], these equations were 
computed based on 114 published studies of BMR. This amalgamated dataset consisted of 
approximately 11,000 BMR values, mainly from European or North American participants, 
with nearly half of the data points from Italian subjects[34]. When applied to some 
populations outside of these regions, there is a common overestimation of BMR [39] [40] [41]. 
Henry [34] attributes this to the large number of Italian males in the dataset, as they 
demonstrated a higher BMR per kg of body weight compared to other populations within the 
dataset. Although Henry is highly critical of the WHO equations, his development of the Oxford 
predictive equations utilised data from 166 published studies and excluded all Italian 
participants, outliers and extreme data points, suggesting that, like the WHO equations, the 
Oxford equations are not appropriate for all populations.  
Total body weight is often used as a coefficient in prediction equations because it is 
easy and convenient to measure, thus it allows computation of predicted REE at any facility. 
However, it assumes that there is a consistent contribution of fat, lean and bone mass to the 
estimation of REE, which may be true for a healthy population of adults but may not be the 
case in other populations such as disease groups, the elderly and children. Instead, prediction 
equations using lean or fat-free mass may be more appropriate for describing the variation in 
REE, especially in those who display atypical lean or fat mass.  
Prediction equations such as those derived by Neilson et al [42], Nelson et al [43], 
Cunningham [44], Mifflin et al [36] and Goran et al [45] (in children) offer the means to use 
either lean or fat-free mass to predict REE. However, some studies have still found significant 
differences between REE predicted by the aforementioned equations and measured REE [46 
47]. The differences between measured and estimated REE may suggest that there are 
variables other than lean mass and fat-free mass that explain some existing variation in REE. 
Fat mass and age have been shown to hold small but significant contributions to REE, as have 
thyroid hormone levels and physical activity parameters [44 48]. The differences in bias seen 
in REE prediction equations may also lie in the method used for assessment of lean mass, such 
as DXA, bioelectrical impedance analysis (BIA) or the amalgamation of FFM estimates from 
existing literature. 
1.2.2. Predicting body composition in adults 
In the literature, predictions of body composition have primarily focused on body fat 
as this has been directly linked to obesity and other health issues. Predictions of lean or fat 
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free mass are typically derived from BIA methods [49-53], which have the advantages of being 
easy to use and relatively low cost, but as a result, the measurements obtained are less 
accurate compared to criterion methods such as DXA or 4-C models [54-56]. Accurate 
prediction of lean mass or FFM may improve the accuracy of REE predictions if the lean mass 
or FFM variable were to be inserted into a regression equation. However, again, caution 
should be applied when using regression equations derived from populations that differ from 
the population being studied and variables are obtained using measurement techniques of 
questionable accuracy.  
When presented in the literature, REE is often divided by lean mass in order to exclude 
the influence of lean mass on any variation in REE. In a healthy population, REE should increase 
with lean mass and vice versa [57]. For example, in healthy obese populations, weight gain is 
associated with a higher REE, because of both an increase in fat mass and a curvilinear increase 
in fat-free mass as a result of the increased energy cost of carrying more body weight [58]. 
The elderly often present with low REE and lean mass as a result of an age-associated decline 
in mobility and physical activity levels [59].  
1.2.3. Describing resting energy expenditure in children 
In children, lean mass is the primary determinant of variation in REE across the age 
groups. However, during puberty, REE increases; this can largely be accounted for by FFM, but 
other factors such as growth and pubertal hormones also play a role [60]. Age is often used as 
a proxy for maturation, but children do not enter puberty at the same age; girls tend to enter 
puberty from the ages of 8 to 12 years old and boys 9-14 years old [61]. Therefore, the timing 
and tempo of pubertal changes in body composition and REE vary considerably.  
Puberty is characterised by the development of secondary sex characteristics, gonadal 
maturation and reaching reproductive capacity [61]. The onset of puberty is initiated by a 
gonadotropin-releasing hormone from the hypothalamus, marked by an increase in amplitude 
of luteinising hormone (LH) and follicle-stimulating hormone (FSH) pulses [62 63], which in 
turn act on the gonads to produce sex steroids such as growth hormone (GH) and oestradiol. 
The increase in sex steroids is crucial for linear growth and increases in mass of bone and 
muscle [64]. The timing of puberty varies greatly and is influenced by both environmental and 
genetic factors. 
In boys and girls, puberty induces changes such as a growth spurt, changes in body 
composition and pubic hair growth. In girls, menarche is a key marker for the timing of 
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puberty, along with breast development, increases in body fat mass and altered fat 
distribution. In boys, puberty presents with testicular and penile enlargement and an increase 
in whole body muscle mass [61].  
Physical developments associated with puberty can be assessed using a variety of 
techniques: self-assessment questionnaires, physical assessment or biochemical assessment. 
Self-assessed questionnaires, first proposed by Tanner et al [65], contain pictures of different 
stages of breast and pubic development in girls and testicular, penile and pubic development 
in boys; images are selected by the participant based on their interpretation of their own 
development [66].  
Previous validation studies of pubertal assessment questionnaires have highlighted a 
risk of under and over-interpretation of self-reported development compared to parental or 
clinician interpretations [67]. In girls, age at menarche is commonly reported in addition to 
physical sex characteristics. A physical assessment by a qualified health professional can also 
be undertaken to assess the development of secondary sex characteristics but may be deemed 
too intrusive for research into healthy participants and may reduce recruitment of participants 
onto studies if this were an integral part of the data collection. Finally, this leaves the 
assessment of hormonal markers of puberty, such as LH or FSH, by a small blood test. 
Increases in LH and FSH concentrations in the plasma may be an indicator of the production 
of sex hormones and an early marker of the onset of puberty before the appearance of 
secondary sex characteristics. This may be the most reliable marker of pubertal status; 
however, the pulsatile nature of gonadal hormones may make a single assessment difficult, as 
these hormones are subject to diurnal fluctuations and individual variability [61].  
The inclusion of a pubertal score or stage of puberty in predicting REE is rare; instead, 
age is used as an indicator of puberty. Lazzer et al [68] developed prediction equations in over 
800 healthy obese children and adolescents and included a pubertal score by Tanner 
assessment within the analysis. The model that explained the greatest variation in REE 
consisted of pubertal stage, FFM and fat mass (R2 = 0.70).   
1.2.4 Standard deviation and Z-score use in interpretation 
Describing what is “normal” in anthropometry and body composition is more common 
in the paediatric literature than the adult literature. Growth charts are used to establish 
normal growth and development for paediatric age ranges using percentiles, with 0.4th being 
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the lowest, 50th regarded as average and 99.6th as the highest percentile displayed on many 
such charts [69].  
Bone density interpretation within the adult and paediatric literature uses an age- and 
gender-matched Z-score based on data-points from large, healthy cohorts (WHO/NHANES) to 
distinguish normal bone density trends with age, tracking the increase in bone density with 
age in paediatrics and the decline with advancing age in adults. It also identifies, in adults, 
where osteoporosis and osteopenia begin.  
The use of Z-scores or percentiles in other areas of body composition and energy 
expenditure is less common and has only recently been explored in DXA and 4-C 
measurements in order to determine “normal” in the adult and paediatric literature. Kelly et 
al [70], using the National Health and Nutrition Examination Survey (NHANES) from 1999-
2004, developed Z-scores and percentiles for DXA-measured body composition. These data 
provide reference ranges for multiple components of body composition, including fat mass, 
lean mass and bone mineral content (BMC), for regions including arms, legs and trunk for 
populations of white, black and Mexican American origins. Percentiles were derived from Z-
scores calculated from the standard deviation of each measurement for the whole population. 
The measurements were performed on Hologic QDR4500 DXA scanners. More recently, 
Imboden et al [71] derived healthy adult reference percentiles (n=3327, 1251 men and 2076 
women) based on fat mass measurements performed on recent models of GE DXA scanners 
to replace the existing NHANES (1999-2004) dataset. Although its application may be 
restricted to GE systems and Caucasian populations, it is a useful up-to-date tool for providing 
meaningful interpretation of DXA fat mass measurements in healthy adults.  
In children, Wells et al and Atherton et al [56 72] have generated Z-scores and standard 
deviation scores (SDC) in measures such as fat mass and FFM using robust and accurate 
methods of measurement (DXA and 4-C) in children aged 3-23 years.  Reference data Z-scores 
in energy expenditure are yet to be found within the paediatric or adult literature.  
1.3. Metabolic disorders 
Clinical examples of metabolic disorders focus on thyroid hormone (TH) disorders and 
lipodystrophy as these complex genetic conditions present with very different dissociations in 
body composition and REE compared to each other and healthy controls.  
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1.3.1. Resistance to thyroid hormone 
Thyroid hormones (TH), thyroxine (T4) and triiodothyronine (T3), are essential for 
normal growth, development and metabolism of most cell and tissues. The hypothalamic-
pituitary-thyroid (HPT) axis controls the synthesis and secretion of TH from the thyroid. 
Circulating TH feedback at hypothalamic and pituitary levels to regulate their own synthesis. 
Thyrotropin-releasing hormone (TRH) neurons in the PVN secrete TRH in response to low 
circulating T4 and T3 levels. Consequently, TRH signalling in the pituitary stimulates the 
secretion of thyroid-stimulating hormone (TSH), which triggers the release of T4 and T3 from 
the thyroid gland into the blood stream [73]. These signals maintain the complex mechanisms 
involved in TH homeostasis. The effect of TH on physiological processes are mediated by 
thyroid hormone receptor (TR) proteins. TRα and TRβ are encoded by genes THRA and THRB 
on chromosomes 17 and 3 [74 75]. Two proteins are generated from THRA; TRα1 and TRα2. 
TRα1 is particularly abundant in the central nervous system, myocardium, gastrointestinal 
tract and skeletal muscle. TRα2 is expressed in a variety of tissues such as the brain and testis 
but does not bind thyroid hormone, so its physiological role is unclear. THRB generates two 
thyroid hormone receptors, TRβ1 and TRβ2. TRβ1 is widely expressed, predominantly in the 
liver and kidney whilst TRβ2 is present in the hypothalamus, pituitary, inner ear and retina 
[76].  
Thyroid hormone also has profound effects on skeletal muscle. Hyperthyroidism 
often presents with reduced muscle mass and myopathy [77]. Skeletal muscle is one of the 
main determinants of resting energy expenditure (REE). REE is also closely dependent on 
thyroid hormone status and altered by small changes in thyroid hormone. Thyroid hormones 
are known to upregulate many genes involved in metabolism and are also known to increase 
mitochondrial uncoupling, thereby providing a mechanism for increasing energy expenditure 
[78].  
Thyroid hormones also have important interactions with adipose tissue and this is 
important for weight control and energy balance [79]. Hormonal signals from adipose tissue 
(e.g. leptin) act on the central nervous system to regulate energy intake and also the activity 
of the HPT axis.  Thyroid hormones, in particular T3, regulates adipogenesis of white adipose 
tissue (WAT) and brown adipose tissue (BAT) and genes involved in lipid metabolism; 
lipogenesis and lipolysis.  The lipolytic effects of thyroid hormones can be indirect. 
Specifically, hyperthyroidism enhances tissue sensitivity to catecholamines and this includes 
9 
 
adipose tissue lipolysis. The isoforms of thyroid hormone receptors TRα1 and TRβ1 are 
present in both WAT and BAT [80]. Mutations in human TRα1 are associated with increased 
body fat, visceral adiposity and reduced adaptive thermogenesis [81]. Within BAT, whose 
function is the production of heat under cold exposure, T3 is known to regulate uncoupling 
protein 1 gene expression via TRβ1 thereby increasing fatty acid oxidation in BAT and its 
metabolism [82].  
 Thyroid hormone resistance (RTH) is a rare dominantly-inherited syndrome caused by 
mutations in either of two different thyroid hormone receptor isoforms, TRα and TRβ, [74 75]. 
The mutant receptors exhibit reduced function and also inhibit their wild type counterparts in 
a dominant negative manner [83]. Mutations in these receptors cause RTHα and RTHβ, 
respectively.  
RTHβ is characterised by elevated circulating free thyroxine (T4) and triiodothyronine 
(T3) and normal or slightly elevated thyroid-stimulating hormone (TSH). The incidence of RTHβ 
is approximately 1 in 40,000 [84]. Clinically, RTHβ is highly heterogeneous and ranges from 
asymptomatic to highly symptomatic. The majority of individuals with RTHβ achieve normal 
growth and development because high TH levels compensate for tissue resistance. However, 
due to divergent expressions of TRα and TRβ in different tissues, some individuals with RTHβ 
exhibit features of hyperthyroidism, such as tachycardia and weight loss, or osteoporosis 
(Figure 1.1) [85]. Both total cholesterol and LDL cholesterol are raised in RTHβ [86], which may 
reflect hepatic resistance to the effect of thyroid hormone, and dyslipidaemia improves with 
thyroxine treatment [86]. Hypothyroidism is also known to increase intrahepatic lipid levels, 
which can lead to non-alcoholic fatty liver disease (NAFLD).  
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Figure 1.1. Resistance to thyroid hormone due to defective thyroid receptor beta. TRβ 
mutations markedly increase liver mass with an excess deposition of lipids, so patients 
consequently present with fatty liver and raised cholesterol. TSH = thyroid stimulating 
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RTHα mutations are much rarer, with just fourteen cases having been identified to 
date. Patients exhibit hypothyroid features, such as delayed growth, neuro-developmental 
retardation, weight gain and a slow heart rate, reflecting hormone resistance in TRα-
expressing tissues, in the face of near-normal circulating TH levels (figure 1.2) [87].Common 
findings in the reported RTHα patients include short stature, high BMI and low muscle tone 
[75 88-90]. Body composition and energy expenditure are not always reported, but some 
RTHα cases demonstrate high fat mass and low resting energy expenditure [87 88]. In contrast, 
Mitchell et al [78] reported elevated REE in RTHβ patients compared to controls. 
 
3.2. Thyrotoxicosis 
Thyrotoxicosis is a state of thyroid hormone excess, encompassing hyperthyroidism 
where the thyroid secretes and synthesises excessive quantities of thyroid hormone.  Both T4 
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Figure 1.2. Resistance to thyroid hormone due to defective thyroid receptor alpha. TSH = 
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and T3 concentrations are elevated and TSH is undetectable because of negative feedback 
inhibition. Extremely elevated TH concentrations cause weight loss (mediated by raised 
metabolic rate), fast heart rate, and muscle weakness due to catabolic tissue effects (figure 
1.3) [91]. The most common cause of thyrotoxicosis is Graves’ disease, which is an 
autoimmune condition. Physical characteristics of Graves’ disease depend on the severity of 
the disorder, but common symptoms include weight loss, fatigue, muscle weakness, 
decreased appetite and cardiac arrhythmias.  
Hyperthyroidism is associated with increased REE [92] and decreased fat and lean mass 
[93 94], demonstrating a dissociation between energy expenditure and body composition in 
this disease cohort. The increased REE has been correlated with elevated TH levels, which can 
be treated with anti-thyroid drugs, radioactive iodine or surgery to restore the euthyroid state; 
however, these treatments result in reduced REE, which may contribute to weight gain and 
increased fat and lean mass after thyrotoxicosis treatment.  
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Figure 1.3. Hyperthyroidism due to thyrotoxicosis. TSH = thyroid stimulating hormone. 
13 
 
1.3.3. Lipodystrophy 
Lipodystrophy (LD) is a disorder characterised by a lack of adipose tissue or fat tissue. 
In contrast to ‘leanness’, a state characterised by ‘empty’ but otherwise healthy adipocytes 
(fat cells), in LD the adipocytes are either absent or dysfunctional. LD is categorised in terms 
of aetiology (genetic or acquired) and the extent of fat loss (generalised or partial).  The major 
metabolic consequences of LD, which include severe insulin resistance, dyslipidaemia and 
hepatic steatosis, are consistent across the forms of LD but vary in severity depending on the 
extent of adipocyte loss/dysfunction [95]. The types of LD are explained below, and the clinical 
and metabolic features of LD are detailed in figure 1.4.  
Inherited lipodystrophies:  
1) Congenital generalised LD (CGL), also known as Berardinelli-Seip congenital 
lipodystrophy (BSCL), is a rare autosomal recessive disorder, characterised by a general 
loss of adipocytes, therefore it is considered the most severe form of LD. A loss of 
function in several genes (AGPAT2, BSCL2, CAV1 and PTRF) has been identified as the 
basis of CGL [95 96].  
2) Familial partial LD (FPLD) is characterised by a partial lack and/or re-distribution of 
adipocytes and is often more prominent peripherally, in the limbs [97]. The loss of 
adipose tissue often becomes apparent around the time of puberty, whereas CGL is 
usually observed from birth. Loss-of-function mutations in the LMNA, PPARG, 
ZMPSTE24, AKT2, CIDEC, PLIN1, LIPE and ADRA2A genes have been identified as 
contributing factors in the development of FPLD [95], [98-100].  
Acquired lipodystrophies:  
1) Acquired partial LD (APL) is the most common form of partial LD. It is associated 
with the use of antiretroviral therapy for the treatment of human immunodeficiency 
virus (HIV) and is found in approximately 50% of HIV patients undergoing treatment.  
2) Acquired generalised lipodystrophy (AGL), also known as Lawrence syndrome, is 
characterised by a gradual loss of subcutaneous fat in the face, trunk and extremities. 
It can be recognised during childhood or adulthood, and it often occurs in conjunction 
with other auto-immune disorders.  
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Figure 1.4. Triad of the effects, symptoms and consequences of lipodystrophy, dependent on 
severity, in inherited or acquired forms. SHBG = sex hormone binding-globulin, IGF1 = insulin-
like growth factor 1, PCOS = polycystic ovary syndrome.  
Typically, LD has been associated with an absolute increase in muscle mass and an 
accompanying increase in REE [101]. The increase in REE has predominantly been explained 
by high lean body mass; however, there is a lack of information on the relationship between 
body composition and REE in different forms of LD. Other metabolic contributions, such as 
from organomegaly, may be more evident in different genetically-defined subtypes of the 
disorder.  
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1.4. Aims and objectives 
The aims of this thesis are: 
 To develop a new approach to describe resting energy expenditure and body 
composition in healthy adults (Chapter 4).  
 To further explore and develop an approach to describe resting energy expenditure in 
healthy children and adolescents (Chapter 5).  
 To apply the above approaches to three metabolic conditions, resistance to thyroid 
hormone (alpha and beta forms), thyrotoxicosis and lipodystrophy, in order to 
describe divergence in energy expenditure and body composition in these disorders in 
comparison to healthy controls.   
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2. Methods. 
This chapter explores the principles of each method of measurement used throughout 
this thesis, including the equipment’s accuracy and precision.  
2.1. Body Composition 
The term body composition, used frequently within this thesis, refers to four main 
compartments of the body; fat, lean, bone mineral and water. These compartments can be 
assessed at a whole body level or can be further compartmented into components, regions or 
depots, depending on the measurement technique applied. 
Within this thesis, the method of measuring body composition; fat, lean and bone 
mineral, is dual energy X-ray absorptiometry (DXA). Its accuracy for whole body fat 
assessment, however, is challenged by the comparison to a technique incorporating four 
components of body composition, body volume, mass, water and bone mineral (Chapter 3). 
DXA can also provide regional analysis of bone and soft tissue, a significant benefit of the 
method which cannot be compared to a four component model.  
2.1.1. Dual Energy X-ray Absorptiometry (DXA) 
DXA is a 2-Component (2-C) method and has the ability to separate body mass into 
soft tissue and bone mineral. With the help of scientific algorithms based on known densities 
of different tissue it is able to differentiate between lean and fat tissue. Two DXA machines 
have been used throughout this thesis, a GE Lunar Prodigy, encore software version 12.3 and 
a GE Lunar iDXA, encore software version 15 and 16 (GE Healthcare, Madison, WI, USA).  
The fundamental principles of DXA consist of passing two X-ray beams at different high 
and low photon energies, through bone and tissue in the body. The beams are split by a thin 
sheet of metal in the beam to create two separate peaks in the X-ray spectrum [1]. The 
attenuation, reduction in intensity of the X-ray beam, by body tissues is measured by the 
detector and converted to a thickness of bone mineral and attenuation of soft tissue around 
the bone. For a given thickness the attenuation increases with the density of the material, 
bone indicating a higher attenuation than soft tissue [2]. It is the difference in attenuation of 
the two energies which determines bone density and body composition [3]. When a DXA scan 
is analysed the data creates a pixel-by-pixel map of bone density and soft tissue. An edge 
detection algorithm is  used to find the bone edge and then bone mineral content (BMC) is 
calculated from multiplying bone mineral density (BMD), calculated as the mean BMD over all 
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the pixels identified as bone, by bone area (BA), derived by summing the pixel from within the 
bone edge [4]. Unpublished algorithms derived by the manufacturer provide the fat, lean and 
bone mass interpretation. Different versions of software with algorithm updates can be 
controversial during a longitudinal study [5]. There are substantial differences between the 
two DXA machines, Prodigy and iDXA, especially in body composition measures possibly due 
to the development not only of the software but the element technology of the iDXA. The 
iDXA has the same narrow-angle fan beam as the Prodigy but with a greater number of 
detectors, providing an improved resolution (1.05mm longitudinally, 0.6mm laterally) and 
image quality [2]. It also has a new metal filter to create a greater spectrum allowing more 
attenuation being detected resulting in greater bone edge and tissue detection [6 7].  
The iDXA also comes with an increased radiation dose compared to the Prodigy which 
along with the detector improvements helps to provide greater precision in the images. A 
whole-body scan on the Prodigy administers an effective radiation dose of 0.08 µSv and takes 
approx 6-10 min depending on scan mode. There are three scan modes on both the Prodigy 
and the iDXA which can be applied to a participant based on the weight entered; thin, standard 
and thick which in turn use differing radiation doses and length of time to scan. On the iDXA 
using the standard scan mode, the radiation dose is greater, 1uSv for an adult and 1.6uSv for 
a child. Both the prodigy and the iDXA use a method called smart-scan which means only the 
area covered by the participant is scanned, limiting excess radiation exposure. The doses on 
both scanner are still considered low in the context of daily reported background radiation of 
6-7 µSv around Cambridgeshire [8].  
For the studies reported in this thesis, whole-body scans are performed in both adults 
and children to acquire whole-body fat mass, lean mass and bone mineral content (BMC). 
Furthermore, bone mineral density (BMD), bone area (BA) and BMC measures were made on 
additional sites, femoral hip and lumbar spine, in adults. These additional sites are recognised 
areas of degradation of bone density with age [9].  
2.1.1.1. Precision 
Precision values for iDXA are presented in Chapter 3 along with accuracy data for iDXA and 
Prodigy.   
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2.1.2 Four-Component (4-C) model 
The 4-C model expresses fat mass in terms of body volume (BV), total body water 
(TBW), bone mineral (BMC) and body mass (M).  Body volume can be determined by under-
water weighing or from air-displacement plethysmography (ADP) using the BODPOD. Total 
body water is estimated using the deuterium dilution method by Isotope ratio mass 
spectroscopy (IRMS) and bone mineral content (BMC) from dual energy X-ray 
Absorptiometry. Body mass can be measured by either a simple set of calibrated scales, the 
mass measurement taken at the point of ADP assessment or derived from the sum of DXA 
measured masses; fat, lean and BMC. The study within this thesis (chapter 3) used mass from 
the ADP assessment as this closely resembled a naked weight measurement. Combined, these 
measures derive values for the estimation of fat mass by coefficients of mineral, water, fat 
and protein.  A 4-C model is commonly used as a reference comparison for other 2 or 3-C 
methods because of its incorporation of further components of whole body composition. The 
4-C equation used for the estimation of fat mass within the work presented in this thesis is 
based on the Fuller et al analysis [10]. 
FM (kg)  =  [2.747 ∗ 𝐁𝐕) – (0.710 ∗  𝐓𝐁𝐖)]  +  [(1.460 ∗  𝐁𝐌𝐂) – (2.050 𝐌)] 
(1) 
Other 4-C models are available ranging from Selinger et al 1977 [11] to the most recent 
developed models such as Wang et al [12]. The models display similar coefficients for the 
components but the recent models have derived the measurements from newer techniques 
such as iDXA. Wang et al used the latest DXA model from GE to generate the expressions 
compared to Selinger who used single photon absorptiometry (SPA), a predecessor to DXA. 
Body volume was also measured by under-water weighing in the early studies compared to 
ADP, and TBW has been estimated by the deuterium dilution method which has superseded 
H218O due to its expense and tritium (3H2O) due to its radioactive properties. Other models 
have attempted to incorporate a 5th or 6th components such as extracellular (ECW) and 
intracellular water (ICW) or a glycogen factor [11]. Selection of the appropriate formula will 
be based on the methods used to derive the equations and the techniques available in the 
current research. The equation by Fuller et al [10], was chosen for analysis within this thesis 
because the methods applied to derive the 4-C model were applicable to the methods 
available in the current research studies.  
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2.1.3. Air Displacement Plethysmography (ADP) 
ADP is a 2-C model that considers the body as having fat and fat-free compartments 
characterised by their densities. For fat this density was set by Siri (1956) at 0.9kg/l and 0.1 
kg/l for fat-free mass. From the measurement of body mass (M) and body volume (V), body 
density may be derived (Db) and proportioned to fat and fat-free compartments.  
 The trade name for the instrument is BODPOD (Life measurement, Inc, Concord, CA) 
which is a system that provides the means of determining body volume using Poisson’s Law. 
This describes the pressure – volume relationship under conditions that allow gains and losses 
of temperature and pressure (unlike Boyles law) during expansion and compression 
(adiabatic), although the total heat content of the air remains constant:  
𝑃1 /𝑃2 =  (𝑉2 / 𝑉1)
𝛾 
(2) 
 where γ is the ratio of the specific heat of the gas at constant pressure to that of constant 
volume and is equal to 1.4 for air [13-15]. 
The BODPOD consists of two chambers, a test chamber and a reference chamber, connected 
by a diaphragm, in which oscillations can produce pressure changes in the chambers. The ratio 
of the pressures is a measure of the ratio of the test chamber to the ratio of the chamber 
volume. Some of volume of air, however, is still maintained under isothermal rather than 
adiabatic conditions and must be accounted for independently, for example air contained in 
the lungs, and near skin/hair or clothing. For this reason, tight fitting clothing is worn along 
with a swimming hat to contain the hair and minimise the surface area artefact (SSA). SSA, 
which is typically -1.0 L for an average sized adult [13], is generated automatically by the 
BODPOD as: 
𝑆𝑆𝐴 (𝐿) = 𝑘 (
𝐿
𝑐𝑚²
) ∗ 𝐵𝑆𝐴 (𝑐𝑚²) 
(3) 
Where 𝑘 is a constant derived by the manufacturer and body surface area (BSA) is calculated 
by body weight and height using DuBois and DuBois [16]  
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The volume of air in the lungs can be measured or predicted from built in equations in the 
BODPOD software. In the studies reported in this thesis predicted lung volumes were used. 
Ottersletter et al [17] found no significant differences in body volume when lung volume was 
measured and predicted. 
The measurement of body volume using the BODPOD involves 3 steps 
1. A 2-point calibration process starting with the chamber empty to establish a 
baseline volume and then with a 50 L calibration cylinder. 
2. The participant’s volume in the chamber is measured (Vbraw) not corrected for 
thoracic gas volume (VTG) or surface area artefact (SSA). 
3. The last step is then repeated to check for agreement that the measurements are 
within 0.2 % or 150 mL, if the first two are inconsistent then a 3rd measurement is 
taken. 
The participant’s volume is then corrected for SSA  and VTG (VBcorr) by estimations based on 
predictions by Crapo et al [18]. 
Body volume by BODPOD is therefore calculated by: 
𝑉𝑏𝑐𝑜𝑟𝑟(𝐿) = 𝑉𝑏𝑟𝑎𝑤(𝐿) − 𝑆𝐴𝐴(𝐿) + 40% 𝑉𝑇𝐺(𝐿) 
(4) 
Where Vbcorr is body volume corrected for VTG and SAA, Vbraw is body volume before correction 
for VTG  and SSA.  
2.1.3.1. Precision and Accuracy 
The precision and accuracy of the BODPOD have been widely reported for the assessment of 
%body fat [19-21] but not as widely for body volume. Our own precision calculations from two 
repeated measures across body volumes ranging from 16 – 103 L, demonstrate %CV of 0.44 
and a least significant change (LSC) of 1.2 L (unpublished). The cohort of child body volumes 
ranging from 16-80 L demonstrates a %CV of 0.65 and LSC of 1.8 compared to %CV 0.28 and 
LSC of 0.78 L in the adults (range of 38-103 L).  
2.1.4. Total Body Water (TBW) 
Isotope dilution is the reference standard technique for measuring the volume or mass 
of large quantities of water [16]. Isotopes are elements that are chemically identical but have 
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different masses due to different numbers of neutrons [22]. In this thesis the deuterium 
dilution method (2H) was used in chapter 3.  
A known amount of deuterium oxide (2H20) is given orally (0.1g/kg body mass for mass 
spectroscopy), this equilibrates with body water typically reaching a plateau in enrichment 
after 2-5h [23]. In children, an equilibrium or plateau is reached sooner than in adults as their 
smaller size means they have a higher water turnover, therefore sampling may occur sooner 
than 2hrs. However, in the elderly turnover may be slower and therefore samples should be 
collected for longer [23]. 
Prior to dosing, a reference saliva sample is taken to establish natural abundance. 
Saliva is collected by absorption into cotton wool which is then syringed out into 1ml aliquots. 
Further saliva samples are taken from 2 hours and then 3, 4, and 5 hours post dose. The 
rationale for this is to observe the plateau 2H enrichment in body water. Once the labelled 
saliva samples have been collected, they are refrigerated on collection and then frozen for 
future analysis by IRMS.  
The saliva samples are equilibrated with hydrogen gas in the presence of a platinum catalyst 
and heated for 6 hours at 22°C before analysis by IRMS.  
Total body water = 
 
𝑇𝐵𝑊 (𝑘𝑔) = (𝑊 𝑥
𝐴
𝑎
) 𝑥 
(
∆𝐷𝐷
𝛿𝑠𝑎𝑚𝑝 − 𝛿𝑏𝑘)
(1000𝑥1.041)
− (𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑓𝑙𝑢𝑖𝑑 𝑖𝑛𝑡𝑎𝑘𝑒 (𝑘𝑔)) 
(5) 
Where W and ‘a’ refer to a portion of the dose that has been diluted for analysis. W is the 
amount (g) of water used to make this dilution and ‘a’ is the amount (g) of the dose used in 
the dilution. ‘A’ is the dose (g) taken by the participant, ∆DD is the enrichment measured in 
the diluted dose (measured abundance in the diluted dose – abundance in the local drinking 
water used to dilute it) and δsamp-δbk is the enrichment measured in body water (Delta samp 
(relative to SMOW) – delta background). 1.041 represents a coefficient for deuterium that 
enters non-aqueous, distribution space, such as fat and protein. This is termed hydrogen 
exchange [24]. 
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2.1.5. Isotope ratio mass spectrometer (IRMS). 
 
Figure 2.1. Schematic of an IRMS from Muccio et al, 2009. 
Figure 2.1 illustrates the function of an IRMS. Firstly, the sample is introduced to the 
spectrometer in the form of a pure gas. The gas is then ionised by electrons emitted from a 
hot filament within a high vacuum. An ion repeller forces the ions to pass through a series of 
focusing lenses directing the ions into the magnetic analyser. The analyser separates the ions 
relative to their mass to charge ratio. The ions are then detected by the Faraday detectors 
[25]. IRMS measures the ratio of isotope in the sample relative to the ratio in a reference gas 
(equation 6). 
The stages of the sample analysis by IRMS is as follows; firstly, the results off the IRMS 
are delta values relative to the reference gas (equation 6). Similarly, the machine will give the 
internal standard (MLO) relative to the reference gas (equation 7). Where R refers to the ratio 
of the mass 3 to mass 2. 
δ𝑠𝑎𝑚𝑝, 𝑟𝑒𝑓 = (𝑅𝑠𝑎𝑚𝑝 𝑟𝑒𝑓⁄ − 1)103 
(6) 
𝛿𝑀𝐿𝑂, 𝑟𝑒𝑓 = (𝑅𝑀𝐿𝑂 𝑟𝑒𝑓⁄ − 1)103 
(7) 
The following calculations must then be applied to ultimately get the delta of the 
sample relative to VSMOW, the international standard.   
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Firstly, the δsamp needs to be made relative to MLO (equation 8). 
𝛿𝑠𝑎𝑚𝑝
𝑀𝐿0⁄
= (
(𝛿𝑠𝑎𝑚𝑝
𝑟𝑒𝑓⁄
+ 103)
(𝛿𝑀𝐿0
𝑟𝑒𝑓⁄
+ 103)
− 1) 103 
(8) 
Then knowing that δMLO/SMOW, is a measured machine specific constant, δsamp relative to 
SMOW can be calculated (equation 9). 
𝛿𝑠𝑎𝑚𝑝
𝑆𝑀𝑂𝑊⁄
= (
(𝛿𝑠𝑎𝑚𝑝
𝑀𝐿0⁄
+ 103) (𝛿𝑀𝐿0
𝑆𝑀𝑂𝑊⁄
+ 103)
106
− 1) 103 
 
(9) 
 2.1.5.1. Precision 
To determine the precision the IRMS measured deuterium (Delta samp ref) we calculated the 
%CV between QC standardised samples (MLO), corrected for SMOW, across 38 runs measured 
in duplicate. During each run two QC samples at delta 250 and 750 were performed. For the 
250 samples we report a %CV of 0.54 and for the 750 samples we report a %CV of 0.26. 
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2.2. Measurement of Energy Expenditure 
Energy expenditure can be defined as the rate at which heat is lost from the body 
(measured by direct calorimetry) or produced in the body (indirect calorimetry).  
Direct calorimetry measures heat loss by radiation, convection, conduction and from the 
heat rising from the vaporisation of water [26]. This requires extremely technical equipment 
and expertise with the research interests in heat loss and heat storage. The physical properties 
of a direct calorimeter are determined by whether it is an isothermal system, heat sink or 
convection system [26]. Heat sink calorimeters are a heavily insulated chambers to prevent 
heat loss and liquid-cooled heat exchangers to collect the heat produced. Alternatively, in an 
isothermal system, the chamber can be lined with a thin layer of material of a constant 
thickness which is maintained at a constant temperature along with a network of other 
measures of evaporation and air conditioning [27]. This method of calorimetry is rarely 
employed in human physiology nowadays but exists mainly in animal research.  
Indirect calorimetry describes the process of estimating heat production based on 
respiratory gas exchange and often including urea excretion. Measurements can be 
performed over short periods of time (10min) or as long as 24 hours or up to 7 days. There are 
two types of indirect calorimetry used within human metabolism; room/chamber calorimetry 
or ventilated canopy/mask calorimetry.  In this thesis, energy expenditure is assessed using 
two methods of indirect calorimetry: whole body room calorimetry (chapter 4) and ventilated 
canopy calorimetry (chapters 4, 5).  
Room calorimetry has the benefit of assessing oxygen and carbon dioxide gas exchange 
over longer durations in a reasonably comfortable controlled environment whilst maintaining 
a relatively normal level of habitation. Twenty four hour measurements can be broken down 
into smaller time frames and analysis periods. These can include sleeping metabolic rate 
(midnight to waking), basal or resting metabolic rate (upon waking, typically a 60min 
measurement), diet induced thermogenesis after the consumption of a meal or physical 
activity energy expenditure by inducing periods of exercise within the room (30min exercise). 
However, the room calorimeter is at a disadvantage for shorter analysis periods. The volume 
of the room results in a slow response between participant gas exchange and analysis of a 
sample which is also related to the flow rate needed for the size of the room. To minimise this, 
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the ventilated canopy method is used in addition to room calorimetry for the data collection 
of shorter periods of interest, such as resting energy expenditure.  
The volume of the canopy is substantially less than the room, requiring a lower flow rate 
and therefore a smaller response time. The canopy is, however, only physically appropriate 
for shorter periods of time as it requires the participant to remain still and in a supine resting 
condition. For exercise testing that require gas exchange measurements during increased 
mobility and physical activity, a mask or mouth piece is used as the connector to the gas 
exchange instrument. With these instruments instead of there being a controlled constant 
flow rate, the flow rate is driven by expiration resulting in a breath-by-breath analysis.  
Macronutrient oxidation can be derived from all gas exchange methods with 
appropriate energy conversion equations. This provides information about whole body fat, 
carbohydrate and protein oxidation (with the inclusion of urea and creatinine).  
2.2.1 Indirect calorimetry 
 Indirect calorimetry can adopt a push or pressure ventilation system (room 
calorimetry) or a pull or suction ventilation system (ventilated canopy).   
2.2.1.1. Whole-body room calorimeters  
Figure 2.2.2 is a diagram of a modern room calorimeter, designed to mimic a normal 
bedroom, containing a bed, wash basin, portaloo, TV, DVD, computer with internet, telephone 
and a window. The floor area is 10.4m2 and the room volume is 24m3 
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The room is ventilated with a constant and measured supply of fresh air. All air entering 
the calorimeter is measured and controlled.  This is referred to as “push” or pressure 
ventilation. A “pull” or suction ventilation method will control the air coming out of the 
chamber. The measurement of respiratory gas exchange has been described by Brown [28].  
Where Fi and Fo are the flow rates of the moist air in and out of the chamber and RG is the 
rate of respiratory gas exchange: 
 𝑑 𝑑𝑡⁄ (𝑉 Ψ𝑜𝑓𝐺𝑜) =  (𝐹𝑖 Ψ𝑖  𝑓𝐺𝑖) + 𝑅𝐺 − (𝐹𝑜 Ψ𝑜 𝑓𝐺𝑜) 
(10) 
The rate of increase of volume of gas inside the chamber = rate of volume flow of gas into the 
chamber + rate of net volume production of gas by the subject – rate of volume flow of gas 
out of the chamber. Each calculation requires corrections which for simplicity are represented 
as Ѱ. in the equation above: 
Figure 2.2. Diagram of a modern day room calorimeter for the measurement of 24 or 36 hour 
EE (Diagram by PR Murgatroyd). 
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1. The volume of dry air is converted to the proportion of the gas in wet air, which is then 
multiplied by the volume of the calorimeter to obtain the volume of gas under 
standard conditions 
𝑥 (1 −
𝑃𝑤
𝑃
) 
(11) 
where PW is the vapour pressure of water in the air and P is the atmospheric pressure. 
2. The resulting volume is then adjusted to standard temperature and pressure, STP, 
where TS is 273 oK and PS is 1013 mbar. 
(𝑥
𝑇𝑠
𝑃𝑠
𝑥
𝑃
𝑇
) 
(12) 
Therefore:    Ψ = (1 −
𝑃𝑤
𝑃
) 𝑥
𝑇𝑠
𝑃𝑠
 𝑥 𝑃/𝑇 
(13) 
The analysers produce outputs that are proportional to the molecular density of the 
relevant gas in the analyser cell and therefore the resulting ƒG value is directly related to the 
density of the air analysed [28]. fG also needs to be corrected separately for changes in 
atmospheric pressure occurring after the time of calibration of the analyser.  
The rate of gas production (RG) for a push calorimeter is expressed as: 
𝑅𝐺 = 𝐹𝑜 Ψ𝑜 𝑓𝑁20 + 𝑉𝑑/𝑑𝑡(Ψ0𝑓𝑁20)) (
𝑓𝐺𝑜
𝑓𝑁20
−
𝑓𝐺𝑖
𝑓𝑁2𝑖
) + 𝑉Ψ𝑜 𝑓𝑁20
𝑑
𝑑𝑡
(
𝑓𝐺𝑜
𝑓𝑁20
)  
(14) 
2.2.1.2. Ventilated canopy or portable indirect calorimetry.  
Ventilated hood indirect calorimetry (Figure 2.3) share the basic principles with room 
calorimetry, however it instead uses a pull ventilation system rather than a push system and 
as the volume is significantly smaller than a room, it is not necessary account for it within the 
expression (15). 
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For a pull calorimeter (ventilated canopy) where the volume is expressed as 0 as the size is 
negligible: 
𝑅𝐺 =  𝐹𝑖  Ψ𝑖𝑓𝑁2𝑖 (
𝑓𝐺𝑜
𝑓𝑁20
−
𝑓𝐺𝑖
𝑓𝑛2𝑖
) 
(15) 
 
 
 
 
 
 
Figure 2.3.  Indirect calorimetry using a ventilated canopy and face mask techniques.  
The ventilated hood technique of indirect calorimetry is typically the preferred method 
used to assess resting energy expenditure (REE). The concept of REE was developed by 
researchers such as Harris and Benedict [29], and Dubois [16]. REE and basal metabolic rate 
(BMR) are often used interchangeably, which is acceptable if the conditions of the 
measurement are the same. For accurate measurement of REE, the measurement conditions 
should be those of complete rest, preferably in the early morning on waking, 13 hours after 
the last meal and at thermoneutral temperature. The duration of the measurement can range 
from 10min to an hour depending on the protocol and how long the participant can remain 
still and comfortable for. The ventilated canopy fits over the participant’s head whilst they are 
lying down.  
2.2.2. Macronutrient Oxidation 
Room calorimeter gas concentrations are measured every 200s by the analysers and then 
using software with built in expressions from Murgatroyd et al [30] the O2 and CO2 exchange 
are converted into carbohydrate, fat and protein oxidation rates:   
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𝐹𝑎𝑡 = [𝐶𝑂2 −  𝑅𝑐 𝑂2 + (𝑅𝑐 −  𝑅𝑝)𝑉𝑝 𝑘 𝑁]/𝑉𝑓 (𝑅𝑓 −  𝑅𝑐) 
(16) 
𝐶𝐻𝑂 = [𝐶𝑂2 −  𝑅𝑓 𝑂2 + (𝑅𝑓 −  𝑅𝑝)𝑉𝑝 𝑘 𝑁]/𝑉𝑐 (𝑅𝑐 −  𝑅𝑓) 
(17) 
[30] 
Where 𝑅𝑓, is the ratio of carbon dioxide production to oxygen to consumption per gram 
oxidised for fat, 𝑅𝑐 for CHO and 𝑅𝑝 for protein, also referred to as respiratory quotients (RQ). 
Vf, Vc, and Vp are the volumes of oxygen consumed per gram oxidised for fat, CHO and protein. 
k is the constant that relates protein oxidation to nitrogen excretion, leaving N to represent 
protein oxidation. The primary method of nitrogen disposal is through urine excretion. Urine 
samples are analysed for Urea and Creatinine the main product in urine excretion. Nitrogen 
has the atomic weight of 14, and therefore 28g of nitrogen are lost with 1mol of urea and 42g 
are lost with 1mol of creatinine. Using this we can calculation N and therefore estimate protein 
oxidation. 
Using the constants of Elia and Livesey [31] (Table 1), macronutrient oxidation can be 
calculated as follows:  
𝐹𝑎𝑡 =  −1.7 [𝐶𝑂2 −  𝑂2 + 0.98 𝑁] 
(18) 
𝐶𝐻𝑂 = 4.6 [𝐶𝑂2 − 0.71 𝑂2 − 0.74 𝑁] 
(19) 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 = 6.25 𝑁 
(20) 
Where Fat, CHO, Protein and Nitrogen are in grams when O2 and CO2 are in litres. 
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 Table 2.1. Respiratory quotients (RQs) of macronutrients [31] 
Macronutrient RQ 
Fat 0.710 
Carbohydrate 1.000 
Protein 0.835 
 
Most dietary intakes consist of a combination of macronutrients, typically of 35% fat, 
50% CHO and 15% protein by energy. Before assessing energy expenditure it is ideal that the 
participant is in a state of energy balance so that any manipulation within the diet (e.g. high 
CHO) are not influencing on the total oxidation rate or individual oxidation of macronutrients. 
However, to reach this state may require weeks of consuming standardised meals with known 
compositions. At the least, knowledge of the composition of the last meal eaten may prove 
helpful when analysing and interpreting the gas exchange the following morning.  
 Figure 2.4 demonstrates typical macronutrient oxidation rates generated from a 24 hr 
whole-body calorimeter visit for a healthy participant.  
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Figure 2.4. Macronutrient oxidation results from a 24 hour visit analysed at a 60min time 
interval. The three peaks in energy expenditure result from three exercise periods on a static 
bike (dashed line). For the shaded periods 0-7 hours and 23-24 hours, the participant is asleep.   
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2.2.3. Precision of indirect calorimetry 
2.2.3.1. Room calorimetry 
Repeated measurements of 24 hr whole body room calorimetry (unpublished) was calculated 
across 15 participants. This demonstrated a %CV of 7.1 and an LSC of 1.1 MJ/d. For repeated BMR 
measured by room calorimetry %CV was 4.68 and LSC 0.6 MJ/d.  
2.2.3.2 Ventilated hood calorimetry 
Repeated measurements of resting energy expenditure using the ventilated hood and portable gas 
exchange instrument demonstrated a %CV of 3.8 and LSC of 0.5 kJ/min (0.72 MJ/d). This was based on 
three repeated measurements on eight participants, all performed under the same conditions and 
using the same instrument.  
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3.  An investigation into the differences in bone density and body composition measurements 
between two GE Lunar densitometers and their comparison to a four component model. 
Watson LPE, Venables MC, and Murgatroyd PR. An investigation into the differences in bone 
density and body composition measurements between two GE Lunar densitometers and 
their comparison to a four component model. J Clin Densitometry; 2017 Jul 27. 
3.1 Abstract  
Background. We describe a study to assess the precision of the GE Lunar iDXA and the 
agreement between the iDXA and GE Lunar Prodigy densitometers for measurement of 
regional and total body bone and body composition in normal to obese healthy adults.  We 
compare the whole body fat mass by DXA to measurements by a four component (4-C) model. 
Methods. Sixty nine participants, aged 37 ± 12 years, BMI 26.2 ± 5.1 kg/cm2, were measured 
once on the Prodigy and twice on the iDXA. The 4-C model estimated fat mass from body mass, 
total body water by deuterium dilution, body volume by air displacement plethysmography 
and bone mass by DXA. Agreement between measurements made on the two instruments 
and by the 4-C model were analysed by Bland-Altman and linear regression. Where 
appropriate translational cross-calibration equations were derived. Differences between DXA 
software versions were investigated. 
Results. iDXA precision was less than 2% of the measured value for all regional and whole 
body bone and body composition measurements with the exception of arm fat mass (2.28%). 
We found signifcant differences between iDXA and Prodigy (P < 0.05) whole body and regional 
bone, fat (FM) and lean mass (LM), with the exception of hip bone mass, area and density and 
spine area. Compared to iDXA, Prodigy over-estimated FM and under-estimated LM.  
However, compared to 4-C, iDXA showed a smaller bias and narrower limits of agreement 
than Prodigy. No significant differences between software versions in FM estimations existed. 
Conclusion. Our results demonstrate excellent iDXA precision. However significant differences 
exist between the two GE Lunar instruments, Prodigy and iDXA measurement values. A 
divergance from the reference 4-C observations remains in FM estimations made by DXA even 
following the recent advances in technology.  Further studies are particularly warranted in 
individuals with large fat mass content.  
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3.2. Introduction 
Dual-energy X-ray absorptiometry (DXA) is widely used for bone density 
measurements within the clinical environment. Within the research community there is 
perhaps more emphasis on body composition measurement, driven by the increasing 
prevalence of obesity. In both contexts the ability to detect changes in measurements is 
arguably of more interest than the absolute value of the measurement so that an apparent 
change in bone or fat mass should not be generated and interpreted falsely. 
DXA instruments have improved over time, most evidently in reduced scan times.  As 
the technology has matured the focus of development has shifted to image quality, which has 
improved through advances in detector design yielding a higher pixel density.  Major benefits 
of this are better discrimination of bone edges and better imaging of soft tissue, particularly 
in the thoracic region [1].  Both translate to improved repeated measures precision [2 3].  
These benefits come at the cost of a new instrument, compounded by the complexities of 
managing the migration from old to new which involve performing cross-calibration 
assessments to identify any differences between instruments and account for them using 
translational regression equations [4]. 
The iDXA is the latest densitometer to come from GE Lunar, a development of the GE 
Lunar Prodigy and Prodigy Advance. A new detector and x-ray filter (producing different 
energy spectra) provide improved resolution and image quality by better bone edge detection 
[1]. This also suggests there may be improved soft tissue algorithms within the software 
compared to previous instruments. Repeated measures precision describes the variability 
between two measurements caused the instrument itself, by re-positioning and by operator 
error and so sets the threshold for discriminating biological change between two 
measurements [5].  Several authors have documented the iDXA’s enhanced precision for 
repeated measures compared to previous models [2 3 6]. 
Here we report an investigation which extends the previously reported work.  The 
primary purpose of this study is to evaluate the precision and accuracy of the iDXA. Secondly 
we aim to produce translational regression equations for relating scans between the Lunar 
Prodigy and iDXA. Further, we have determined accuracy of iDXA measured fat mass 
measurement by comparison with a four-component model (4-C) [7]. The 4-C model is widely 
accepted as a reference against which the accuracy of other body composition methodologies 
is evaluated. 
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3.3. Material and Method 
3.3.1. Participants 
Sixty nine healthy men (n = 33) and women (n=36) were recruited for the purposes of 
this study. Two participants were excluded from the hip analysis, one for poor positioning and 
one for an artificial joint. One participant was excluded from the total body water analysis 
because of an insufficient sample volume. The demographic data of the cohort is presented 
in Table 3.1. All participants were made aware of the risks associated with the measurements 
and provided informed consent in writing.  Participants were healthy, free from disease and 
non-smoking; they were excluded if they were pregnant or receiving any metabolism-
influencing medications. Participants were recruited locally from advertisements around 
Addenbrookes Hospital in Cambridge and Cambridge University. The study was approved by 
the Cambridge Central Ethics Committee. 
Each participant arrived at NIHR/Wellcome Trust Clinical Research Facility, 
Addenbrooke’s biomedical campus, Cambridge at noon on the day of their visit to undertake 
three procedures: whole body water determination using deuterium dilution; DXA; and body 
volume determination using air displacement plethysmography (ADP).  The participants wore 
light, metal-free clothing and refrained from food and drink for 30 min before and during the 
measurements.  
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Table 3.1. Descriptive data of the participants 
  
Men n=33 
 Mean ± SD 
 
Range 
Female n =36                               (n=3 BMI >35) 
Mean ± SD         Range                Mean, Range 
 
Age (years) 38.0 ± 12.0 19.9 – 64.1 37.8 ± 12.7 19.2 – 57.9 33.7, 25.3 – 44.6 
Height (m) 1.80 ± 7.9 1.62 – 2.01 1.66 ± 6.7 1.53 – 1.83 1.71, 1.66 – 1.78 
Mass (kg)1 81.0 ± 12.0 54.1 – 106.9 73.9 ± 18.1 49.1 – 129.6  124.4, 120.7 – 129.6 
BMI (kg/m2) 25.3 ± 3.2 20.2 – 34.2 27.0 ± 6.3 18.4 – 47.5 43.06, 38.8 – 47.5 
Fat mass (kg) (4-C) 16.8 ± 8.1 4.1 – 33.4 28.0 ± 14.4 9.6 – 71.5 66.8, 62.0 – 71.5 
% Fat (4-C) 20.1 ± 8.0 5.8 – 34.4 36.0 ± 9.5 18.5 – 55.1 53.7, 51.4 – 55.1 
SD; standard deviation, BMI; Body mass index, 4-C; 4 Component model (n=68). Hip analysis 
n = 67. Scan mode: Standard n =65, thick n=4. 1 ADP mass (mean difference ± SD in mass (kg) 
between ADP and iDXA; 0.15 ± 0.50, and Prodigy; -0.02 ± 0.65). Three female participants with 
the largest fat mass and BMI are also described in the last column but are included within the 
total female cohort. 
 
3.3.2. Protocol 
3.3.2.1. Deuterium dilution 
A baseline saliva sample was obtained from the participant shortly after arrival.  Height 
and weight were then measured.  Height was measured on a stadiometer and recorded to the 
nearest millimetre (SECA 242 digital stadiometer, Seca, Hamburg, Germany).  Weight was 
measured on electronic scales to the nearest gram (Kern & Sohn GmbH, Germany).  The 
participant then consumed a dose of 70 mg per kg body mass of 2H2O (99.8 %, CK Isotopes 
Ltd., Ibstock, Leicestershire, UK) [8].  Further 1ml saliva samples were collected at 3, 4 and 5 
hours post dose.  Food and drink were withheld for 30 min prior to the collection of each saliva 
sample. The saliva samples were frozen at -20°C until later analysis using dual inlet isotope 
ratio mass spectrometry (Isoprime, GV Instruments, Wythenshawe, UK). 
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3.3.2.2. DXA 
Each participant was scanned twice on the iDXA (GE Healthcare Lunar, Maddison, WI, 
USA, EnCore software version 16 (enhanced analysis)), with repositioning in between scans, 
and once on the GE Lunar Prodigy (EnCore software version 12.3). The Prodigy data (basic 
analysis) was re-analysed on the iDXA using software version 16 to provide enhanced Prodigy 
analysis. All three scans were performed on the same day by the same operator. Sites scanned 
were hip (left femur) and lumbar spine (L2-L4) for bone mass, area and density and whole-
body for both whole body bone mass, area and density and body composition.  Calibration 
block quality assurance and encapsulated spine phantom quality control scans were 
performed on each instrument at the start of each scanning day. 
The scans were performed by three trained operators who performed scans according 
to the manufacturers positioning and scanning protocols (Precision for each operator, 
represented by %CV of repeated scans, ranged from 0.7 % to 1.5 % for lumbar spine and 0.5 
% to 1.0 % for total hip, below the recommended 1.9 % for lumbar spine and 1.8 % for total 
hip by the International Society of Clinical Densitometry (ISCD) [4]). Subsequent analysis of all 
scans was carried out by a single operator to ensure consistency throughout the study. Inter-
operator variability was not significant for hip BMD (F=0.322, P = 0.726) and spine BMD 
(F=0.676, P=0.512).  
 
3.3.2.3. Air displacement plethysmography 
The participants were asked to pass urine before the ADP procedure (BODPOD®, 
Cosmed Srl, Rome, Italy).  Tight fitting swim wear and a swimming cap were worn to minimise 
air trapped in clothing and hair.  Lung volume was estimated by the BODPOD software to 
provide a net body volume estimate. The weight obtained during the ADP procedure was used 
as the body mass value for the total body water and 4-C analysis. 
3.4. Analysis and Calculations  
3.4.1. TBW plateau method 
TBW was calculated according to the method of [8]. In brief, aliquots of 0.2 ml, drawn 
from the saliva samples were placed in 3.7 ml glass bottles with rubber septa (non-evacuated 
vials, Labco Ltd, Lampeter, UK) and equilibrated with hydrogen in the presence of a platinum 
catalyst.  Data was drift corrected off-line and all measurements were made relative to Vienna 
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standard mean ocean water (V-SMOW) using laboratory standards traceable to the 
international standard.   
2H2O dilution space was determined using the following equation [9]: 
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Where: T and ‘d’ refer to a portion of the dose that has been diluted for analysis. T is the 
amount (g) of water used to make this dilution and ‘d’ is the amount (g) of the dose used in 
the dilution. ‘D’ is the dose (g) taken by the participant. 
Ed is enrichment of the diluted dose d in T; Et is the enrichment of the tap water 
diluent; Es is the mean enrichment of saliva samples at 3, 4 and 5 hours; Ep is the enrichment 
of the pre dose sample. 
Total body water (TBW (kg)) was then calculated by reducing 2H2O dilution space 
values by 4% to account for the exchange of deuterium with non-aqueous hydrogen [10].  
3.4.2. Four component model (4-C) 
Fat mass (FM, kg) using the 4-C model was calculated using the following equation of 
Fuller et al [7]: 
𝐹𝑀 = 2.747 × 𝐵𝑉 − 0.710 × 𝑇𝐵𝑊 + 1.460 × 𝐵𝑀𝐶 − 2.050 × 𝐵𝑊 
Where: BV is body volume and determined using ADP; TBW is total body water and 
determined using deuterium dilution; BMC is whole body bone mineral content and 
determined using DXA and BW is body weight determined during the ADP procedure. 
3.5. Statistical analysis 
Descriptive data are reported as mean ± (standard deviation) unless otherwise stated. 
Statistical analysis revealed the body composition data was normally distributed. 
Precision of the iDXA was expressed as the root mean square standard deviation (RMS-
SD) and % CV according to ISCD recommendations.  Least significant change (LSC) was 
calculated (2.77 x RMS-SD) to establish the smallest change between repeated scans which 
could be identified with 95% confidence as originating from the participant rather than 
instrument and positioning variability [5]. 
Paired sample t tests were performed to determine the difference between 
instruments. 
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Bland-Altman analysis was performed to determine the association and agreement 
between the two instruments and between each instrument and 4-C derived fat mass. Where 
appropriate linear regression analysis was used to derive cross-calibration equations between 
Prodigy data, using enhanced analysis mode and iDXA data. It should be noted that enhanced 
analysis mode is only available on Lunar Prodigy Advanced and iDXA instruments running 
software versions 15 and 16. If an earlier version of the Lunar Prodigy instrument is being 
used, refer to Table 3.7 where we have given whole body and regional bone and body 
composition cross-calibration regression equations to translate from Lunar Prodigy 
measurements analysed in basic mode to Lunar iDXA measurements. 
Repeated measures ANOVA was applied to test for significance in fat measurements. 
Post hoc comparisons with Bonferroni correction were applied to discover significance 
between methods (4-C, iDXA, Prodigy Enhanced and Prodigy Basic). iDXA values were 
calculated as the mean of two iDXA measurements. 
GraphPad Prism (Version 6.00 for Windows, GraphPad Software, San Diego California 
USA) was used to generate Bland-Altman analyses and IBM SPSS (IBM Corp. Released 2012. 
IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp) was used for all other 
statistical analyses. 
Significance was assumed for p < 0.05 for all statistical tests. 
3.6. Results 
3.6.1. iDXA precision 
Precision error for repeated iDXA scans is shown in Table 3.2. Precision error, when 
represented by %CV, was less than 2% for all measures with the exception of arm fat mass 
(2.28%). A greater precision was demonstrated for lean mass compared to fat mass. 
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Table 3.2. Precision variables of two iDXA whole-body and regional body composition 
measurements. 
Region Variables Mean ± SD Mean 
Difference 
RMS-SD CV (%) LSC 
Hip BMC (g) 35.98 ± 7.61 -0.07  0.46 1.05 1.29 
 Area (cm2) 33.21 ± 3.98 0.06  0.28 0.59 0.77 
 BMD (g/cm2) 1.08 ± 0.16 -0.00  0.01 0.72 0.03 
Spine BMC (g) 58.74 ± 12.09 -0.44  0.71 0.86 1.96 
 Area (cm2) 46.59 ± 5.61 0.02  0.42 0.54 1.16 
 BMD (g/cm2) 1.25 ± 0.15 -0.01 0.01 0.74 0.04 
Whole Body BMC (kg) 2.82 ± 0. 58 -0.00  0.02 0.44 0.04 
Arms Fat mass (kg) 2.26 ± 1.11 -0.01  0.06 2.28 0.16 
  Lean mass (kg) 5.61 ± 1.78 0.01  0.09 1.20 0.25 
Legs Fat mass (kg) 8.38 ± 4.45 -0.05  0.18 1.32 0.50 
  Lean mass (kg) 18.24 ± 4.00 -0.07  0.19 0.74 0.52 
Trunk Fat mass (kg) 6.12 ± 6.49 -0.00  0.26 1.58 0.72 
  Lean mass (kg) 24.03 ± 4.64 0.11  0.29 0.93 0.80 
Whole Body Fat mass (kg) 23.57 ± 11.51 -0.07  0.24 0.86 0.65 
  Lean mass (kg) 51.00 ± 10.39 0.07  0.28 0.42 0.78 
RMS-SD, root mean square standard deviation; %CV, percent coefficient of variance; LSC, ideal 
least significant change. 
 
3.6.2. iDXA fat mass accuracy 
iDXA measured fat mass and 4-C derived fat mass are highly correlated (r2 = 0.99, 
P<0.05) with a slope of 0.892 and an intercept of 3.39.  However, there is a significant 
difference between iDXA measured fat mass and 4-C derived fat mass (mean difference (SD), 
-0.936 (1.83), P < 0.05) with wide limits of agreements (-4.53 – 2.65). It can be seen in Figure 
3.1 that there is a significant positive proportional bias.  Furthermore, at an average fat mass 
of 32.12 kg the iDXA shifted from over-measuring to under-measuring fat mass compared to 
4-C derived fat mass. 
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Figure 3.1. Bland-Altman plot of iDXA and 4 Component model derived fat mass (n=68). Solid 
black linear regression line demonstrates the systematic bias, hashed grey box corresponds to 
the 95% CI of the systematic bias, dashed lines represent the limits of agreements and the 
dotted lines present the crossover of over - to under - measuring fat mass at 32.12 kg. 
 
3.6.3.iDXA vs Prodigy 
There were significant differences in whole body and spine bone masses between iDXA 
and prodigy enhanced measurements, these differences were not seen in any hip 
measurements (Table 3.3). 
The comparison of body composition measurements between the instruments reveals 
significant differences in fat and lean masses across all regions (Table 3.4). 
Differences in whole body and regional bone and body composition measurements 
between Prodigy basic mode and iDXA enhanced mode analyses are presented in table 3.5 
and 3.6. Significant differences were present in whole body and spine bone measurements 
and in all regions of body composition. Therefore relevant cross-calibration regression 
equations were derived and can be found in table 3.7. Hip and spine measurements for 
Prodigy basic and Prodigy Enhanced were identical. 
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Table 3.3. Whole body and regional iDXA and Prodigy enhanced bone density measurements. 
Region Variables iDXA Prodigy Enhanced Bias LOA 
Whole Body BMC (kg) 2.8 ± 0.6 2.8 ± 0.6 0.02 ± 0.05* -0.07 – 0.12 
  Area (cm
2
) 2255.1 ± 234.3 2219.4 ± 236.9 35.8 ± 51.0* -64.2 – 135.7 
  BMD (g/cm
2
) 1.24 ± 0.15 1.25 ± 0.16 -0.01 ± 0.02* -0.06 – 0.04 
 Hip BMC (g) 36.0 ± 7.6 36.1 ± 7.6 -0.07 ±1.148 -2.32 – 2.18 
 
Area (cm
2
) 33.2 ± 4.0 33.2 ± 3.9 0.06 ± 0.87 -1.64 – 1.76 
 
BMD (g/cm
2
) 1.08 ± 0.16 1.08 ± 0.15 -0.00 ± 0.02 -0.04 – 0.04 
Spine BMC (g) 58.7 ± 12.1 59.2 ± 12.3 -0.44 ± 1.21* -2.82 – 1.93 
 
Area (cm
2
) 46.6 ± 5.6 46.6 ± 5.6 0.02 ± 0.76 -1.48 – 1.51 
 
BMD (g/cm
2
) 1.25 ± 0.15 1.26 ± 0.15 -0.01 ± 0.02* -0.05 – 0.04 
Mean ± standard deviation.  * P < 0.05. BMC, bone mineral content; BMD, bone mineral 
density. 
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Table 3.4. Whole body and regional iDXA and Prodigy enhanced body composition 
measurements. 
Mean ± standard deviation, *P < 0.05. 
Table 3.5. Difference between iDXA enhanced and Prodigy basic software analysis: whole-
body and regional bone mass, area and density measurements 
Region Variables iDXA Prodigy Difference 
Total Body BMC (kg) 2.8 ± 0.6 3.0 ± 0.7 -0.20 ± 0.14* 
  BA (cm
2
) 2.3 ± 0.2 2.4 ± 0.3 -0.14 ± 0.16* 
  BMD (kg/cm
2
) 1.24 ± 0.15 1.25 ± 0.13 -0.01 ± 0.04* 
 Hip BMC (g) 36.0 ± 7.6 36.1 ± 7.6 -0.06 ± 1.15 
 
BA (cm
2
) 33.2 ± 4.0 33.2 ± 3.9 0.06 ± 0.87 
 
BMD (g/cm
2
) 1.08 ± 0.16 1.08 ± 0.15 0.00 ± 0.02 
Spine BMC (g) 58.7 ± 12.1 59.2 ± 12.3 -0.44 ± 1.21* 
 
BA (cm
2
) 46.6 ± 5.6 46.6 ± 5.6 0.02 ± 0.76 
 
BMD (g/cm
2
) 1.25 ± 0.15 1.26 ± 0.15 -0.01 ± 0.02* 
Means ± Standard Deviations *P < 0.05 
Region Variables iDXA Prodigy 
enhanced 
Bias LOA 
Whole body Fat mass (kg) 23.6 ± 11.6 24.9 ± 11.7 -1.29 ± 0.56* -2.53 – 0.05 
 Lean mass (kg) 51.0 ± 10.4 49.9 ± 10.1 1.18 ± 0.57* 0.00 – 2.24 
Arm Fat mass (kg) 2.3 ± 1.1 2.5 ± 1.2 -0.25 ± 0.19* -0.62 – 0.12 
 
Lean mass (kg) 5.6 ± 1.8 5.4 ± 1.8 0.20 ± 0.33* -0.46 – 0.85 
Leg Fat mass (kg) 8.4 ± 4.5 8.9 ± 4.5 -0.54 ± 0.30* -1.13 – 0.05 
 
Lean mass (kg) 18.2 ± 4.0 17.8 ± 3.9 0.46 ± 0.63* -0.77 – 1.68 
Trunk Fat mass (kg) 12.1 ± 6.5 12.6 ± 6.4 -0.46 ± 0.42* -1.28 – 0.35 
 
Lean mass (kg) 24.0 ± 4.7 23.6 ± 4.4 0.41 ± 0.72* -1.00 – 1.81 
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Table 3.6. Difference between iDXA enhanced and Prodigy basic software analysis: whole-
body and regional body composition measurements 
Means ± Standard Deviations *P < 0.05  
 
  
Region Variables iDXA Prodigy Difference 
Whole body Fat mass (kg) 23.6 ± 11.6 26.0 ± 14.4 -0.79 ± 1.73* 
 Lean mass (kg) 51.0 ± 10.4 49.9 ± 10.9 1.18 ± 1.99* 
Arm Fat mass (kg) 2.3 ± 1.1 2.1 ± 12.7 -0.16 ± 0.21** 
 
Lean mass (kg) 5.6 ± 1.8 5.4 ± 1.8 0.17 ± 0.23** 
Leg Fat mass (kg) 8.4 ± 4.5 8.8 ± 5.0 -0.44 ± 0.71** 
 
Lean mass (kg) 18.2 ± 4.0 17.4 ± 4.1 0.85 ± 0.89** 
Trunk Fat mass (kg) 12.1 ± 6.5 12.8 ± 6.7 -0.67 ± 1.11** 
 
Lean mass (kg) 24.0 ± 4.7 23.7 ± 4.9 0.29 ± 1.24 
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Table 3.7. Cross calibration equations relating Prodigy data collected and analysed using 
Encore basic software versions to iDXA enhanced analysis. 
 Variable Slope 95% CI Intercept 95% CI r2 
Whole body BMC (kg) 0.886 0.841-0.931 0.147 0.007-0.286 0.957 
 BA (cm2) 0.661 0.570-0.751 0.672 0.452-0.891 0.760 
 BMD (kg/cm2) 1.199 1.146-1.252 -0.254 -0.320- -0.187 0.968 
 Fat mass (kg) 0.909 0.885-0.934 1.416 0.740-2.093 0.988 
 Lean mass (kg) 0.941 0.899-0.983 4.117 1.969-6.265 0.967 
Regional Spine BMC (g) 0.978 0.954-1.001 0.877 -0.537-2.290 0.990 
 Spine BA (cm2) 0.990 0.956-1.023 0.504 -1.046-2.055 0.982 
 Spine BMD (g/cm2) 0.986 0.950-1.022 0.008 -0.038-0.054 0.978 
 Arm fat mass (kg) 0.874 0.847–0.902 0.421 0.354-0.489 0.983 
 Arm lean mass (kg) 0.973 0.943-1.004 0.317 0.141-0.493 0.984 
 Leg Fat mass (kg) 0.882 0.864-0.901 0.599 0.407-0.791 0.992 
 Leg Lean mass (kg) 0.963 0.910-1.015 1.500 0.565-2.434 0.953 
 Trunk Fat mass (kg) 0.963 0.923-1.003 -0.201 -0.733-0.370 0.972 
CI, Confidence intervals; adjusted r2, model variance. 
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Figure 3.2. Bland-Altman analysis of the agreement between iDXA and Prodigy measured 
whole body fat (a) and lean mass (b).  
Solid black line corresponds to the systematic bias, hashed grey box corresponds to the 95% 
CI of the systematic bias, and the dotted lines represent the limits of agreements. 
 
Figure 3.2 illustrates the agreement between instruments in fat mass and lean mass 
by Bland-Altman analysis. Compared to iDXA, Prodigy overestimates fat mass (mean 
difference -1.29 kg) and underestimates lean mass (mean difference 1.18 kg).  
Due to the observed differences between instruments (Table 3.3 and Table 3.4) linear-
regression cross-calibration equations were derived where appropriate and can be seen in 
Table 3.8.  
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Table 3.8. Cross-calibration equations (Prodigy enhanced to iDXA).   
 Variable Slope 95% CI Intercept 95% CI r2 
Whole body BMC (g) 1.003* 0.983 – 1.023 0.017 -0.041 – 0.074 0.993 
 BA (cm
2) 0.966* 0.914 – 1.017 112.0 -3.543 – 227.6 0.953 
 BMD (g/cm
2) 0.965* 0.928 – 1.001 0.035 -0.011 – 0.081 0.976 
 Fat mass (kg) 0.991* 0.978 – 1.005 -1.016* -1.393 – -0.639 0.997 
 Lean mass (kg) 1.029 1.013 – 1.045 -0.262 -1.058 – 0.535 0.996 
Spine  BMC (g) 0.978* 0.954 – 1.001 0.877 -0.537 – 2.290 0.990 
 BA (cm
2) 0.990* 0.956 – 1.023 0.505 -1.045 – 2.055 0.981 
 BMD (g/cm
2) 0.986 0.950 – 1.022 0.008 -0.038 – 0.054 0.978 
Regional Arm fat mass (kg) 0.962* 0.923 – 1.001  -0.155* -0.262 - -0.048 0.973 
 Arm lean mass (kg) 0.972* 0.927 – 1.016 0.350* 0.097 – 0.603 0.966 
 Leg Fat mass (kg) 0.989* 0.973 – 1.005 -0.444* -0.604 - -0.284 0.996 
 Leg Lean mass (kg) 1.024* 0.985 – 1.063 0.036 -0.673 – 0.746 0.976 
 Trunk Fat mass (kg) 1.010* 0.995 – 1.026 -0.591* -0.811 - -0.372 0.996 
 Trunk Lean mass (kg) 1.042* 1.003 – 1.080 -0.576 -1.494 – 0.341 0.978 
CI, Confidence intervals; Adjusted r2, model variance, *P < 0.05.  
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3.6.4. Prodigy Accuracy 
Prodigy enhanced fat mass and 4-C derived fat mass are highly correlated (R2 = 0.993), 
with a slope of 0.883 and intercept of 4.80.  As observed with the iDXA (Figure 3.1), there is a 
significant difference between Prodigy enhanced fat mass and 4-C fat mass (mean difference 
(SD) -2.16 (2.05) kg). There are also wider limits of agreement (-6.17 – 1.86) and a more 
negative systematic bias than for the iDXA (Figure 3.3b & 3.3c) 
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Figure 3.3. Demonstration of the difference and progression between 4-Component model 
and Prodigy Basic analysis (a), Prodigy Enhanced (b) and iDXA (c) with 95% limits of agreement. 
Solid black line corresponds to the systematic bias, hashed grey box corresponds to the 95% 
CI of the systematic bias, and the dotted lines represent the limits of agreements with 
corresponding 95% CI  represented by grey boxes.  
The measurement of fat mass was significantly affected by method (F(3,201) = 41.057, 
P <0.05). There was a significant difference between 4-C derived fat mass and iDXA (mean diff 
-0.936, P = 0.000), Prodigy Enhanced (-2.157, P = 0.000) and Prodigy Basic (-1.720, P = 0.000) 
fat mass. However, there was no significant difference between Prodigy basic and Prodigy 
enhanced fat mass measurements (0.437, P = 0.275).  
Figure 3.3 and Table 3.9 show that iDXA limits of agreement with 4-C (-4.78, 2.63) are narrower 
compared to Prodigy in basic mode (-5.56, 2.12) which in turn are narrower than Prodigy 
enhanced mode (-6.17, 1.86). 
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Table 3.9. Comparison of different measurement techniques against the four component 
model. 
Model vs 4-C Mean difference 
 ± SD 
RMS SD LSC CI Lower CI Upper LOA 
iDXA -0.9 ± 1.8 1.5 4.0 -3.4 to -1.9 3.8 to 5.3 -4.8 to 2.6 
Prodigy Basic -1.7 ± 2.0 2.1 5.8 -2.9 to -1.3 4.7 to 6.4 -5.6 to 2.1 
Prodigy Enhanced -2.2 ± 2.1 1.8 5.1 -2.7 to -1.0 5.3 to 7.0 -6.2 to 1.9 
4-C; four-component model, SD; Standard deviation, RMS SD; Root mean square standard 
deviation, LSC; Least significant change, CI; Confidence Intervals, LOA; Limits of agreement.   
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3.7. Discussion 
The aim of this study was two-fold: firstly, to determine the precision and accuracy of 
the GE Lunar iDXA and secondly, to determine if cross-calibration equations are necessary to 
relate data from the GE Lunar Prodigy to the iDXA densitometers.  The difference between 
software versions for the Prodigy were also investigated.  
When introducing a new DXA instrument the ISCD recommend that a cross-calibration 
of at least 30 participants, representative of the facility’s patient population, should be 
performed. Participants should be scanned twice on the new system and once on the old, on 
those anatomical sites most commonly measured [4].  We compared the iDXA and Prodigy 
densitometers for regional and whole body bone mineral density, bone mineral content and 
bone area and, reflecting our interest in body composition, for lean and fat mass. Where cross-
calibration equations were deemed necessary they were derived using linear regression.  
3.7.1. iDXA Precision 
Precision of the iDXA was assessed by %CV of repeated bone and body composition 
measurements. We found excellent precision in whole body and regional bone density with 
all values below 2 %. This was also observed for whole body and regional body composition 
measurements with the exception of arm fat mass, which had a lower precision of 2.28%. 
Our findings support previously published literature which has reported similar 
precision data for whole body and regional bone density and body composition using iDXA [2 
3 11 12]. Additionally, both Rothney et al [11] and Kaminsky et al [12] support our findings of 
a lower precision in arm fat mass (2.8% and 4.2% Rothney and Kaminsky respectively).  The 
larger precision error may be due to re-positioning of the participants or the inclusion of breast 
tissue in the arm region of interest in some re-scans therefore offering the potential for larger 
errors [13]. To test this theory we separated arm fat by gender to determine whether breast 
tissue may have had an impact, but we found no significant differences in the precision of arm 
fat mass between genders.  
Compared to the iDXA, previously published reports from its predecessor, the Prodigy 
have demonstrated similar precision for bone density with precisions reported below 2% by 
Oldroyd et al [14] and Krueger et al [15]. However, when exploring body composition, both 
Oldroyd et al and Bilsborough et al [16] reported whole body fat mass precision values of 2.5% 
for Prodigy.  This is a much lower precision than that of 0.9% for the iDXA in the current study.  
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These comparisons suggest that the precision of iDXA when measuring bone density 
remains similar to the Prodigy.  However, there appears to be a worthwhile improvement in 
precision in whole body and regional fat mass. This may be due to the improvement in soft 
tissue assessment as a result of enhanced bone edge detection technology [17]. 
3.7.2. iDXA vs Prodigy 
When scan analysis was carried out using the same software version, significant 
differences between iDXA and Prodigy were identified in all regions of bone mass, area and 
density except for the femoral hip BMD and lumbar spine (L2-L4) BA, with Prodigy over-
reading all values with the exception of hip area. This has been similarly observed in other 
studies [18-20] with Hull et al [19] reporting significantly higher mean BMC values in the 
Prodigy than the iDXA in both males and females (males; 3.11 kg vs. 3.06 kg, Prodigy vs. iDXA 
respectively and females; 2.37 kg vs. 2.31 kg, Prodigy vs. iDXA respectively). Rhodes et al [20] 
also found Prodigy BMC values were significantly higher compared to the iDXA in all regions 
of bone mass (BMC, 2842 g vs. 2651 g, Prodigy vs. iDXA respectively).  Furthermore, Morrison 
et al [21] compared iDXA to Prodigy and found significant differences in whole body and 
regional bone density (mean whole body; 1.25 g/cm2 vs. 1.22 g/cm2, Prodigy vs. iDXA 
respectively). Prodigy basic comparisons to iDXA also displayed significant differences in 
whole body bone measurements, however hip and spine measurements were identical to hip 
and spine measurements analysed using Prodigy Enhanced mode. This suggests that any 
changes in software algorithms were not applied to regional bone analysis, only whole body 
bone measurements.  
When investigating body composition, we also observed significant differences 
between iDXA and both Prodigy basic and enhanced, with Prodigy tending to over-read fat 
mass and under-read lean mass relative to iDXA. The only study we found in the literature to 
make a similar comparison was that of Morrison et al [21] who reported that only leg lean 
mass and arm soft tissue measurements were significantly different between instruments (leg 
lean mass mean difference (kg); 0.586, arm fat mass; -0.109, arm lean mass; -0.228). 
The significant differences observed between the two DXA instruments warranted the 
development of cross-calibration regression equations. The differences and those observed 
across the published literature highlight the importance of generating instrument specific 
cross-calibration equations when undergoing a system upgrade. It is also important that the 
cross-calibration equations are relevant to the population under investigation as 
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demonstrated by the apparent outliers at the top end of the fat mass range. A possible 
limitation of the comparison of iDXA and Prodigy lies in the calculation of the mean of two 
iDXA measurements. This may lead to an unfair comparison against Prodigy due to a lower 
random error compared to a single measurement.  
3.7.3. DXA accuracy 
The accuracy of our DXA fat mass measurements was evaluated by comparing fat mass 
estimated by DXA to that derived from a four-component (4-C) model. The 4-C model, as well 
as whole body MRI, are recognised standards in body composition measurements as they 
account for inter-individual variability in total body water and bone mineral mass [22-24]. Our 
results demonstrated good correlation between iDXA and 4-C derived fat mass (r = 0.994) but 
a proportional bias between the two fat mass estimates was evident. The disadvantage of 
fixed and proportional bias is that the bias is driven by the measured variable, in this case fat 
mass, either by a constant amount or a proportional amount and therefore difficult to account 
for. To our knowledge there is no literature that discusses the accuracy of either iDXA or 
Prodigy fat mass measurement using the 4-C model. However, previous literature has 
reported significant differences between fat mass (%) measured by various DXA models 
(QDR2000, QDR2000W, DPX/L, and Lunar) and the 4-C model [25]. When comparing Prodigy 
and the 4-C model, Williams et al [25] found significant differences in fat mass (1.35, 1.21 and 
1.58 kg in non-obese men, women and obese women, respectively). They also reported that 
the fat mass bias was positively associated with BMI. Although it appears that the accuracy of 
DXA has improved over the years, a systematic bias still remains between the iDXA and the 4-
C model. 
The differences identified between the two methods could have several origins. DXA 
assumes that the hydration value for fat-free mass remains constant [26], however this may 
not be true for participants across a range of masses. Participant mass itself may inflict a bias 
in soft tissue estimation because of the influence of tissue depth on bone edge detection by 
DXA, therefore as subject mass increases, so may the error in detecting soft tissue. Although 
4-C is considered a reference measure against other methods there is still concern that errors 
arising from the individual methods may amalgamate to a large error in the final fat mass 
estimate. However, Fuller et al found a measurement error of less than 1% for fat and fat free 
mass derived from 4-C. 
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Comparisons between GE software versions (Basic and Enhanced) for Prodigy and a 4-
C model have not been investigated before. There are many publications that demonstrate 
the transitions between instruments, but few that detail the differences when upgrading 
software versions. In the final part of this study we investigated the differences in whole body 
fat mass measurements between basic and enhanced software versions on the Prodigy and 
compared this to the iDXA and 4-C model. 
Prodigy basic analysis mode compared to 4-C demonstrated a good agreement over a 
wide range of fat masses. However, in the highest fat masses the agreement was less good, 
consistent with previous studies [25 27 28]. As referred to earlier, Williams et al [25] reported 
the largest difference between 4-C and Prodigy (Encore 2002) in obese women (mean bias 
1.58 kg) and Wells et al [27] (Software version not stated), reported that Prodigy significantly 
over-estimated FM compared to 4-C by 0.9 kg with the greatest variability being observed at 
the highest fat masses.  
In summary, the latest DXA instrument from GE, the iDXA, comes with new hardware 
in the form of a more powerful X-ray tube, enhanced image resolution and therefore better 
bone edge detection. Furthermore the latest software, Encore version 15 & 16, comes with 
developed soft tissue algorithms. The enhancement in technology has led to an improvement 
in the accuracy and precision of iDXA compared to its predecessor Prodigy demonstrated by 
smaller differences between repeated iDXA measurements and compared to 4-C 
measurements in fat mass. However this means that differences exist between the iDXA and 
Prodigy instruments and therefore cross-calibration equations are essential if comparisons 
between instruments are unavoidable. Even with these improvements, accuracy issues 
remain at the highest fat masses, reinforcing the importance of deriving cross-calibration 
equations that are relevant to the population under investigation and also that further 
comparative studies are warranted in an obese population. 
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4. An approach to quantifying abnormalities in energy expenditure and lean mass in 
metabolic disease.  
Watson LPE, Raymond-Barker P, Moran C, Schoenmakers N, Mitchell C, Bluck L, Chatterjee 
VK, Savage D, and Murgatroyd PR. An approach to quantifying abnormalities in energy 
expenditure and lean mass in metabolic disease. Eur J Clin Nutr 2013, 1 – 7. 
4.1 Abstract 
Background: Our objective is to develop approaches to expressing resting energy 
expenditure (REE) and lean body (LM) mass phenotypes of metabolic disorders in terms of Z 
scores relative to their predicted healthy values. 
Methods: Body composition and REE were measured in 135 healthy participants. Prediction 
equations for LM and REE were obtained from linear regression and the range of normality 
by the standard deviation of residuals. Application is demonstrated in patients from three 
metabolic disorder groups (Lipodystrophy  n = 7, Thyrotoxicosis n = 16, and Resistance to 
Thyroid Hormone (RTH)β n = 46, RTHα n = 5) in which altered REE and/or LM were 
characterized by departure from the predicted healthy values, expressed as a Z-score. 
Results: REE (kJ/min) = Prediction equations were derived for REE and LM. For REE the most 
significant contributing variables were age, fat mass (FM) and fat-free mass (FFM): 
-0.010 x age (y) + 0.016 x FM (kg) + 0.054 x FFM (kg) + 1.736 (R2 =0.732, RSD = 0.36 kJ/min). 
For LM, gender specific equations were derived. The most significant contributing varables 
were bone mineral content (BMC) and height2 in the males and FM and height2 in the 
females: LM (kg) = 5.30 x BMC (kg) + 10.66 x Height² (m) + 6.40 (Male), LM (kg) = 0.20 x FM 
(kg) + 14.08 x Height² (m) – 2.93 (Female) (Male R2 = 0.55, RSD = 3.90kg; Female R2 = 0.59, 
RSD = 3.85kg).  
We found average Z scores for REE and LM of 1.77 and -0.17 in the RTHβ group, -2.25 for 
REE and 2.10 for LM in RTHα, 5.82 and -1.23 in the thyrotoxic group and 2.97 and 4.20 in the 
LD group. 
Conclusion: This approach enables comparison of data from individuals with metabolic 
disorders with those of healthy individuals, describing their departure from the healthy 
mean by a Z score. 
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4.2. Introduction 
Many metabolic disorders such as thyroid disease or lipodystrophy are associated with 
changes in body composition, energy expenditure or both [1 2]. In describing the 
phenotypes of such conditions it is often desirable to describe the extent to which body 
composition or energy metabolism deviates from that of healthy individuals, but this is not 
always straight forward. Comparisons against standard predictions of energy expenditure [3-
5] may be compromised by atypical body composition, while comparisons based on body 
composition proxies such as body mass index (BMI) may not reveal unusual relationships 
between fat and lean masses. 
Commonly used predictions of resting energy expenditure (REE) may be troublesome due 
to their dependence on age and gender as well as body mass and height [6]. Their piecewise-
linear nature can lead to substantial differences between predicted REE just above and 
below the intersection of adjacent regression ranges. The use of fat free mass (FFM = lean 
mass (LM) + bone mineral content (BMC) in kg) as a predictor of REE is more accurate and is 
widely accepted [6] and, when allowed an intercept, is disassociated from gender 
differences in body composition. 
Against this background, we have set out an approach to characterise REE and LM in 
metabolic disorders by reference to measurements in a metabolically healthy cohort. It 
utilises the accurate and precise measurements of body composition which are now widely 
available using dual-energy x-ray absorptiometry (DXA) [7-16]. The key to our approach is 
the quantification of the difference between measurements and predictions by the 
assignment of a Z score applied to patients with metabolic disorders. This allows us to 
quantify the probability of whether an individual data point observed lies within a healthy or 
metabolic disordered cohort, therefore allowing the discussion of whether a disorder 
presents with altered REE or body composition phenotype, or indeed both.  
Three conditions (Resistance to thyroid hormone (RTHα and RTHβ), Thyrotoxicosis, and 
lipodystrophy (LD)) in which abnormal energy expenditure and lean body mass have been 
previously documented provide ideal examples to illustrate our method. RTH is a rare 
autosomal dominant genetic condition as a result of mutation in either the thyroid receptor 
TRα or TRβ which are encoded on the genes THRA and THRB [17 18]. TRα is most abundant 
in the central nervous system, myocardium and skeletal muscle. TRβ is largely expressed in 
  
68 
 
the liver and kidney. Mutations in these receptors lead to two different conditions, RTHα 
and RTHβ. RTHβ, a dominantly inherited disorder, with an incidence of 1 in 40,000 [19 20], 
characterised by elevated circulating thyroid hormones (TH) together with central 
(hypothalamo-pituitary) and variable peripheral tissue refractoriness to thyroid hormone 
action [21]. RTHα cases are much rarer with only 14 cases identified to date. The condition is 
characterised by hypothyroid tissue responses to near normal thyroid function and 
circulating TH levels [18]. The characteristics of the disorder are relatively consistent across 
patients.  
Thyrotoxicosis (or hyperthyroidism) is due to excess TH secretion from the thyroid gland. 
Most commonly (50-80% of cases), thyrotoxicosis is caused by Grave’s disease which affects 
~0.5% of the population [22], and is due to autoantibodies causing excess TH production by 
stimulating the TSH receptor in the thyroid gland [23].  
Lipodystrophy can be either genetic or acquired [24] and is characterised by reduced 
adipocyte storage capacity and loss of adipose tissue with significantly increased lean body 
mass, contributing to metabolic complications such as insulin resistance and diabetes 
mellitus [25]. We have extensive data in these disorders, which are of particular interest to 
us, and so have invoked them here for demonstration, though we believe our approach is 
more generally applicable. 
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4.3. Methods 
4.3.1. Participants 
Healthy volunteers were recruited by local advertisement in the East Anglian region of the 
UK. We recruited 135 male and female non-smokers, aged between 17 and 65 years who 
had no known medical conditions, were not taking any medications or supplements likely to 
influence energy expenditure or body composition and who did not normally exercise for 
over an hour a day. Volunteers were from different ethnic backgrounds (126 Caucasian, 2 
Black, 6 Asian, and 1 Hispanic). All participants provided written, informed consent.  
Volunteers from the metabolic disorder groups (LD n = 7, thyrotoxicosis n = 16, RTHα = 5 
and RTHβ n = 46) were recruited following referral to Addenbrooke’s hospital and provided 
written informed consent to participation in their studies. Participants were non-smoking, 
not on any beta-blockers or anti-arrhythmic treatment and had no current or past history of 
eating disorder. Thyrotoxic patients were identified based on thyroid function tests 
suggestive of thyroxicosis (serum TSH < 0.03mU/L, free T4 >22.5pmol/L) and had Graves’ 
disease, as evidenced by elevated anti-TSH receptor antibody titres. Details on the 
recruitment of the lipodystrophic participants have been previously documented [26]. The 
lipodystrophic patients varied on genotype and extent of lipodystrophy. Three patients had 
partial lipodystrophy with C131Y, FS/PPP and R482W LMNA genotypes, and four patients 
had total lipodystrophy with R482L LMNA, AGPAT2, R482W LMNA and AGL genotypes.  
Healthy participants and metabolically disordered participants were asked to refrain from 
strenuous physical activity, alcohol and caffeine for 24 hours prior to their visit. Each 
participant arrived at the NIHR/Wellcome Trust Clinical Research Facility (CRF) in Cambridge 
at 14:00 on day 0 and remained until 12:00 on day 1. After informed consent and medical 
examination on day 0, height, weight and body composition were measured. Body 
composition (fat mass, lean mass and bone mineral density) was assessed by dual energy x-
ray absorptiometry (DXA; GE Lunar Prodigy GE Healthcare, Madison, WI, software version 
12.2).  At 18:00 a standardised dinner was served.  The energy content of the meal was 1/3 
of a participant’s daily requirements estimated from predicted resting metabolic rate [3] 
multiplied by an activity factor of 1.35 [27]. Meal composition was 30-35% fat, 12-15% 
protein, and 50-55% carbohydrate by energy. The participant retired to bed at 23:00 and 
  
70 
 
was woken the next morning at 07:00. REE was measured between 07:00 and 08:00 by 
ventilated canopy respiratory gas exchange (GEM, GEMNutrition, Daresbury, UK). 
Measurements were recorded at 30s intervals over 20min. The lipodystrophy participants 
REE was measured by indirect room calorimetry for 60min and has been previously 
described [26]. All participants were asked to remain awake and still, without any 
interactions, for the duration of the measurement. Energy expenditure was calculated from 
the macronutrient respiratory quotients and energy equivalents of oxygen published by Elia 
and Livesey [28].  Following the REE measurement fasting blood samples were taken for 
renal and liver function tests, plasma glucose and thyroid function (free T3, T4 and TSH). 
Urinary metanephrines were also measured.  
To determine least significant change (LSC) in REE measurement, three repeated 
measurements were performed on eight participants giving an LSC of 0.5kJ/min. For LSC in 
lean mass, previously reported values of 1.13kg [29] for Prodigy were used. 
Body composition and REE measurements were performed in all healthy and 
metabolically disordered volunteers and are summarised in Table 4.1 - 4.4. 
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Table 4.1. Characteristics of metabolically healthy participants 
Variable Female N = 88 Male N = 47 
 Mean ± SD Range Mean ± SD Range 
Age (years) 34.8 ± 12.0 19.1-62.5 36.6 ± 12.9 17.4-62.2 
Height (m) 1.65 ± 0.07 1.52-1.88 1.79 ± 0.7 1.62-1.92 
Weight (kg) 66.4 ± 14.6 43.9-119.6 78.1 ± 10.9 56.6-102.8 
BMI (kg/m²) 24.2 ± 4.6 17.6-38.6 24.3 ± 2.8 18.7-31.5 
FM (kg) 22.8 ± 10.4 7.9-61.5 17.0 ± 8.2 3.9-38.4 
LM (kg) 40.3 ± 5.7 28.6-55.6 57.5 ± 5.9 43.7-68.1 
FFM (kg) 42.8 ± 6.0 30.5-57.8 60.7 ± 6.2 46.5-71.9 
Fat % 33.4 ± 8.5 15.6-52.6 21.1 ± 8.3 6.1-37.7 
BMC (kg) 2.5 ± 0.4 1.5-3.6 3.2 ± 0.4 2.3-4.1 
REE (kJ/min) 4.1 ± 0.5 3.0-5.8 5.0 ±0.6 3.6-6.4 
TSH mU/l (0.4-4.0) 1.6 ± 0.7 0.4-4.0 1.5 ± 0.6 0.5-3.1 
Free T4 pmol/l (9.0 – 20.0) 13.0 ± 1.8 9.3-16.9 13.8 ±1.6 10.9-17.3 
Free T3 pmol/l (3.0 – 7.5) 5.3 ± 0.6 4.0-7.3 5.8 ± 0.6 4.1-6.9 
Plasma Glucose mmol/l 4.5 ± 0.4 3.7 – 6.2 4.7 ± 0.5 3.9 – 5.8 
FM, fat mass, LM, Lean Mass, FFM, Fat-free mass, BMC, Bone mineral content, REE, Resting 
Energy Expenditure. Population reference range for Free T3 (3.0 – 7.5 pmol/l, Free T4 9.0-
20.0 pmol/l, TSH 0.40-4.0 mU/l). 
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Table 4.2. Characteristics of RTHα group 
 RTHα (n = 5) 
Variable 
Female (n =2) 
(Mean) and range 
Male (n = 3) 
(Mean) and range 
Age (years) (53.6) 45.9 to 61.4 (24.8) 17.1 to 30.8 
Height (m) (1.53) 1.48 to 1.58 (1.81) 1.76 to 1.86 
Weight (kg) (82.2) 72.2 to 92.2  (93.4) 72.2 to 85.3 
BMI (kg/m²) (35.6) 29.1 to 42.2 (28.7) 25.3 to 33.3 
FM (kg) (31.0) 24.4 to 37.7 (24.7) 15.8 to 31.3 
%FM (37.8) 34.0 to 41.6 (26.5) 18.3 to 31.6 
LM (kg) (47.7) 45.2 to 50.2 (64.4) 55.7 to 70.4 
FFM (kg) (50.1) 47.3 to 52.9 (67.8) 58.3 to 74.3 
BMC (kg) (2.4) 2.1 to 2.7 (3.4) 2.6 to 3.8 
REE (kJ/min) (3.5) 3.4 to 3.5 (4.8) 4.4 to 5.2 
TSH mU/L (0.4 – 4.0) (4.9) 4.3 to 5.4 (3.6) 2.9 to 4.4 
Free T4 pmol/l (9.0 – 
20.0) 
(8.6) 8.3 to 8.8 (9.2) 9.0 to 9.3 
Free T3 pmol/l (3.0 – 7.5) (5.6) 5.2 to 6.0 (7.4) 6.8 to 8.0 
Plasma glucose mmol/l (4.6) 4.5 to 4.6 (4.2) 4.1 to 4.3 
FM, fat mass, LM, Lean Mass, FFM, Fat-free mass, BMC, Bone mineral content, REE, Resting 
Energy Expenditure. 
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Table 4.3 Characteristics of the RTHβ and Thyrotoxic groups 
 RTHβ (n = 46) Thyrotoxicosis (n=16) 
Variable 
Female (n =34) 
Mean ± SD 
Male (n = 12) 
Mean ± SD 
Female (n = 10) 
Mean ± SD 
Male (n = 6) 
   Mean ± SD 
Age (years) 39.4 ± 13.6 38.1 ± 16.8 45.8 ± 14.2 40.7 ± 14.4 
Height (m) 1.61 ± 0.1 1.74 ±0.1 1.63 ± 0.1 1.76 ± 0.1 
Weight (kg) 71.7 ± 14.4 72.8 ± 10.4 64.5 ± 9.4 74.1 ± 18.8 
BMI (kg/m²) 27.6 ± 5.1 24.1 ± 3.8 24.2 ± 3.4 23.81 ± 3.6 
FM (kg) 29.7 ± 10.0 18.2 ± 8.2 26.4 ± 7.6 20.9 ± 10.6 
LM (kg) 38.6 ± 5.2 51.7 ± 4.8 35.6 ± 5.7 50.6 ± 9.6 
FFM (kg) 40.9 ± 5.5 54.1 ± 5.1 38.1 ± 5.8 53.1 ± 10.1 
BMC (kg) 2.3 ± 0.4 2.4 ± 0.5 2.5 ± 0.3 3.0 ± 0.6 
REE (kJ/min) 4.6 ± 0.7 5.2 ± 0.6 5.5 ± 0.9 7.2 ± 1.4 
TSH mU/L (0.4-4.0) 3.8 ± 3.4 2.2 ± 0.7 0.03 ± 0.0 0.4 ± 0.9 
Free T4 pmol/l (9.0-20.0) 35.1 ± 13.1 29.5 ± 5.1 43.3 ± 19.6 32.4 ± 25.5 
Free T3 pmol/l (3.0-7.5) 12.7 ± 4.3 10.5 ± 1.6 24.3 ± 11.3 22.4 ± 11.1 
Plasma glucose mmol/l 5.0 ± 0.5 4.7 ± 0.8 4.9 ± 0.4 5.5 ± 0.3 
FM, fat mass, LM, Lean Mass, FFM, Fat-free mass, BMC, Bone mineral content, REE, Resting 
Energy Expenditure. 
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Table 4.4. Characteristics of the Lipodystrophy group 
Variable 
Female (n = 5) 
Mean ± SD 
Male (n = 2) 
(Mean) and range 
Age (years) 48.8 ± 13.2 (34.2) 17.6 to 50.8 
Height (m) 1.64 ± 0.05 (1.75) 1.65 to 1.84 
Weight (kg) 66.2 ± 6.9 (78.8) 69.7 to 88.0 
BMI (kg/m²) 24.5± 2.4 (25.8) 25.6 to 26.0 
FM (kg) 9.3 ± 6.8 (5.6) 3.5 to 7.6 
%Fat 13.6 ± 9.2 (6.8) 5.0 to 8.6 
LM (kg) 54.2 ± 6.2 (70.0) 62.6 to 77.5 
FFM (kg) 56.9 ± 6.0 (73.3) 66.1 to 80.4 
BMC (kg) 2.7 ± 0.6 (3.2) 2.9 to 5.3 
REE (kJ/min) 5.6 ± 0.7 (6.3) 5.7 to 6.9 
TSH mU/L (0.4-4.0) 0.7 ± 0.4 (1.2) 1.1 to 1.3 
Plasma Glucose mmol/l 6.9 ± 4.5 (10.4) 8.1 to 10.3 
FM, fat mass, LM, Lean Mass, FFM, Fat-free mass, BMC, Bone mineral content, REE, Resting 
Energy Expenditure. Free T4 and Free T3 measures were not available to report in the 
Lipodystrophy group. 
4.3.2. Ethics 
The study received a favourable opinion from the Cambridge Central East of England 
Research Ethics Committee and was funded by and conducted in the NIHR/Wellcome Trust 
Clinical Research Facility (WTCRF; Cambridge, UK).  
4.3.3. Statistical analysis 
Multiple correlation analyses were undertaken using SPSS19 (SPSS Inc., Chicago, IL, USA) to 
identify variables or combinations of variables that correlate (P < 0.05) to REE and DXA-
measured total body LM. 
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Once the correlating variables were established, forward stepwise multiple linear 
regression analysis was performed to relate REE (kJ/min) to FFM (kg), FM (kg) and age in all 
subjects and to relate LM to FM and height for females and LM to height and bone mineral 
content in males. 
A statistical K-fold cross-validation approach was then undertaken to test the reliability of 
both the models. The dataset was randomly numbered and split into test datasets and a 
validation dataset. For the REE validation the analysis was repeated eight times making sure 
each data point was tested and validated to establish whether the same variables 
significantly contributed to the prediction of REE, then the standard deviations of the 
residuals (the individual differences between predicted and measured values) were 
compared.  For LM cross validation the analysis was repeated five times and was also tested 
on an additional dataset of 19 females and 18 males. 
Residuals were derived for each contributing data point and normality was confirmed for 
the set of all residuals using Shapiro-Wilk test for normality.  This allowed the distributions of 
residuals to be described by their standard deviations, the magnitudes of which were taken 
as a measure of the precision of the prediction. Furthermore each experimental data point 
could be defined in terms of the number of standard deviations from the predicted value (Z-
score). When investigating the disease groups, REE or LM was predicted as though belonging 
to the healthy cohort, and an associated Z-score used as a measure of the deviation from the 
healthy norm.  
Although we have not assigned an absolute threshold for defining whether an individual 
data point is outside of the healthy range, if the Z-score for the patient is 1, then it suggests 
there is a 32% probability that the observation belongs in the healthy cohort.  If the Z-score 
is 2, then the probability falls to 5%, making it 95% likely that the observation is associated 
with a disordered group mean.    
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4.4. Results 
4.4.1. Resting energy expenditure 
 
To establish the appropriate variables to include in the prediction of REE we examined the 
literature and subsequently explored correlations of REE with age, gender, height², bone 
mass, FFM and FM.  
Analysis of variance was carried out to test the effect of ethnicity (white, black and Asian) 
on REE and LM, and showed that in this group of volunteers there was no effect of ethnicity 
on REE or LM (REE, F = 0.286, LM, F = 0.921). Stepwise multiple regression analysis was 
carried out to establish which correlates contributed significantly to the prediction of REE 
and LM. Those that did not contribute were excluded (Table 4.5). 
Table 4.5. Multiple correlations of measured REE (kJ/min) and LM (kg), with demographic 
measurements. (n = 135, males = 47 and females = 88) 
Variable Age Gender Height² FM FFM Bone 
REE 
kJ/min 
Coefficient 
Sig 
-0.133 
0.123 
-0.620 
0.000 
0.675 
0.000 
0.207 
0.016 
0.813 
0.000 
0.740 
0.000 
LM 
kg 
Coefficient 
Sig 
0.004 
0.961 
-0.819 
0.000 
0.845 
0.000 
-0.012 
0.890 
1.000 
0.000 
0.805 
0.000 
REE, Resting Energy Expenditure, LM, Lean Mass. 
The variables that contributed the least to the prediction of REE were gender (R2 = 0.004), 
height² (R2= 0.005), and bone mass (R2 = 0.002). With these removed, age continued to 
contribute to the overall prediction leaving FM (R2 = 0.043), FFM (R2 = 0.660) and age (R2 = 
0.018) in the regression (R2 = 0.732). The resulting expression derived from the 135 healthy 
participants is, 
REE (kJ/min) = -0.010 (age) + 0.016 (FM kg) + 0.054 (FFM kg) + 1.736. 
 
(Model R2 =0.732) 
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4.4.2. REE regression validation 
The regression expression for REE above has been subject to K-fold validation.  The source 
data was randomised into 8 groups and regressions repeatedly derived from 7x17 and 1x16 
subjects and tested in the remaining group.  The coefficients of variation for the resulting 8 
estimates of each regression coefficient were:  Age 7.3%, FM 12.1%, FFM 2.9%, and Constant 
4.9%.  The SD of residuals in the test group for the eight regressions ranged from 0.27 to 
0.49 kJ/min, compared to 0.36 kJ/min for the whole data set. 
4.4.3. Lean mass 
The least significant coefficient, age (P > 0.05) was taken out of the analysis first. Once 
this had been removed fat and height² were highly significant contributors in females but 
height² alone was significant in males. Bone mass was a significant contributor to LM in 
males when it replaced FM but this was not the case in females. Therefore the two gender 
specific regression equations for the prediction of LM are as follows: 
Male LM (kg) (n = 47)   = 5.30 * Bone mass (kg) + 10.66 * Height² (m) + 6.40 
Female LM (kg) (n = 88)  = 0.20 * Fat (kg) + 14.08 * Height² (m) -2.94 
The standard deviations of residuals for these two regressions are respectively 3.90 and 
3.85kg. The Model R2 for males is 0.55, and females is 0.59. 
 
  
78 
 
4.4.4. Lean Mass regression validation 
As with the REE validation process, the male and female lean mass regressions have 
undergone K-Fold validation, randomised into 5 groups and the analysis repeated 5 times. 
The female results indicated the SD of residuals ranged from 3.0 to 4.26kg compared to 3.85 
kg from the whole dataset. The male results indicated a range of 2.38kg to 4.83kg compared 
to 3.90kg from the whole dataset. The data was also tested in independent male and female 
data sets drawn from the entire control group of another study and its ongoing successor (n 
= 18 males and 19 females). For the male group, the mean residual in the test group is -
1.49kg with SD 3.91kg.  The offset of the male mean from zero is predominantly due to a 
single outlier whose residual was double that of any other subject, yet is not significantly 
different from zero.  For the female group the mean residual is 0.15kg (ns) with SD 2.2kg. 
4.4.5. Representation of data: Z Scores. 
4.4.5.1. Resting Energy Expenditure 
To represent the normative data, the residuals of measured REE - predicted REE were 
plotted with corresponding Z-scores (Figure 4.1). 
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Figure 4.1. Measured – predicted REE (kJ/min) in healthy controls with 2 SD. 
 
LM, the strongest predictive variable, is used to separate the data points. To assess the 
utility of this approach in disorder states known to be associated with altered body 
composition and resting metabolic rate, we characterised patients with RTHα, RTHβ, 
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thyrotoxicosis and LD [1 30]. Figure 4.2 presents measured REE and LM data from patients 
with metabolic disorders alongside the healthy volunteer data, demonstrating significant 
differences between health and the disorder states with the exception of RTHα. After 
adjusting measured REE by measured lean mass alone, removes the significant difference 
between the LD patients and the control group but reinstates a significant difference in the 
RTHα group.  
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Figure 4.2. Differences in measured REE between metabolic disorders and the healthy cohort 
and after adjusting REE by LM. * = P < 0.05. 
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 presents  the differences in REE between metabolic disorders and healthy controls, taking 
into account fat, FFM and age in the prediction of REE. Residuals of measured – predicted 
REE were plotted with corresponding Z scores. RTHβ, LD and thyrotoxic metabolic disease 
groups manifest significantly elevated REE (mean Z RTHβ: 1.77, LD: 2.97), compared to 
controls, with the thyrotoxicosis group having the highest REE values with a mean Z score of 
5.8 and a range from 1.5 – 9.6. RTHα on the other hand demonstrated low REE with a mean 
Z score of -2.25 which was not significantly different from controls.  
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4.4.5.2. Lean Mass 
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Figure 4.3. Measured and predicted LM in males and females as measured by DXA presented 
with 1 and 2 SD. 
Figure 4.3 shows the variability in LM within the metabolically healthy males and 
females demonstrated by presenting the residuals of the difference between measured and 
predicted LM together with Z-scores. Height was used to separate the points. 
 
Figure 4.4 illustrates the difference in measured LM measurements between 
metabolic disorders and healthy controls and after adjustment by height2. After adjustment 
for height2 alone the RTHβ was no longer significantly different from the healthy controls, 
however significant differences remain between other metabolic cohorts, specifically LD and 
RTHα, and the healthy controls.  
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Figure 4.4. Difference in measured lean mass and after adjustment by height2 between 
metabolic disorders and healthy controls. * = P < 0.05. 
 
T
h
y
ro
to
x
ic
o
s
is L
D
R
T
H

C
o
n
tr
o
ls
R
T
H

-4 0
-2 0
0
2 0
4 0
4
2
-2
-4
-6
6
8
-8
L
e
a
n
 m
a
s
s
 (
k
g
)
m
e
a
s
u
r
e
d
 -
 p
r
e
d
ic
t
e
d
w
it
h
 m
e
a
n
 ±
 1
 S
E
M
Z
 S
c
o
r
e
10
-10
* *
 
Figure 4.5. Differences between measured and predicted LM (residuals) in metabolic 
disorders and the healthy cohort with corresponding Z scores. * = P < 0.05. 
 
Figure 4.5 demonstrates the differences between measured and predicted LM, taking 
into account height2 and bone mass in males and height2 and fat mass in the females, 
compared to the healthy cohort (mean Z Thyrotoxic: -1.23, RTHα: 2.10 and RTHβ: -0.17). The 
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Thyrotoxic and Lipodystrophy demonstrated significantly different results from the controls, 
whereas the RTH groups did not. The lipodystrophy data (mean Z: 4.20) illustrates the 
substantial excess of lean tissue present in this disorder even after adjustment for height 
and body composition differences.  
LM and REE Z-scores may be plotted orthogonally, where they combine to offer a 
succinct insight into the phenotypes of metabolic disorders.  
Figure 4.7 illustrates the relationship between changes in REE and LM in metabolic 
disorders compared to the healthy group. The lipodystrophic group are characterised by 
elevated LM and elevated REE with Z scores ranging from 2.2 - 7.3 Z for LM and 1.4 – 4.8 Z 
for REE. The thyrotoxicosis group also manifest elevated REE (1.5 – 9.6 Z) but, in contrast to 
the lipodystrophy group, have reduced LM (mean Z = -1.2). RTHα is characterised by low REE 
(mean Z, -2.3) and high lean mass (mean Z, 2.1), in contrast to the RTHβ cohort with elevated 
REE and slightly reduced lean mass (mean REE Z = 1.77 and -0.17 for LM). 
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Figure 4.6. Combination of LM and REE Z Scores to illustrate the contribution to metabolic 
disorders. The circle indicates a Z score of +/- 2 for REE and LM. REE, resting energy 
expenditure, LM, lean mass. 
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Figure 4.8 illustrates REE and LM Z scores throughout treatment of an individual 
RTHα patient. REE Z score was typically low before treatment (pre) with a Z score of -3.4 (a 
residual of -1.2 kJ/min) improving through treatment to a Z score of -1.4 (a residual of -0.5 
kJ/min) but dropping again at the later stages of treatment to -1.9 (a residual of -0.7 kJ/min, 
corresponding to a LSC < 0.5 kJ/min). Lean mass Z scores replicate the changes in REE Z 
scores throughout treatment. Lean mass Z commenced pre-treatment at 3.8 (a residual of 
14.7 kg) reducing to 2.1 (a residual of 8.3 kg, corresponding to a LSC > 1.13 kg) with 
treatment towards the end of visit 6.  
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Figure 4.7. Example of the use of the Z score approach to illustrate changes in metabolic 
parameters in a female RTHα patient at baseline (Pre) and serial visits (1-6) when on 
thyroxine therapy, in comparison to age and gender-matched controls. REE: 1 Z score = 0.36 
kJ/min, LM: 1 Z score = 3.85 kg.  
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4.5. Discussion 
 The aim of this work was to develop approaches to describe metabolic phenotypes in 
terms of the distribution of REE and LM in metabolically healthy people. The novelty of our 
approach lies in the way in which metabolic and body composition data is represented. 
Subtracting a predicted value from measured values produces a residual; and dividing this by 
the standard deviation of residuals in a healthy cohort, we can assign a Z-score. Z-scores are 
commonly used in the analysis of bone densitometry [31] and on growth charts in order to 
highlight individuals whose results deviate from the population average [32]. Here, we 
commend the use of Z scores to highlight individuals and groups of patients with abnormal 
metabolic rates and/or abnormal LM. 
4.5.1. Body composition measurements 
 The body composition measurements on which this paper relies were undertaken by DXA.  
This is a widely-available technique which is able to provide quick and well-tolerated 
estimates of body composition supported by reports of good accuracy and precision [7].  
However, it is important consider whether any disorder to which our proposed methodology 
is applied might generate a bias in the DXA measurements relative to the healthy 
population.  The work of Williams et al [33] offers valuable context for this consideration.  In 
the case of our example disorder groups we do not believe bias in DXA estimates to have 
been a concern.  Body composition data in our most extreme phenotype, lipodystrophy, was 
corroborated by Air Displacement Plethysmography measurements [34]. 
4.5.2. Resting Energy Expenditure  
 The results from the REE multiple regression analysis in this study demonstrate a model 
that predicts REE accurately and with good precision in healthy individuals. The variables 
which contribute to our predictive equation are FFM, FM and age. These have previously 
been documented as appropriate covariates [6 35-37]. FFM is recognised as the main 
predictor of the inter-individual variability in resting energy expenditure. The relationship 
between FFM and REE differs between men and women when constrained through the 
origin, as is implicit when REE is expressed per unit FFM. However in preparing this work, we 
have confirmed that when an intercept is allowed, men and women tend to fall on the same 
regression line. Moreover, the relationship between REE and FFM is strengthened and 
therefore allows one regression equation for both genders. There is, however, conflicting 
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literature regarding the contribution of FM to energy expenditure. In a review, Cunningham 
[6] suggested that FM contributes to energy expenditure in women, but mostly in obese 
women. Our study found that FM explained 4.0% of the variance in energy expenditure and 
when the analysis was broken down by gender there was no significant difference in the 
variance explained by FM between males and females, even though we had a greater 
number of females in the cohort. The most commonly used predictive equations for 
estimating energy expenditure in a clinical setting are Schofield and Henry [3 5]. They 
include simple measurements such as height and weight, age and gender, regardless of 
literature that disputes their accuracy and precision, especially when applied to individuals 
outside the original datasets [38 39]. Weijs, et al. [40] performed a meta-analysis of common 
REE prediction equations on 48-outpatients and 45-inpatients with conditions including 
anorexia, overweight, thyroid disease and inflammatory bowel disease, all of which have 
body compositions and energy expenditures differing from healthy controls [41-45]. They 
saw errors ranging from 975 to 1782 kJ/d, with at most only 40% of inpatients having an 
accurately predicted REE when compared to measured REE. Johnstone, et al. [46] 
demonstrated an average increase in accuracy of 32.9% (240kJ/d) when including body 
composition (FFM and FM) and anthropometric measurements (skinfold thickness and 
circumference) compared with the Schofield equation [3]. 
 FFM and FM may explain between 60-85% of the variance in REE [6], leaving at least 15% 
unaccounted for. Our results demonstrated that FFM and FM combined account for 70%, 
leaving 30% unexplained. Age, gender, ethnicity and physical activity have been reported to 
contribute to this variance [36]. In our study we found a significant but small contribution of 
age to the prediction of REE (2%). Nielsen [35] investigated whether adjusting FFM for 
extracellular fluid would improve the prediction of REE, but found that this was not the case. 
Johnstone et al, [47] investigated the influence of FFM, FM, age, thyroxine (T4), 
triiodothyronine (T3) and leptin levels on REE. They concluded that REE was not influenced 
by age, gender, leptin or T3, although in men 25% of the variance was associated with 
circulating T4 levels. 
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4.5.3. Lean Mass 
 Predictions of FFM or LM are less frequently documented. Previous publications 
predicting LM have used bioelectrical impedance and skin fold thickness with DXA acting as 
the reference measurement [48]. The variables chosen for the LM prediction equation in the 
current study were height2 and FM for the female group and height2 and bone mass for the 
male group. The presence of height2 in the equation reflects the fat and fat free mass index 
concept [49 50], which recognises a relationship between body composition and in body size 
and offers the prospect of discrimination between health and individuals with abnormal fat 
or fat free mass for their size. 
4.5.4. Cross-validation 
 To test our prediction equations we performed an observational analysis of the 
coefficients from published studies that have also used FM, FFM and age as variables for 
prediction of REE (Table 4.6).  
Table 4.6. Previously published multiple regression coefficients compared with this current 
equation. 
Regression Intercept FFM FM Age 
Cambridge   n = 135 1.736 0.054 0.016 -0.010 
Nielson (f)   n = 153 
            (m)   n = 100 
2.582 (f) 
2.076 (m) 
0.047 (f) 
0.045(m) 
0.023 (f) 
0.023(m)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
-0.014 (f) 
 -0.015 (m) 
Horie            n =120  1.629 0.041 - - 
Nelson          n = 213 - 0.075 0.012 - 
Cunningham n =213 1.076 0.063 - - 
 
 Table 4.6 suggests that our coefficients for FFM, FM and age are similar to those 
previously published [6 35 51-53]. Of this published work, only Nielson’s [35] used DXA for 
composition measurement; Horrie used bio-impedance [52] while Nelson [51] and 
Cunningham’s [6] papers were based on data previously published by others. When applied 
to the current dataset, the Nielsen equations produced a residual SD of 0.37 compared to 
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0.36 produced by our equation. In the light of this sparsity of robust comparative data we 
performed a K-fold cross-validation analysis on REE and LM models to test their reliability. 
Comparison of means and standard deviations of residuals in these test groups with those of 
the training groups suggest that the regressions may be applied beyond the training group 
with some confidence, though we accept that testing in a larger group would increase this 
confidence. We would encourage readers who would like to apply our approaches to derive 
and publish prediction regressions from their own reference cohorts until such time as the 
published coefficients have converged to a closer consensus than we have presented in 
Table 4.6 – perhaps when published predictions agree to within 1 pooled SD of their 
residuals. 
4.5.5 Application examples 
 4.5.5.1. Thyroid disorders 
 Thyroid conditions such as thyrotoxicosis and Resistance to Thyroid Hormone (RTH) result 
in altered body composition and energy expenditure. Mitchell et al [43] showed that REE is 
raised in RTHβ and markedly elevated in thyrotoxic patients. In both conditions there was a 
higher fat to lean mass ratio compared with the healthy controls, though the data suggest 
that in thyroid disorders the dominant abnormality lies in REE rather than body composition. 
Our results from the lean mass regression equation suggest that the thyrotoxic group have a 
slightly reduced LM (Z = -1.23), whereas the RTHβ group have normal LM (Z = -0.17) despite 
the increased REE.  
 The RTHα patient displayed a contrasting disassociation in body composition and energy 
expenditure compared to RTHβ and Thyrotoxicosis. The RTHα subject demonstrated lower 
REE, as described by Moran et al [18 54 55] and increased lean mass.  
Our results confirm that REE is higher in a cohort of RTHβ participants and lower in RTHα 
participants compared to healthy controls; however in patients with thyrotoxicosis, the 
magnitude of elevation in REE is more substantial. In RTHβ, predominant expression of 
defective TRβ in the hypothalamus and pituitary mediates resistance to hormone action 
within the pituitary-thyroid feedback axis, resulting in elevated levels of circulating free 
thyroxine (T4) and triiodothyronine (T3) with normal or increased levels of TSH [17]. Energy 
expenditure is raised since some peripheral tissues (e.g. myocardium, skeletal muscle) which 
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express normal TRα, retain sensitivity to elevated levels of TH [43]. In RTHα, defective TRα 
expressed in the central nervous system, myocardium and skeletal muscle, inhibits the 
capability of TRα to respond normally to T3.  Such refractoriness to TH actions induces a 
hypothyroid state in these tissues and low REE response, despite the elevated lean mass. In 
contrast, both beta and alpha receptor-mediated signalling is intact in conventional 
thyrotoxicosis, with preserved responsiveness of tissues to elevated TH, resulting in much 
more markedly increased energy expenditure, despite a reduction in lean body mass [56].   
4.5.5.2. Lipodystrophy 
 Lipodystrophic subjects are characterised by an elevated REE and LM [26]. Importantly, 
this is not simply a result of a relative reduction in fat mass, which is present in all of these 
patients, but appears to be a true increase in lean mass. Organomegaly and 
pseudoacromegaly are features of lipodystrophy (particularly the generalised form) [24], so 
the increased lean mass probably reflects contributions from several tissues. In healthy men 
organ tissue will have some contribution to the estimation of lean mass although it has a 
relatively small mass of approximately 4.4 kg whereas skeletal muscle mass (approx. 32 kg in 
an average male weighing 84.6 kg) [57] is almost certainly the largest contributing tissue. We 
show a mean residual increase of lean mass of 16 kg (Z score > 4) relative to our healthy 
cohort suggesting an increase in lean mass over an above that expected through organ 
contribution.  
 When measured REE was presented per kg of LM there was no significant difference 
between REE in lipodystrophics and healthy controls. Savage et al [26] also investigated the 
increase in REE in the lipodystrophic participants and concluded that the increase in lean 
mass in lipodystrophy patients accounted for their elevated REE. However we have 
demonstrated through our Z score approach that this picture changes when other variables 
that influence REE in a healthy cohort, such as fat mass and age are also accounted for in 
Lipodystrophy. We have found an elevation in REE with a Z score averaging 2 (range 1.4 – 4.8 
kJ/min) relative to our healthy controls (Figure 4.3).  As our prediction of REE takes into 
account the influence of measured FFM, our Z-scores for REE and LM are effectively 
independent. In doing so, it suggests that there may be a component of the elevation in REE 
in lipodystrophy beyond that which is associated with FFM alone.  
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 As mentioned in the methods, the lipodystrophic participants had REE measured by room 
calorimetry rather than the ventilated canopy measurement. In the light of this, we 
investigated the difference between measurements made using the canopy compared to 
room calorimetry, on a separate cohort. The results indicated a difference of 0.20 kJ/min 
between the two methods suggesting that even after accounting for this difference in 
measurement the lipodystrophic participants would still display an REE Z-score greater than 
2 (mean Z score  = 2.98).  
 A limitation of the prediction of lean mass in women is that within the prediction equation 
fat mass contributes towards the explanation of variance in lean mass. It cannot therefore 
be distinguished whether the difference between measured and predicted lean mass is soley 
due to high lean mass but rather may also be due to low fat mass. Further investigations into 
the prediction of lean mass is warranted.  
 In summary, we offer expressions for REE and LM in health based on FM, FFM, bone 
mineral content, age and height2 measurements. Measurements from individuals with 
uncommon metabolic disorders were examined in the context of data from healthy subjects 
and differences to be expressed as a Z-score. This facilitates the representation and 
differentiation of disease phenotypes. This approach may also aid in the characterisation and 
potentially evaluation of the treatment in such individuals. Further validation of our 
regressions on a separate cohort of healthy individuals is desirable, but we believe the Z-
score approach to metabolic phenotype description will prove valuable and illuminating in 
these and other metabolic disorders. 
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5. An approach to quantifying abnormalities in energy expenditure in paediatric metabolic 
disease. 
5.1. Abstract 
Background. The objective of this study was to develop an approach to describing and 
predicting resting energy expenditure (REE) in a healthy paediatric population in terms of body 
composition. The predictions were then applied to paediatric Thyroid Hormone (TH) disease 
patients to explore departures of measured REE from expectations. 
Methods. Body composition was measured by dual energy X-ray absorptiometry and REE was 
assessed by indirect calorimetry in 107 female and 94 male healthy children and adolescents. 
Prediction equations for REE were derived from the body composition measurements by 
multiple linear regression. Individual Z scores were calculated as the difference between 
measured and predicted REE divided by the standard deviation of the regression residuals 
between measured and predicted REE. The clinical application was demonstrated in 
Resistance to Thyroid Hormone due to mutations in either thyroid hormone receptor β or α 
(β female n= 17, male n= 8, α female n=1, male n=1) in which their deviation of REE from the 
healthy population is expressed as a Z score. 
Results. Prediction equations were derived based on the total cohort; LnREE (kJ/min) = 0.006 
* Fat mass (kg) + 0.012 * Lean mass (kg) – 0.069 * gender (m = 0, f = 1) + 1.006 (R2 = 0.754, SD 
= 0.38 kJ/min), male LnREE = 0.009 * Fat mass (kg) + 0.012 * Lean mass (kg) + 0.991 (R2 = 0.800, 
SD of residuals = 0.38 kJ/min), female LnREE = 0.015 * Lean mass (kg) + 0.931 (R2 = 0.638, SD 
= 0.38 kJ/min). Average REE Z scores based on exponentiated deltas were for male RTHβ = -
0.15 ± 0.84 and female RTHβ = 0.15 ± 1.42. In RTHα, male Z = -0.82 and female Z = -2.16. 
Conclusion. This approach describes the differences between individual patients or groups of 
patients with metabolic disorders to be quantified against a healthy cohort by the simplicity 
of a Z score. This has the potential to facilitate clinical findings throughout a treatment 
process.   
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5.2. Introduction 
Predicting resting energy expenditure (REE) has become a more efficient method of 
assessing nutritional requirements for participants or patients without access to the expertise 
and facilities to accurately measure it. The most common published equations used in a 
paediatric setting are Schofield et al [1], Henry [2], Harris and Benedict [3] and Molnar et al 
[4]. These equations are based on characteristics such as age, gender, height and weight and 
are derived from large, often pooled, diverse cohorts [5 6]. As children grow, the proportions 
of fat and lean mass do not increase at the same rate due to the variability in body composition 
by age, pubertal and gender [7] and therefore the use of mass as a whole when predicting REE 
in children may not result in the most accurate predictions of REE. Many studies have reported 
on the inaccuracies of current REE prediction equations based on traditional height and weight 
measurements across a variety of ages, ethnicities and disease populations [8-12]. The most 
recent published equations based on body composition measurements relevant to healthy 
child age ranges include Muller et al (2004) [5] which consists of coefficients from fat-free 
mass (FFM), fat mass and gender and explains 72% of the variance. However, the population 
is based on data pooled from separate German databases collected over a period of 18 years 
and may not be appropriate for other geographical populations or disease groups. 
REE accounts for around 65 -75% of total daily energy expenditure in most sedentary 
individuals and in adults REE is mostly dependent on the amount of fat-free mass or lean mass 
within the body [13]. In the past there have been discrepancies in estimate of the contribution 
of other variables such as fat mass, gender and age on REE [14]. However, recent publications 
support the concept that fat mass does make a contribution to REE, albeit smaller than lean 
mass [15 16].  
In children, the amount of fat, lean and organ mass increase with growth and puberty 
however the timing of growth and puberty differs substantially within age groups [17]. For this 
reason, puberty should be adequately controlled for when investigating body composition in 
pre and pubertal children, however this does not come without difficulty. Assessing the onset 
of puberty in children has its own limitations. None of the usual methods used to acquire such 
information can accurately pinpoint the onset of puberty and therefore it is often estimated 
or general age ranges are used. 
Puberty is controlled by the hypothalamic pituitary gonadal axis (HPG). During 
childhood gonadotropin-releasing hormone (GnRH) secretion, released from the 
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hypothalamus, is supressed to low concentrations. At the onset of puberty Gonadotropin-
releasing hormone (GnRH) secretion is enhanced and released in a pulsatile manner which 
signals the secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from 
the pituitary. The secretion of LH and FSH act on the gonads to promote the production of sex 
steroids and the development of secondary sex characteristics and menstruation in females 
[18 19].  
Typically in girls puberty usually occurs between the ages of 8-12 y and in boys 
between 9-14y. The first physical sign of puberty in girls is thelarche or age of menarche in 
girls and testicular development in boys, which are often self-reported using validated 
questionnaires [20 21] or by physical assessment by paediatricians. However, the accuracy of 
self-reported techniques are inconclusive [22-24] and physical examination may not be 
appropriate for research in healthy individuals. Therefore, assessing the biochemical markers 
of puberty such as LH and FSH may provide sufficient information of pubertal status without 
the inaccuracies and invasiveness of the alternative methods. 
Metabolic disorders are often associated with altered body composition [15]. In adults, 
metabolic conditions such as thyrotoxicosis, Resistance to Thyroid Hormone (RTH) and 
lipodystrophy (LD) have previously been shown to differ in both body composition and energy 
expenditure [15], [25-28], compared to healthy controls (Chapter 4). In children, these 
conditions are rarely identified, mainly due to lack of early diagnosis. 
RTHβ is a genetic disorder due to the mutations in the thyroid hormone receptor β 
gene, caused by reduced tissue responsiveness to thyroid hormone and its clinical markers 
are typically elevated serum free TH levels with non-supressed TSH levels (Ferrera 2012). The 
characteristics of RTHβ are highly heterogeneous with the majority of individuals being 
asymptomatic in a compensated euthyroid state. Others may demonstrate hyperthyroid 
symptoms including hyperactivity, weight loss and tachycardia. The large unpredictability of 
the manifestations makes management of the disorder in childhood difficult [29]. 
TRα mutations causing RTHα are rare, with 19 patients from 14 families having been 
reported worldwide, 7 of which were children. The symptoms of RTHα are generally more 
severe due to a hypothyroid state in TRα expressing tissues. Characteristics include 
development delay throughout infancy and childhood, learning disabilities and growth 
retardation [30 31], typical features of uncorrected childhood hypothyroidism.  
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Once diagnosed, thyroxine therapy can alleviate some of the symptoms and promote 
normal growth and development in RTHα. Conversely, in RTHβ, treatment with 
triiodothyroacetic acid (TRIAC)m a TH analogue which acts centrally to reduce hormone levels 
but is relatively devoid of thyromimetic effects in peripheral tissues, is used to lower heart 
rate and promote weight gain. Biochemical changes are monitored frequently throughout 
treatment, however, monitoring whole body consequences of the treatment, in relation to 
body composition and energy expenditure, in RTH children compared to healthy controls, has 
not yet been explored. 
The aim of this research is to firstly predict energy expenditure in healthy children aged 
6-16 years. By adjusting energy expenditure measurements by body composition the second 
aim is to describe healthy and disordered energy expenditure by the application of a Z score 
by applying the healthy prediction equations to a cohort of RTH patients.   
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5.3. Methods 
5.3.1. Participants 
Two hundred and one healthy male and female children aged between 6 and 16years 
old (107 females, mean age 11.2 ± 3.0; n = 27 age 6-8, n = 37 age 9-11, n = 29 age 12-14 and n 
= 14 age 15-16, and 94 males, mean age 12.1 ± 3.2; n = 18 age 6-8, n = 29 age 9-11, n = 22 age 
12-14 and n = 25 age 15-16), free from disease and medications took part in the study. After 
reading the relevant information leaflets and having the study fully explained the children 
then assented and parents consented to taking part in the study. The children were recruited 
locally through advertisements and radio and approval was granted by the Cambridge South 
ethics committee.  
5.3.2. Body composition 
On arrival and after the consent process, the children underwent some basic 
observations consisting of blood pressure, temperature and ECG to screen them for any initial 
abnormalities. Height was measured on a stadiometer and recorded to the nearest millimetre 
(SECA electronic stadiometer) and weight was measured on electronic scales to the nearest 
gram (Kern & Sohn GmbH, Germany).  
The participants also a whole body dual energy X-ray absorptiometry (DXA) 
assessment for bone density and body composition (fat mass and lean mass) (GE Lunar Prodigy 
and iDXA, analysed in version 16, enhanced mode).  
During the early phase of the study, the DXA machine at the facility where the 
measurements were performed underwent an instrument upgrade resulting in seventeen 
children having DXA scans using an older DXA instrument, the GE Lunar Prodigy. The rest of 
the cohort had measurements performed on a newer GE Lunar iDXA. To combine the data 
from the Lunar Prodigy with the iDXA data, 71 participants of the original 201 cohort and 24 
participants of a separate study underwent repeated whole-body bone and soft tissue 
composition measurement on each instrument. Cross-calibration equations were derived and 
applied to the Prodigy data. All data was analysed using Encore software version 16 in 
enhanced analysis mode. The additional twenty-four children were consented under a second 
paediatric study (NRES, 13/EE/0233). 
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5.3.3. Energy Expenditure 
The participants stayed overnight at the clinical research facility (CRF), Cambridge. 
They were fed an energy balanced meal based on the Schofield predictions for energy intake 
at their usual dinner time. Usual bedtimes and waking times were also discussed for each 
participant and adhered to.  
Resting energy expenditure (REE) was measured by indirect calorimetry using a 
ventilated hood 30 min after waking. The participants were asked to remain still and awake 
with no interactions for 40 min. The calorimeter was calibrated prior to the measurement 
using 1% CO2 and 78.1% nitrogen. Gas measurements of the room were measured for the first 
10 min as this will be different from the calibration concentrations, then the ventilated hood 
measurement of the participant followed for 20min with a further 10 min of room gas analysis 
at the end of the measurement to account for any offsets. The gas measurements were then 
converted into energy equivalents using calculations by Elia and Livesey [32].  
5.3.4. Pubertal assessment 
For females the onset of menstruation was recorded if applicable. Immediately 
following the morning REE measurement the participants gave a blood sample for various 
metabolic biomarkers, including Luteinising Hormone (LH) and Follicle Stimulating Hormone 
(FSH), a precursor of the gonadArche stage of the pubertal process.  
5.3.5. Statistical analysis 
To begin with the cross-calibration equations were derived so that converted body 
composition data could be used in the REE regression analysis. The differences between 
Prodigy and iDXA instruments were determined by paired t test and Bland-Altman plots were 
used to determine the agreement between the instruments. Linear regression was then 
performed to derive equations for converting Prodigy data to iDXA data for the variables that 
displayed a significant difference. The level of significance was determined at P < 0.05. 
Spearmans correlation determined which variables were significantly related to each 
other and REE. Appropriate variables were then added to a stepwise multiple regression 
analysis to establish how variables contributed towards the prediction of REE. Preliminary 
descriptive investigations into the relationship of REE and the other variables demonstrated a 
skewness in variability with increasing mass and for this reason REE was logged prior to 
entering the regression models and then anti-logged before undergoing Bland-Altman 
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analysis. The difference between measured and predicted REE is described as the residual. 
When an individual residual is divided by the standard deviation of all the gender-specific 
residuals this represents a cohort Z score. SPSS statistical software (version 22) was used for 
descriptive statistics, correlations and regression analysis. GraphPad Prism Version 6 was used 
to generate figures and Bland-Altman analyses.  
5.4. Results 
5.4.1. Cross-calibration of DXA data 
Descriptive statistics of the 95 participants involved in the cross-calibration of the 
Prodigy data to iDXA data are presented in table 5.1. 
Table 5.1 Descriptive statistics of the iDXA-Prodigy cross-calibration analysis 
 Females (n= 50)  Males (n = 45)  
N = 95 (F=50, 
M=45) 
Mean ± SD 
(median) 
Range Mean ± SD 
(median) 
Range 
Age (years) 10.1 ± 2.6 (10.0) 6.0 – 16.0 10.8 ± 2.8 (9.0) 6.0 – 16.0 
Height (m) 1.44 ± 15.7 1.15 – 1.77 1.49 ± 19.0 1.02 – 1.87 
Mass (DXA, kg) 37.9 ± 12.2 23.8 – 61.5 40.1 ± 15.1 16.2 – 79.9 
BMI (kg/m2) 17.6 ± 2.6 13.8 – 24.7 17.4 ± 3.0 14.0 – 29.1 
Fat mass (DXA, kg) 10.5 ± 4.7 4.6 – 23.9 8.9 ± 4.5 2.6 – 26.9 
DXA, dual energy X-ray Absorptiometry, BMI; body mass index. 
Table 5.2 presents the differences between iDXA and Prodigy whole-body 
measurements. All the variables were significantly correlated. However there were significant 
differences between all variables measured on iDXA and Prodigy with the exception of whole-
body bone mineral content (BMC) (mean difference -0.01 ± 0.03, P = 0.07).  
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Table 5.2. Differences between iDXA and Prodigy whole-body bone and soft tissue 
measurements. 
 iDXA Prodigy Difference Sig 
BMC (kg) 1.50 ± 0.60 1.51 ± 0.59 -0.01 ± 0.03 0.067 
BA cm2 1.66 ± 0.35 1.64 ± 0.34 0.03 ± 0.04* 0.000 
BMD (g/cm2) 0.88 ± 0.16 0.89 ± 0.16 -0.02 ± 0.02* 0.000 
Fat mass (kg) 9.7± 4.7 10.4 ± 4.7 -0.65 ± 0.48* 0.000 
Lean mass (kg) 27.7 ± 9.8 26.7 ± 9.6 0.94 ± 0.50* 0.000 
Total mass (kg) 38.9 ± 13.6 38.6 ± 13.5 0.29 ± 0.34* 0.000 
Bone mineral content; BMC, bone area; BA, bone mineral density; BMD, *P < 0.05 
With this in mind, it was therefore appropriate to develop cross-calibration equations 
to translate the Prodigy DXA measurements to iDXA estimates. Cross-calibration equations 
are presented in Table 5.3.  
Table 5.3. Cross-calibration equations for the translation of Prodigy measurements to iDXA 
measurements. 
 Slope CI Intercept CI 
Prodigy BMC (kg)  1.01 1.00 – 1.02 -0.02 -0.04 - -0.01 
Prodigy BA (cm2)  1.03 1.00 – 1.06 -0.02 -0.07 – 0.02 
Prodigy BMD (g/cm2)  1.00 0.97 – 1.02 -0.01 -0.04 – 0.01 
Prodigy Fat (kg)  0.98 0.96 – 1.00 -0.43 -0.66 - -0.20 
Prodigy Lean (kg)  1.02 1.01 – 1.03 0.34 0.06 – 0.61 
Prodigy Total mass (kg)   1.01 1.00 – 1.01 0.10 -0.10 – 0.31 
Bone mineral content; BMC, bone area; BA, bone mineral density; BMD 
5.4.2. Description of REE in healthy children by regression analysis. 
Descriptive statistics for the regression cohort are presented in Table 5.4. There were 
significant differences between the genders in height, age, DXA fat, lean and bone, and REE 
but not in weight (equal variances not assumed).  
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Table 5.4. Descriptive statistics for 201 children included in the multiple regression analysis 
for the prediction of REE. 
 Females n = 107 Males n = 94 
 Mean ± SD Range Mean ± SD Range 
Height (m) 1.47 ± 0.17 1.11 – 1.77 1.54 ± 0.20 1.12 – 1.88 
Weight (kg) 41.3 ± 13.7 18.2 – 84.4 45.5 ± 15.7 20.0 – 78.6 
BMI (kg/m2) 18.6 ± 3.1 9.9 – 29.2 18.5 ± 2.7 13.9 – 29.1 
Age (years) 11.2 ± 3.0 6.2 – 16.97 12.1 ± 3.2 6.1 – 17.01 
DXA Fat mass (kg) 12.3 ± 5.6 4.3 – 32.7 10.3 ± 4.4 3.3 – 26.9 
DXA Lean mass (kg) 27.8 ± 8.8 13.0 – 49.3 33.6 ± 12.7 16.1 – 62.4 
DXA Bone mass (kg) 1.55 ± 0.54 0.70 – 2.95 1.81 ± 0.72 0.81 – 3.43 
REE (kJ/min) 3.91 ± 0.63 2.43 – 5.38 4.49 ± 0.87 2.97 – 6.96 
BMI; body mass index, REE; resting energy expenditure, ± SD; standard deviation, DXA; dual 
energy X-ray absorptiometry. 
Correlation analysis demonstrated that all of the chosen variables were significantly 
correlated to REE (Table 5.5). Weight, DXA mass and BMI were excluded from the analysis as 
they were considered duplicates of other variables such as height, bone, fat and lean mass. 
Table 5.5 illustrates the variables to be inserted into the regression model. 
Table 5.5. Correlation coefficients and significance of REE with potential contributing variables 
  Height 
(m) 
Age 
(years) 
DXA mass 
(kg) 
Bone mass 
(kg) 
Fat mass 
(kg) 
Lean mass 
(kg) 
FFM  
(kg) 
REE kJ/min 0.824 0.736 0.844 0.830 0.511 0.866 0.865 
Sig 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Correlation coefficient; R, P < 0.05, REE; resting energy expenditure, DXA; dual energy X-ray 
absorptiometry, FFM; fat-free mass.  
  
The first step was to investigate the variables that contribute towards the prediction 
of REE in the entire dataset. Figure 5.1 supports this notion by demonstrating a similar 
relationship between REE and LM in males and females.  
106 
 
To present the skewed data so that is appears normally distributed, REE values were 
logged prior to entering all the regression models. The variables in Table 5.5 were entered into 
a stepwise multiple regression model. This resulted in three models of significant variables; 
lean mass, lean mass and gender and lean mass, gender and fat mass (Table 5.6). 
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Figure 5.1. Comparison of male and female lean mass linear regression with REE. Linear 
regression lines have been extended for visualisation purposes. 
Lean and fat mass were entered into the regression model without gender, out of 
curiosity, (model 2) and the same was done for total mass (model 3).   
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Table 5.6. Regression coefficients for the prediction of REE in 201 male (male = 0) and female 
(female = 1) healthy controls.  
Model Variables LnSlope ± SE 95% CI R2 
Model 1 Lean mass (kg) 0.012 ± 0.001 0.011 – 0.014 0.754 
 Gender (kg) -0.069 ± 0.015 -0.098 – -0.040  
 Fat mass (kg) 0.006 ± 0.002 0.003 – 0.009  
 Intercept (kJ/min) 1.006 ± 0.023 0.961 – 1.052  
Model 2 Lean mass (kg) 0.014 ± 0.001 0.012 – 0.015 0.728 
 Fat mass (kg) 0.003 ± 0.002 0.000 – 0.006  
 Intercept 0.957 ± 0.022 0.915 – 1.000  
Model 3 Total mass (kg) 0.011 ± 0.000 0.010 – 0.012 0.693 
 Intercept 0.953 ± 0.023 0.907 – 0.998  
Ln, loge, SE, standard error, CI, confident intervals, R2 adjusted R2 representing the fit of the 
model. 
Gender presented as the second highest significant coefficient, following lean mass, in 
model 1 of the stepwise regression (Table 5.6). This justifies exploring the analysis separately 
by gender. Age did not significantly contribute towards the prediction of REE and was 
therefore excluded by stepwise regression. Figure 5.2 illustrates gender based differences 
between body composition variables, fat and lean mass.  
 
Figure 5.2. Illustration of the relationship fat and lean mass present with resting energy 
expenditure in males and females. Linear regression lines have been extended for visualisation 
purposes. 
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Stepwise multiple regression for the female group demonstrated that only lean mass 
remained a contributing variables towards the prediction of REE (model 4, Table 5.7). For the 
males DXA mass explained the most amount of variance in REE (model 7), however, as 
demonstrated in Figure 5.2, the fat and lean components of body mass demonstrate different 
relationships with REE  between the genders and therefore lean, fat and bone mass 
contributions were explored separately, excluding DXA mass from the analysis. The resulting 
regression analysis for the males produced two models, model 8 containing only DXA lean 
mass and model 9 containing both DXA lean and fat mass. Out of interest, fat and lean mass 
were entered into the female regression (model 5) and DXA mass was entered (model 6), 
however, it made little difference to the regression output. As with the genders combined, 
age was removed during stepwise regression as its contribution remained insignificant.   
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Table 5.7. Stepwise regression coefficients for the prediction of REE in females and males. 
 Model Variable  LnSlope ± SE  LnIntercept ± SE R2 
Females 4 Lean mass 0.015 ± 0.001 0.931 ± 0.032 0.638 
      
 5 Lean mass 0.014 ± 0.002 0.932 ± 0.032 0.639 
  Fat mass 0.003 ± 0.002   
      
 6 DXA mass 0.009 ± 0.001 0.961 ± 0.032 0.611 
      
Males 7 DXA mass 0.011 ± 0.001 0.988 ± 0.027 0.801 
      
 8 Lean mass 0.013 ± 0.001 1.041 ± 0.027 0.764 
      
 9 Lean mass 0.012 ± 0.001 0.991 ± 0.028 0.800 
  Fat mass 0.009 ± 0.002   
Ln, loge, SE, standard error, R2 adjusted R2 representing the fit of the model, DXA, dual energy 
X-ray absorptiometry.  
5.4.3. Prediction of REE in healthy children 
The coefficients of the variables from model 1 in Table 5.6 were applied to the whole 
dataset. The resulting predictions were then exponentiated and the difference between 
measured and predicted REE, residuals, were calculated as 0.06 kJ/min and the standard 
deviation of that difference was 0.38 kJ/min (Z score). 
The regression coefficients from models 4 and 9 were then applied separately to the 
male and female datasets as gender was found to be a significant contributor to the prediction 
of REE. The predictions were also exponentiated and the difference between measured and 
predicted REE was calculated. For the males the mean and standard deviation of the residuals 
was 0.00 and 0.38 kJ/min. For the females, the mean and standard deviation of the residuals 
were 0.04 and 0.38 kJ/min. The range of Z scores for females were -2.04 to 2.70 and males 
were -2.28 to 3.34. Atypical Z scores in this cohort can therefore be defined as greater than -
2.0 and 2.0.   
The variations between the measured REE and the predicted models in the whole 
dataset and separately by gender are presented by Bland-Altman plots in Figure 5.3. For all 
the models, the prediction of REE was significantly correlated to measured REE (combined R; 
0.873, males; 0.910 and females, 0.822).  
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Figure 5.3. The variation between measured and predicted REE based on reversed lnREE 
models derived on the entire dataset, the males or females only. 
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5.4.4. Pubertal contributions 
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Figure 5.4. The relationship between body composition (fat and lean mass (a) and percent 
body fat (b)) and age in males and females. 
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Figure 5.5. The relationship between age and REE in males and females using non-linear 
quadratic polynomial regression. 
Figures 5.4 and 5.5 illustrate the relationship that both body composition and age have 
with REE. With increasing age, the rate of change between age, lean and fat mass differs with 
gender (Figure 5.4). Fat and lean mass values increase with growth (a), although percent fat 
in the males decreases with age (b). In REE (Figure 5.5), the relationship in the males is similar 
to that of body composition, however in the females the relationship becomes non-linear at 
around 12-14 years, suggesting a pubertal effect on REE, rather than age alone.  
One hundred and twenty four of the original cohort (64 males and 60 females) 
provided blood samples for the assessment of pubertal contribution, by LH and FSH, towards 
the prediction of REE. The cohort was first studied without separating by gender and then 
gender was studied separately as with the regression analysis above. LH and FSH was 
significantly correlated to REE in both males and females. However, in the stepwise regression, 
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LH and FSH failed to add any contribution to the prediction of REE when the cohort was 
studied as a whole and separately by gender. Lean mass remained the most significant 
contributor in the whole cohort (R2 0.740), with DXA mass leading as the most significant in 
the males (R2, 0.835) and height in the females (R2, 0.562).  
5.4.5. Clinical Application  
 
Table 5.9. Characteristics of RTHβ n = 25 and RTHα n =2 patients. 
 RTHβ RTHα 
 Female n=17 Male n=8 Female n=1 Male n=1 
Age 10.6 ± 3.8 10.7 ± 2.9 5.8 15.5 
TSH 3.4 ± 1.07 3.3 ± 1.07 1.04 2.07 
FT4  46.1 ± 30.2 51.7 ± 30.2 5.7 8.4  
FT3 17.8 ± 7.67 19.1 ± 7.67 6.9 9.1 
Total mass (kg) 39.8 ± 21.9 27.5 ± 8.7 22.7 49.2 
Fat mass (kg) 13.6 ± 12.5 3.7 ± 2.8 4.6 8.4 
Lean mass (kg) 24.8 ± 9.4 22.7 ± 6.6 17.5 39.1 
REE kJ/min 3.86 ± 1.06 3.62 ± 0.55 2.40 3.98 
Mean ± standard deviation, RTH; resistance to thyroid hormone, TSH; thyroid stimulating 
hormone, REE; resting energy expenditure. Normal reference ranges are based on age and 
range from 9.01 - 22.7 for FT4 and 2.63 – 7.6 for FT3.  
Table 5.9 demonstrates the characteristics of the RTH patient groups and Figure 5.6 
illustrates the raw REE measurements between groups. In this form RTHβ present on average 
a lower REE compared to controls and RTHα demonstrating the lowest REE value, however 
statistically these were not significantly different from the controls. 
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Figure 5.6. Differences between measured REE between controls and disease groups. Solid 
line represents the mean REE in control group (4.185 kJ/min). 
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Figure 5.7. Differences between measured REE adjusted for lean mass between control and 
disease groups. Control mean presented by solid line (0.15 kJ/min/kg). *P < 0.05. 
When REE is simply adjusted for lean mass (Figure 5.7), the RTHβ group now display a 
significantly increased REE compared to the controls and increased compared to the RTHα 
groups. Within the RTHα group the male now exhibits much lower REE compared to the 
female.  
When the gender specific linear regression equations (models 4 and 9) which adjust 
for lean mass in the females but lean and fat mass in the males, were applied to patients with 
known metabolic disorders prior to treatment it is possible to see yet another difference 
between the healthy controls and the patient groups. 
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Figure 5.8 illustrates RTHβ and RTHα against gender matched healthy controls. The 
male and female RTHβ group display similar differences in measured and predicted REE. There 
was no statistical difference in REE between the male and female RTHβ patients and the 
healthy controls  (males; mean difference, -0.06 ± 0.32 kJ/min, Z score -0.15 ± 0.84, females; 
mean difference 0.08 kJ/min ± 0.63, Z score 0.20 ± 1.65). The RTHα patients displayed a lower 
energy expenditure for both the male and the female participants (female difference -0.90 
kJ/min Z score -2.00, male difference -0.31 kJ/min, Z score -0.81) but due to the sample size 
statistical significance could not be determined.  
Figure 5.9 demonstrates the multiple regression method being utilised in tracking 
changes in REE in an RTHα patient with thyroxine treatment against age and gender matched 
controls. Z scores are presented alongside the differences between measured and predicted 
REE. The Z score is determined by applying the SD of the difference in healthy male (0.38) and 
female (0.38) controls to the difference in measured and predicted REE in disordered 
metabolism. Figure 5.9 illustrates the change in REE with thyroxine treatment in a male RTHα 
patient. At pre-treatment at the age of 15 REE was lower than the age and gender matched 
control group (mean difference -0.31 kJ/min, Z score, -0.81) returning to normal at the age of 
16 (Z score, -0.03) showing lowest metabolic rate at 17 years (Z score, -0.51) compared to their 
pre-treatment Z score. Figure 5.9 also shows the serial measurement in a female RTHα patient 
starting at the age of 5, prior to treatment. REE, at baseline, is at the lowest range of the 
healthy controls (Z score, -2.37). As thyroxine treatment progresses, REE rises with values at 
ages of 7 and 8 being closest to the mean of the healthy controls (Z score, -0.23 and -0.75 
respectively), then declining at age of 8 (Z score, -1.50) and rising again following increases in 
thyroxine dosage, at the age of 10 (Z Score, -0.74). 
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Figure 5.8. Representation of disordered metabolism in males and females against healthy 
controls. The residuals of measured and predicted REE have been plotted with the right y-axis 
corresponding to a Z score. 
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Figure 5.9. Illustration of individual RTHα patients resting energy expenditure response to 
treatment over the years in comparison to an age and gender matched healthy control group. 
REE residuals are plotted (left axis) with the right y-axis demonstrating the corresponding Z 
score. 
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5.5. Discussion 
The aim of this study was to first describe resting energy expenditure (REE) in healthy 
children and adolescents. Predictions of REE were then developed in healthy children based 
on body composition measurements and then applied to paediatric cohorts and individuals 
with disordered metabolism to describe their differences in energy expenditure and body 
compositions compared to a healthy cohort. The novelty of the concept lies in the derivation 
and application of a Z score by subtracting a predicted value from a measured value, giving a 
residual, and dividing this by the standard deviation of residuals in the healthy comparable 
cohort in which the prediction equation was derived. This has previously been demonstrated 
in an adult population (chapter 4), but its application to a paediatric population in REE has not 
yet been explored. 
Frequently in research where data collection spans many years an institution may face 
an instrument upgrade or replacement with a newer model. During the time course of this 
research the DXA scanner used for the measurement of body composition (GE Lunar Prodigy) 
was replaced with a newer model (GE Lunar iDXA) which had undergone significant 
improvements both in its technical specifications and the subsequent precision of data 
acquisition [33] (Chapter 3). Testing the precision and accuracy is recommended when 
replacing a system with either an upgrade of the same model or a different model [34]. 
Furthermore, if there are significant differences between the instruments then cross-
calibration equations relevant to the population being studied should be derived and applied 
to the existing data so that all the data within a cohort is comparable [34]. 
In the current study, significant differences were found between the two instruments 
in whole body bone masses and body composition therefore cross-calibration equations were 
derived. Before the research question could be addressed, the derived equations were applied 
to all Prodigy data in both the healthy cohort and patient cohort so that it could all be in a 
comparable condition.  
Typically, REE prediction equations have been derived based on particular populations 
of interest; children, obese, elderly, or disease groups [8-12]. Their purposes have been either 
for assessing nutritional requirements or for explaining changes in body composition such as 
weight loss or gain. This study proposes the use of prediction equations, not for the purpose 
of accurately predicting REE in metabolically disordered groups, but to describe and illustrate 
their deviation from a healthy population. 
117 
 
The analysis began with the description of REE in healthy children and adolescents. 
Firstly, the cohort was investigated without the separation of genders. This revealed a similar 
relationship between lean mass and REE in the males and females. When the relevant 
variables were entered into the stepwise regression analysis to generate a prediction of REE, 
lean mass was indeed the most significant contributor. The model that could explain the 
greatest amount variation in the prediction of REE was based on lean mass, gender and fat 
mass explaining 75.4 % of the variation in REE. Goran et al [35] and Muller et al [5] have also 
used these variables as determinants of REE explaining 63% and 72% of the variation in REE in 
healthy non-obese children.  
Gender significantly contributed to the prediction of REE. To explore this further 
gender was removed from the regression which left fat and lean mass explaining 72.8% 
highlighting that the majority of the variance was explained by body composition, but an extra 
2 % could be attributed to gender differences. When the analysis was subsequently separated 
by gender, lean mass remained the strongest and only significant variable in the females. In 
light of this, total body mass, the sum of lean, fat and bone mass, was entered into the 
regression to establish whether it explained as much variance as lean mass alone. The results 
demonstrated that DXA mass explained 61 % compared to 63.8 % explained by lean mass. This 
was possibly because of the highly significant correlation between lean and fat mass in the 
females and what is being presented within lean mass is the contribution of both variables. In 
the males both fat mass and lean mass came through as strong predictors. These variables 
were also less correlated to each other than demonstrated in the females. DXA mass was also 
entered into the regression for the males, which resulted in the same amount of variance 
being explained as fat and lean mass combined. The significance of keeping lean and fat mass 
in the prediction, rather than total mass, is that it highlights that the variance is explained by 
lean and fat mass with no additional contribution of bone mass.  
Of the studies that have derived REE equations in healthy children, few have chosen 
to analyse the genders separately, instead gender has been added to an equation as a 
contributing variant as seen in model 1. However, as the results in the current study have 
demonstrated, different variables have differing contributions to REE between the genders.   
We have demonstrated that there are gender differences in body composition and REE across 
the age range of 6 to 16 years. Levels of fat mass increase at a greater rate in females 
compared to males, lean mass increases linearly with age, although the gradient of the 
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increase is less in females than in males and around the ages of 12-14 years tapers off. These 
gender differences are associated with gender specific increases in growth hormones such 
insulin-like growth factor 1 (IGF-1), gonadotrophin and sex steroids [7], which in turn alter 
energy metabolism during the pubertal phase of life.  
Previously published prediction equations have shown to differ in accuracy based on 
pubertal stage [36].  Lazzer et al [37] proposed two REE prediction equations in obese children 
based on body mass or body composition. Their body composition equation was determined 
by the variables; FFM, FM, gender and pubertal stage using Tanner and Marshall scales (R2 
0.70) [38 39]. The inclusion of pubertal stage in relation to REE by Lazzer et al reiterates the 
importance of using pubertal status rather than chronological age when investigating children 
with atypical body composition or REE. Lazzer studied children with mild to severe obesity, 
discussing that children with higher levels of fat mass may influence pubertal development 
due to hormonal mechanisms within adipose tissue and boys often display delayed pubertal 
development by mechanisms that are less clear. In the current study, the clinical biomarkers, 
LH and FSH, were used as markers of puberty. LH and FSH are gonadotrophins, whose rate of 
secretion rises as pubertal progresses [40]. Clinically, there is no defined value for LH and FSH 
representing the onset of puberty, however there is some published literature indicating 
normal reference ranges based on age ranges in males and females [41].  
In this study, LH and FSH values were entered into the regression analysis on the 124 
participants who provided blood samples alongside their metabolic measurements. The 
pubertal markers in this instance did not significantly contribute to the prediction of REE, Few 
studies have investigated the influence of puberty on REE in healthy children. Rodriguez et al 
[42] also found no significant contribution of puberty, by Tanner scales, to the prediction of 
REE in healthy obese and non-obese children and adolescents.   
Despite the evidence suggesting pubertal status does not account of any of the 
variation, the lack of contribution may be down to the way that puberty is assessed. This is 
the first study, to our knowledge, that has combined biochemical markers to the traditional 
body composition variables in the hope of further expressing REE in growing children. 
Hormones such as LH and FSH act in a pulsatile manner [18] making an accurate assessment 
difficult in a spot measurement. Although investigations into the triggers of puberty remain 
elusive, further investigations into alternative biochemical markers and their contribution to 
REE should be explored. McNeilly et al [43] investigated whether urinary LH and FSH could 
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differentiate between pre and post pubertal children in comparison to self-assessment by 
Tanner scale. Their results demonstrated that LH:FSH ratios were higher in pubertal children 
than pre pubertal children, although differences were not significant in the females. 
Additionally, Soeborg et al [44] documented that biochemical levels of sex steroids; 4-
androstenedione (Adione), testosterone, and androgen, were found to significantly increase 
with each genital stage in males and testosterone increased with each breast stage in females. 
Importantly, these metabolite concentrations increased markedly with the onset of puberty 
(clinically assessed rather than self-assessed). Further investigation into the relationship 
between these sex hormones (in addition to LH and FSH) and REE would be valuable.  
The aim of generating the prediction equations was to apply them in the context of 
metabolic disorders. The gender specific prediction equations were applied to patients with 
disorders of thyroid hormone action to describe the magnitude of the difference in REE 
compared to a healthy population. Chapter 4 describes this approach in adults [15], where 
thyrotoxicosis, lipodystrophy and RTHβ all displayed the elevated energy expenditure Z 
scores. Energy expenditure in children with TH disorders is less well documented because of 
the rarity of the disease and diagnosis in childhood. The results of the current study 
demonstrate differences in REE in two disorders, RTHβ and RTHα. In RTHβ, the males exhibit 
a normal albeit slightly decreased REE with a mean Z score of -0.15 and the females display 
normal REE with a Z score of 0.21. These results are consistent with the known variability of 
the RTHβ phenotype. Some patients present as asymptomatic whilst others exhibit 
hyperthyroid symptoms suggesting the degree of peripheral tissue resistance varies [25 45]. 
Mitchell et al [25] found that in both adults and children REE was substantially increased with 
values 20 % above that of predicted REE in children, based on previously published equations 
[3 4].  
In the RTHα patients low REE Z scores were documented, but with clear differences 
between the male and female. The male patient demonstrated a Z score of -0.81 with a Z score 
of -2.37 in the female patient. These Z scores correlate with the hypothyroid phenotype of the 
disorder and are in agreement with previously published case reports [30 46]. This includes 
the description of another adolescent male RTHα patient with decreased REE but within a 
normal range [30] and two additional female RTHα patients with hypothyroid features in 
whom REE or body composition was not measured [47 48].  
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The concept of applying a healthy prediction equation serially in individual, 
metabolically disordered, patients has also been demonstrated in this study. As a patient with 
hypothyroid features is treated with thyroid hormone, one would expect an improvement in 
thyroid status and therefore an improvement in their REE. By tracking or monitoring a patients 
REE Z score over time, provides an indirect indication of whether thyroxine therapy is 
effective. The advantage of presenting patient data using a Z score, rather than in a raw 
format, is that their REE has been adjusted for changes in body composition and also enables 
comparison with healthy controls.  
Several limitations of this study should be considered. First, the prediction equations 
should be validated against an independent healthy paediatric subject cohort [49]. Ideally this 
would have been undertaken prior to its clinical application, however, due to the numbers of 
participants required per dataset this has not been possible within this time frame. Further 
work is in progress to validate the prediction equations. Second, the dataset used to derive 
the equations was lacking in sample size in some age groups. To apply the equations with 
confidence in an age range of 6-16y a larger, more consistent sample size needs to be 
generated. Lastly, reiterating the need for a larger sample size, more studies into a method 
for accurately describing pubertal status and its effect on REE are warranted.  
In summary, gender differences in body composition and energy expenditure have 
been described in a cohort of healthy children and adolescents aged 6-16 years. REE was 
predicted in the healthy cohort by equations generated using gender-specific body 
composition measurements. REE measurements from patients with rare disorders of TH 
action have been made and calculated in the context of healthy age and gender matched 
counterparts using a Z score approach. This approach may facilitate the phenotyping of a 
metabolic disorder, aid in the interpretation of REE in metabolic disease and assist in the 
evaluation of patient therapy over time.  
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6. General Discussion 
The objective of this thesis was to develop a new approach to describe resting energy 
expenditure (REE) and body composition in healthy adults and children. With this approach, 
normative resting energy expenditure and body composition are defined by the assignment 
of Z-scores derived from studying the difference between measured and predicted REE and 
lean mass (LM) in a healthy population. Z-scores are then applied to measurements of REE 
and LM in patients with metabolic disorders in order to characterise their deviation from a 
healthy population. 
6.1. Measurement of body composition by DXA 
Throughout the studies described in this thesis, body composition in adults and 
children was assessed by Dual-energy X-ray Absorptiometry (DXA), a method that is a well-
established in the literature. During the course of these studies, the DXA instrument was 
upgraded from a GE Lunar Prodigy to a GE Lunar iDXA, which prompted the investigation 
(Chapter 3) into the precision and accuracy of DXA for the measurement of regional and 
whole-body bone and body composition in adults. This was achieved by first establishing the 
precision of the iDXA by performing repeated measurements, then comparing iDXA and 
Prodigy measurements to enable the development of cross-calibration equations in order 
that a combined dataset could be used. Finally, the accuracy of fat mass measurements 
performed on the iDXA were evaluated against fat mass derived from a 4-component (4-C) 
model.  
In an adult population, the iDXA demonstrated excellent precision of bone and body 
composition measurements in all regions, with the exception of arm fat mass, which was 
consistent with previously published literature [1-4]. The improved precision of the iDXA 
over that previously reported for the Prodigy [5], especially in body composition 
measurements, is largely attributed to the improvements in hardware within the instrument, 
such as the new x-ray filter and detector, which enhance bone edge detection. The 
advantage of improved precision is that clinically, when performing repeat scans at follow-
up appointments, smaller biological changes in body composition can be detected. This is of 
significant benefit when studying individual patients or small disease cohorts.  
Significant differences between the Prodigy and the iDXA were found to be present in 
all regions of bone and body composition with the exception of the hip. Based on these 
findings, cross-calibration equations were developed, specific to the healthy adult 
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population being studied (Chapter 3). As significant differences between whole-body 
composition measurements from the two instruments were also observed in children, 
separate cross-calibration equations were developed for a paediatric population (Chapter 5). 
Investigations into the accuracy of DXA fat mass measurements compared to a 4-C 
model revealed a positive bias across DXA instruments. This bias was accentuated in the 
latest versions of the software, demonstrating the largest inaccuracies at the highest fat 
masses. The clinical implications of this include poor validity of DXA fat mass measurements 
in patients with large quantities of adipose tissue, such as patients with obesity. A limitation 
of this study was the lack of participants with high fat mass; further insights into the 
behaviour of DXA and 4-C in this cohort will be valuable. Knowledge of the strengths and 
limitations of body composition measurements from DXA instruments, or measurements 
made by any other method, is imperative when interpreting data from participants that 
present with atypical proportions of fat and lean mass, such as those observed in clinical 
populations.  
6.2. Prediction of REE and lean mass in healthy adults 
Chapter 4 investigates the development of multiple regression equations to predict 
healthy resting energy expenditure (REE) and lean mass (LM) in adults; these equations are 
extended to paediatrics in chapter 5. Gender did not significantly contribute to the 
explanation of the variance in predictions of REE in adults, therefore one equation consisting 
of the significant variables, age (years), fat mass (FM) (kg) and fat-free mass (FFM) (kg), was 
derived for both genders; this explained 73% of the variance in REE. However, gender did 
significantly contribute towards the variance in the prediction of lean mass in adults, 
therefore two gender-specific equations were derived based on the significant variables. In 
males, the significant variables were bone mineral content and height2, whereas fat mass 
and height2 were the significant variables in females. These equations explained 55% and 
59% of the variance in lean mass in males and females, respectively.  
Predicting REE in a healthy cohort is not a novel concept; predicted REE is often used 
to predict energy intake. There are many publications of REE predictions based on large, 
amalgamated datasets of healthy participants. However, several of these publications state 
that their REE predictions are inaccurate when applied to cohorts outside the demographics 
of their dataset [6-8]. For this reason, it is common for cohort-specific prediction equations 
to be derived, such as in obesity [9 10] or childhood [11-13]. Differences between prediction 
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equations are often due to differences in the measurement conditions and methods, such as 
the use of height and weight versus bioelectrical impedance analysis and DXA, or 
dissimilarities in the characteristics and demographics of the sample, such as age, ethnicity 
or geographical location. 
Using normative data acquired from the studies conducted for this thesis, the 
differences between measured REE and predictions of REE in a healthy cohort by the most 
commonly used equations (Schofield [14], Henry [15] and Harris-Benedict [16]) and our 
newly developed prediction equations can be illustrated in adults and children (Figure 6.1).  
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Figure 6.1. Measured and predicted REE in healthy adults (a) and children (b). Data are mean 
± SE. “Watson” REE equations are derived within this thesis for adults and children (chapter 4 
and 5). 
Significant differences were found between Henry [15] and both our measured and 
predicted REE. This emphasizes the variation in prediction equations across healthy cohorts. 
Within a disease cohort, the severity of the disease can vary substantially between patients. 
It is, therefore, not always appropriate to derive a prediction equation for a specific disease 
group, especially when the disease cohorts are small. Using the concept being presented in 
this thesis, the use of a Z-score describes how close an REE or lean mass measurement is to 
the expected value, based on healthy participants. By applying this approach to individual 
patients or disease conditions, specifically thyroid hormone (TH) disorders and 
lipodystrophy, the degree by which these conditions deviate from a normal population can 
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be illustrated. More importantly, the change within an individual patient over a course of 
treatment can also be quantified.  
6.2.1. Clinical Application 
6.2.1.1. RTHβ 
In adult RTHβ patients, average Z-scores were 1.77 for REE and -0.17 for lean mass. 
The increased REE is a manifestation of the elevated levels of circulating thyroid hormones, 
which are characteristic of the condition. The lower lean mass Z-score is most likely to be 
linked to clinical features of RTHβ such as muscle weakness caused by hormone sensitivity in 
TRα-expressing peripheral tissue. However, the RTHβ condition is a diverse disorder, with 
many patients displaying typical scores of REE and lean mass, emphasising the complexity of 
the condition and suggesting that within this condition it is possible for the body to continue 
to regulate energy expenditure and body composition.  
6.2.1.2. RTHα 
Five adult RTHα patients, two females and three males, were identified for the 
application of the healthy prediction equations. We found these RTHα patients to have low 
REE (mean Z-score of -2.3) and high LM (mean Z-score of 2.1), in contrast to the RTHβ 
cohort. The average REE Z-score was lower in the females (-2.6) compared to the males (-
2.0). However, the LM Z-score was higher in the females (3.2) than the males (1.4). Larger 
sample sizes will be required in order to conclude whether a true gender difference exists. 
The REE results are in accordance with clinically reported hypothyroid features of the 
condition [17]. High LM has not been reported previously, but it is a common feature across 
the five RTHα patients investigated. The increased LM may be linked to the resistant TRα 
receptor in skeletal muscle over-compensating, resulting in an increase in protein 
deposition.  Alternatively, as previously reported in lipodystrophy [18], it could be related to 
muscle hypertrophy.  
6.2.1.3. Thyrotoxicosis 
 In the thyrotoxic group, the average Z-score for REE was the highest of the three 
conditions, at 5.8. In contrast, the average Z-score for lean mass was the lowest, at -1.2, 
revealing the greatest dissociation between REE and LM across the three conditions. The 
elevated REE Z-score reflects the metabolic effects of the thyroid hormone excess associated 
with Graves’ disease. The reduced LM reflects the catabolic state of the disorder, leading to 
weight loss and muscle weakness. Again, the severity of the disorder varied between the 
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seven patients studied, with REE Z-score ranging from 1.5 to 9.6, but despite this, there is a 
clear separation between healthy controls and thyrotoxicosis. 
6.2.1.4. Lipodystrophy 
Typically, lipodystrophy (LD) patients are characterised by an elevated REE and LM 
[18 19]. In chapter 4 we confirm an increased REE and LM in LD with an REE Z score of 2.97 
and a lean mass Z score of 4.2. However, the Z scores demonstrate a disproportionate 
increase in REE and LM. The increased LM may explain a proportion of the elevated REE 
reported in the LD group. When measured REE was adjusted for measured LM, no significant 
difference was evident between LD and healthy controls, as reported in a previous study 
[19]. However, this assumes that LM is the only influence on REE and that the relationship 
between REE and LM has no intercept. Reporting REE based on predictions using multiple 
regression analysis derived from healthy controls, not only quantifies the difference in REE 
and LM between LD and healthy but is also independent of body composition influences and 
the presence of an intercept. Therefore it suggests that there are components of the 
elevation in REE and lean mass that are still unaccounted for. Organomegaly is a common 
feature of LD and may account for some of the increased LM present in the LD group. 
Another  mechanism involved in the presence of increased LM may be due to the spillover 
effects of hyperinsulinemia on IGF-I receptors [20]. However the exact mechanisms involved 
in increased muscle mass in LD is not fully understood and requires further investigation. 
The increase in REE independent of LM may be explained by increased fat oxidation due to 
the consumption of dietary fat within the meals provided. Although meals were 
standardised across all studies within this thesis (30-35% fat), this may induce levels of 
dietary fat greater than is typical for an individual. Excess dietary fat has been previously 
reported to increase total energy expenditure in LD patients due to the impairment in their 
ability to store fat subcutaneously [19]. Further studies into the oxidation and storage of 
dietary fat in LD would prove valuable. 
A key benefit of the Z-score approach is its suitability for serial application in 
individual patients, which is often necessary in rare conditions where sample sizes are very 
small. Such serial Z-score measurements have highlighted REE and lean mass as strong 
markers of abnormal metabolism which respond to thyroxine treatment as expected for 
other parameters. Therefore, it may be possible to use REE and lean mass as markers of 
treatment response over time, which could inform clinical practice. When applied to the four 
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metabolic conditions described, the trend throughout the analysis was a dissociation 
between REE and LM, in contrast to the normative data.  
6.3. Predicting REE in paediatrics 
Chapter 5 replicated the Z-score approach from chapter 4 in a cohort of healthy 
paediatric subjects. First, cross-calibration equations were derived from a paediatric healthy 
cohort and applied to body composition and bone data obtained from the Prodigy DXA 
within the dataset. As demonstrated in the adult population in chapter 3, significant 
differences were observed between measurements from the two DXA instruments in the 
paediatric cohort.   
In contrast to the adult population, REE prediction equations were found to differ 
significantly by gender in the paediatric cohort. In the boys, LM and fat mass explain 80% of 
the variance in REE, whereas in girls, only LM contributed significantly, explaining 60% of the 
variance. The separation of the equations by gender in paediatrics but not in adults indicates 
gender-specific differences in energy expenditure that are mediated by growth. During 
puberty, body mass increases in both boys and girls; however, the increases in proportions 
of fat and LM differ by gender. The increase in body mass in boys is primarily due to an 
increase in LM, as body fat percentage appears to reduce with age. In girls, on the other 
hand, both fat mass and LM increase with linear growth, yet fat mass does not contribute to 
the variation in REE in girls; this may be because both fat mass and LM are so highly 
correlated.  
6.3.1. Pubertal contributions to REE 
The effect of puberty on REE in boys and girls was explored by investigating the 
influence of luteinising hormone (LH) and follicle-stimulating hormone (FSH), biochemical 
markers of puberty, combined with body composition. In boys, LH stimulates testosterone 
production and FSH supports sperm maturation. In girls, LH and FSH stimulate ovarian 
production of oestrogen, progesterone and testosterone [21]. 
Of the 201 paediatric participants studied, 124 gave blood samples which were 
analysed for sex hormone levels. The analysis demonstrated that LH and FSH, as pubertal 
markers, did not contribute towards the prediction of REE in this subset of participants. The 
reason for this may have been due to the difficulty in capturing a reliable hormone level in a 
fasted, morning, spot measurement due to the pulsatile manner of its secretion [22]. 
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Assessment at night during the initial phase of puberty has been suggested, along with 24 
hour assessment of LH and FSH as puberty advances [23]. Additionally, in girls, before the 
onset of puberty, the pre-ovulatory surge required for ovulation may also raise plasma LH to 
levels that could be mistaken for pubertal levels [24]. Since LH and FSH act on the production 
of testosterone in boys and oestrogen, progesterone and testosterone in girls, further 
investigations into these and other sex steroid hormones as indicators of pubertal status 
may help to explain the variance in REE within and between genders.  
Most pubertal literature relies on self-assessment of pubertal status based on Tanner 
stages, or physical assessments performed by clinicians and compared to Tanner stages. 
These methods have their limitations, such as the intrusiveness of a physical examination 
and the inaccuracy of self-assessments compared to physical assessments. Therefore, the 
addition of biochemical markers for estimating stages of puberty is an ideal for supporting 
existing methods.  
6.3.2. Clinical applications 
6.3.2.1. RTHβ 
Twenty five RTHβ children were studied: eight boys and seventeen girls. The mean Z-
score in the boys was -0.15, ranging from -1.9 to 0.8, and in girls, the mean Z-score was 0.20 
with a range from -1.9 to 4.1. The mean Z-scores differ between boys and girls, with boys 
displaying lower REE and a smaller range of values whilst girls exhibit higher REE and a 
greater range of Z-scores compared to the healthy controls. However, in both groups these 
Z-scores are not different from those observed in the healthy controls; in contrast, the adult 
RTHβ cohort exhibited elevated Z-scores for REE.  
The difference in REE results for two overlapping paediatric RTHβ cohorts, that 
reported by Mitchell et al. [25] (n=13) and the cohort described in chapter 5 (n=25), 
warrants discussion. Mitchell predicted REE using Schofield equations, demonstrating a 
significantly high ratio between measured and predicted REE of 118%. When I applied 
Schofield equations to predict REE in the RTHβ cohort reported in chapter 5 their ratio 
between measured and predicted REE was lower at 112%, indicating that my RTHβ sample 
had slightly lower REE. To investigate the contribution of choice of prediction equation to 
the difference in findings, I applied the Schofield equation also to the healthy control cohort 
in chapter 5 and found their ratio between measured and predicted REE was 109%.  This 
suggests that the Schofield equations slightly under-predict REE, and this will also contribute 
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to the high ratio between measured and predicted REE in the RTHβ cohort reported by 
Mitchell et al. [25]. A large difference between the two healthy child cohorts, Schofield and 
the healthy control cohort in chapter 5, is the sample size and the multiple populations 
within the Schofield cohort. Schofield’s healthy cohort consisted of 7173 European and 
North American children, an amalgamation of data from 114 published studies totalling 7173 
data points. By contrast, my healthy child cohort in chapter 5 comprised 201 measurements 
from a solely UK population [15]. Studies that have applied Schofield’s equations have 
reported a mix of over estimation and underestimation of REE in children depending on their 
nationality [15].  This emphasizes the extent to which the population from which the 
prediction expressions are developed may influence the accuracy of predictions when 
applied in other populations. When employing prediction expressions it is important that 
they are developed in a population comparable with that in which they are to be applied. 
Aside from a population difference, it is also not clear how controlled the measurements of 
REE were within the Schofield cohort as it consists of data from previously published studies 
including group mean values [15]. Therefore measurement techniques and instrument error 
may well also contribute towards the differences in the predictions of REE.  
6.3.2.2. RTHα 
RTHα is a rare thyroid hormone (TH) disorder with only fourteen cases having been 
identified world-wide to date, five of which are in children. In this thesis, two children are 
studied, one boy and one girl. Both RTHα children demonstrated low REE Z-scores at the pre-
treatment stage, with the girl demonstrating a much lower REE Z-score than the boy (-2.4 
compared to -0.8 respectively). As with the RTHβ patients, we are presented with a gender 
difference; however, there is a large age gap between these patients, with the boy being 
diagnosed at the age of 15 years compared to just under 6 years in the girl. In contrast to the 
RTHβ patients, the RTHα children are consistent with the RTHα adults, showing lower REE 
compared to controls and lower REE Z-scores in the female patients compared to the males. 
As for RTHβ, further studies involving higher numbers of participants are necessary in order 
for reliable conclusions to be drawn.  
The Z-score is a useful tool for distinguishing between the two RTH mutations and 
supporting the other clinical diagnostic parameters used to identify a patient with this 
disorder. In addition to its use in the study of a disease cohort as a whole, the Z-score 
approach can also be applied to individual patients to monitor their response to treatment 
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over time, with regard to the effect of TH on REE. An increase in an REE Z-score approaching 
the mean of the control group could reflect an improvement with TH therapy, whereas a 
drop in REE could indicate a need for a change in thyroxine dose. Figure 8 of chapter 5 
illustrates this in a male patient where, as a result of the decrease in REE at the age of 17 
years, dosage of thyroxine therapy was increased.    
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6.4. Summary, conclusions and future work 
 In summary, the work of this thesis has demonstrated the unique role of the use of Z-
scores to quantify the differences between healthy and disordered REE and body 
composition. The generation of equations to predict REE in healthy adults and children and 
lean mass in adults has allowed the description of disordered metabolism relative to a 
prediction of normal REE or LM based on body composition.  Presentation of the Z-scores on 
an individual basis can assist in the evaluation of the patient’s disorder and treatment 
progress.  
 The main findings of the thesis are as follows: 
 DXA is a precise method for the measurement of body composition, but its accuracy 
compared to a 4-C model should be explored further in patients with high fat masses.  
 Newly-derived equations accurately predict REE and LM in European healthy adults. 
 Application of the prediction equations and Z-scores to adults with metabolic 
disorders indicates increased REE in thyrotoxicosis, lipodystrophy and RTHβ patients 
but reduced REE in RTHα subjects. Reduced LM is described in RTHβ and 
thyrotoxicosis, whereas this is elevated in lipodystrophy and RTHα. 
 In children and adolescents, two gender-specific prediction equations were derived 
from a healthy cohort. When applied to RTHβ patients, REE was not different from 
healthy controls, but RTHα patients exhibited decreased REE. 
 Z-scores can describe an individual patient’s progress during treatment. 
 Further research will be undertaken to validate the paediatric prediction equations 
on a separate cohort of healthy children ranging from 6 – 16 years of age. Future work will 
also include the exploration of body composition measurements by DXA compared to a 4-C 
model in children and adolescents. 
In addition to validating the existing equations, further exploration of pubertal 
contributions to body composition and energy expenditure will be undertaken by using 
other measures to assess pubertal stage. It would also be interesting to explore the 
application of serial Z-scores in further RTH cases and in other disorders in which the 
relationship between body composition and energy expenditure is atypical.  
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ORIGINAL ARTICLE
An approach to quantifying abnormalities in energy expenditure
and lean mass in metabolic disease
LPE Watson1, P Raymond-Barker1, C Moran2, N Schoenmakers2, C Mitchell2, L Bluck1,3, VK Chatterjee2, DB Savage2 and
PR Murgatroyd1,2
BACKGROUND/OBJECTIVES: The objective of this study was to develop approaches to expressing resting energy expenditure
(REE) and lean body mass (LM) phenotypes of metabolic disorders in terms of Z-scores relative to their predicted healthy values.
SUBJECTS/METHODS: Body composition and REE were measured in 135 healthy participants. Prediction equations for LM and REE
were obtained from linear regression and the range of normality by the standard deviation of residuals. Application is
demonstrated in patients from three metabolic disorder groups (lipodystrophy, n¼ 7; thyrotoxicosis, n¼ 16; and resistance to
thyroid hormone (RTH), n¼ 46) in which altered REE and/or LM were characterised by departure from the predicted healthy values,
expressed as a Z-score.
RESULTS: REE (kJ/min)¼  0.010 age (years)þ 0.016 FM (kg)þ 0.054 fat-free mass (kg)þ 1.736 (R2¼ 0.732, RSD¼ 0.36 kJ/min).
LM (kg)¼ 5.30bone mineral content (kg)þ 10.66 height2 (m)þ 6.40 (male). LM (kg)¼ 0.20 fat (kg)þ 14.08 height2 (m)
 2.93 (female). (male R2¼ 0.55, RSD¼ 3.90 kg; female R2¼ 0.59, RSD¼ 3.85 kg). We found average Z-scores for REE and LM of
1.77 kJ/min and  0.17 kg in the RTH group, 5.82 kJ/min and  1.23 kg in the thyrotoxic group and 2.97 kJ/min and 4.20 kg in the
LD group.
CONCLUSION: This approach enables comparison of data from individuals with metabolic disorders with those of healthy
individuals, describing their departure from the healthy mean by a Z-score.
European Journal of Clinical Nutrition (2014) 68, 234–240; doi:10.1038/ejcn.2013.237; published online 27 November 2013
Keywords: resting energy expenditure; lean mass; body composition; Z-score; metabolic disease
INTRODUCTION
Many metabolic disorders such as thyroid disease or lipodystrophy
(LD) are associated with changes in body composition, energy
expenditure or both.1,2 In describing the phenotypes of such
conditions, it is often desirable to describe the extent to which
body composition or energy metabolism deviates from that of
healthy individuals, but this is not always straight forward.
Comparisons against standard predictions of energy
expenditure3–5 may be compromised by atypical body
composition, whereas comparisons based on body composition
proxies such as body mass index (BMI) may not reveal unusual
relationships between fat and lean masses.
Commonly used predictions of resting energy expenditure (REE)
may be troublesome owing to their dependence on age and
gender, as well as body mass and height.6 Their piecewise linear
nature can lead to substantial differences between predicted REE
just above and below the intersection of adjacent regression
ranges. The use of fat-free mass (FFM¼ lean body mass
(LM)þbone mineral content (BMC) in kg) as a predictor of REE
is more accurate and is widely accepted6 and, when allowed an
intercept, is disassociated from gender differences in body
composition.
Against this background, we have set out an approach to
characterise REE and LM in metabolic disorders by reference to
measurements in a metabolically healthy cohort. It utilises the
accurate and precise measurements of body composition
that are now widely available using dual-energy X-ray
absorptiometry (DXA).7–16 The key to our approach has been the
description of variability in the difference between measurements
and predictions when applied to healthy individuals. This allows
us to state with conﬁdence where an individual data point
observed in a metabolic disorder lies relative to the healthy range,
and so to discuss whether a disorder presents with altered REE or
body composition phenotype, or indeed both.
Three conditions (resistance to thyroid hormone (RTH), thyro-
toxicosis and LD) in which abnormal energy expenditure and/or
increased lean body mass (LM) have been previously documented
provide ideal examples to illustrate our method. RTH is a rare
genetic condition, with an incidence of 1 in 40 000,17,18 that is
characterised by elevated circulating thyroid hormones (THs)
together with central (hypothalamopituitary) and variable
peripheral tissue refractoriness to thyroid hormones. More than
90% of affected individuals with RTH have an identiﬁed mutation
in the THRB gene.19 Thyrotoxicosis (or hyperthyroidism, by which
it is known interchangeably) is due to excess TH secretion from
the thyroid gland. Most commonly (50–80% of cases),
thyrotoxicosis is caused by Graves’ disease, which affects B0.5%
of the population,20 and is due to autoantibodies causing excess
TH production by stimulating the thyroid-stimulating hormone
(TSH) receptor in the thyroid gland.21 LD can be either genetic or
acquired22 and is characterised by reduced adipocyte storage
capacity and loss of adipose tissue with signiﬁcantly increased LM,
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contributing to metabolic complications such as insulin resistance
and diabetes mellitus.23 We have extensive data in these
disorders, which are of particular interest to us, and so have
invoked them here for demonstration, although we believe our
approach is more generally applicable.
SUBJECTS AND METHODS
Healthy volunteers were recruited by local advertisement in the East
Anglian region of the United Kingdom. We recruited 135 male and female
non-smokers, aged between 17 and 65 years who had no known medical
conditions, were not taking any medications or supplements likely to
inﬂuence energy expenditure or body composition and who did not
normally exercise for over an hour a day. Volunteers were from different
ethnic backgrounds (126 Caucasian, 2 Black, 6 Asian, and 1 Hispanic).
All participants provided written, informed consent.
Volunteers from the metabolic disorder groups (LD, n¼ 7; thyrotoxicosis,
n¼ 16; and RTH, n¼ 46) were recruited following referral to Addenbrooke’s
Hospital and provided written informed consent to participation in their
studies. Participants were non-smoking, not on any b-blockers or
antiarrhythmic treatment and had no current or past history of eating
disorder. All patients with RTH had a mutation identiﬁed in the THRB gene.
Thyrotoxic patients were identiﬁed based on thyroid function tests
suggestive of thyroxicosis (serum TSH o0.03mU/l, free thyroxine (T4)
422.5 pmol/l) and had Graves’ disease, as evidenced by elevated anti-TSH
receptor antibody titres. Details on the recruitment of the lipodystrophic
participants have been documented previously.24
Healthy participants and metabolically disordered participants were
asked to refrain from strenuous physical activity, alcohol and caffeine
for 24 h before their visit. Each participant arrived at the NIHR/Wellcome
Trust Clinical Research Facility in Cambridge at 1400 hours on day
0 and remained until 1200 hours on day 1. After informed consent and
medical examination on day 0, height, weight and body composition
were measured. Body composition (fat mass, lean mass and bone mineral
density) was assessed by DXA (GE Lunar Prodigy GE Healthcare,
Madison, WI, USA; software version 12.2). At 1800 hours, a standardised
dinner was served. The energy content of the meal was 1/3 of a
participant’s daily requirements estimated from predicted resting
metabolic rate3 multiplied by an activity factor of 1.35.25 Meal
composition was 30–35% fat, 12–15% protein and 50–55% carbohydrate
by energy. The participant retired to bed at 2300 hours and was
woken the next morning at 0700 hours. REE was measured between
0700 and 0800 hours by ventilated canopy respiratory gas exchange
(GEM; GEMNutrition, Daresbury, UK). Measurements were recorded
at 30 s intervals over 20min. The LD participants’ REE was measured by
indirect room calorimetry for 60min and has been described
previously.24 All participants were asked to remain awake and still,
without any interactions, for the duration of the measurement. Energy
expenditure was calculated from the macronutrient respiratory quotients
and energy equivalents of oxygen published by Elia and Livesey.26
Following the REE measurement, fasting blood samples were taken for
renal and liver function tests, plasma glucose and thyroid function (free
triiodothyronine (T3), T4 and TSH). Urinary metanephrines were also
measured.
Body composition and REE measurements were performed in all healthy
and metabolically disordered volunteers and are summarised in
Supplementary Table 1, Table 1 and Table 2.
Ethics
The study received a favourable opinion from the Cambridge Central
East of England Research Ethics Committee and was funded by and
conducted in the NIHR/Wellcome Trust Clinical Research Facility (WTCRF,
Cambridge, UK).
Statistical analysis
Multiple correlation analyses were undertaken using SPSS19 (SPSS Inc.,
Chicago, IL, USA) to identify variables or combinations of variables that
correlate (Po0.05) to REE and DXA-measured total body LM.
Once the correlating variables were established, forward stepwise
multiple linear regression analysis was performed to relate REE
(kJ/min) to FFM (kg), FM (kg) and age in all subjects and to relate LM
to FM and height for female subjects and LM to height and BMC in male
subjects.
Table 1. Characteristics of the RTH and thyrotoxic groups
Variable RTH (n¼ 46) Thyrotoxicosis (n¼ 16)
Male (n¼ 12) Mean±s.d. Female (n¼ 34) Mean±s.d. Male (n¼ 6) Mean±s.d. Female (n¼ 10) Mean±s.d.
Age (years) 38.1±16.8 39.4±13.6 40.7±14.4 45.8±14.2
Height (m) 1.74±0.1 1.61±0.1 1.76±0.1 1.63±0.1
Weight (kg) 72.8±10.4 71.7±14.4 74.1±18.8 64.5±9.4
BMI (kg/m2) 24.1±3.8 27.6±5.1 23.81±3.6 24.2±3.4
FM (kg) 18.2±8.2 29.7±10.0 20.9±10.6 26.4±7.6
LM (kg) 51.7±4.8 38.6±5.2 50.6±9.6 35.6±5.7
FFM (kg) 54.1±5.1 40.9±5.5 53.1±10.1 38.1±5.8
BMC (kg) 2.4±0.5 2.3±0.4 3.0±0.6 2.5±0.3
REE (kJ/min) 5.2±0.6 4.6±0.7 7.2±1.4 5.5±0.9
TSH (mU/l) 2.2±0.7 3.8±3.4 o0.03±0.9 o0.03±0.0
Free T4 (pmol/l) 29.5±5.1 35.1±13.1 47.2 ±41.5 43.3±19.6
Free T3 (pmol/l) 10.5±1.6 12.7±4.3 22.4±11.1 24.3±11.3
Plasma glucose (mmol/l) 4.7±0.8 5.0±0.5 5.5±0.3 4.9±0.4
Abbreviations: BMC, bone mineral content; BMI, body mass index; FFM, fat-free mass; FM, fat mass; LM, lean mass; REE, resting energy expenditure; RTH,
resistance to thyroid hormone; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone.
Table 2. Characteristics of the lipodystrophy group
Variable Male (n¼ 2)
Mean±s.d.
Female (n¼ 5)
Mean±s.d.
Age (years) 34.2±23.5 48.8±13.2
Height (m) 1.75±0.13 1.64±0.05
Weight (kg) 78.8 ±13.0 66.2±6.9
BMI (kg/m2) 25.8±0.3 24.5± 2.4
FM (kg) 5.6± 2.9 9.3±6.8
LM (kg) 70.0±10.5 54.2±6.2
FFM (kg) 73.3±10.1 56.9±6.0
BMC (kg) 3.2±0.4 2.7±0.6
REE (kJ/min) 6.3±0.9 5.6±0.7
TSH (mU/l) 1.2±0.1 0.7±0.4
Plasma glucose (mmol/l) 10.4±3.3 6.9±4.5
Abbreviations: BMC, bone mineral content; BMI, body mass index;
FFM, fat-free mass; FM, fat mass; LM, lean mass; REE, resting energy
expenditure; TSH, thyroid-stimulating hormone. Free T4 and free T3
measures were not available to report in the lipodystrophy group.
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A K-fold cross-validation approach was then undertaken to test the
reliability of both the models. The data set was randomly numbered and
split into test data sets and a validation data set. For the REE validation, the
analysis was repeated eight times making sure each data point was tested
and validated to establish whether the same variables signiﬁcantly
contributed to the prediction of REE, and then the standard deviations
of the residuals (the individual differences between predicted and
measured values) were compared. For LM cross-validation, the analysis
was repeated ﬁve times and was also tested on an additional data set of 19
female subjects and 18 male subjects.
Residuals were derived for each contributing data point and normality
was conﬁrmed for the set of all residuals using Shapiro–Wilk test for
normality. This allowed the distributions of residuals to be described by
their standard deviations, the magnitudes of which were taken as a
measure of the precision of the prediction. Furthermore, each experi-
mental data point could be deﬁned in terms of the number of standard
deviations from the predicted value (Z-score). When investigating the
disease groups, REE or LM was predicted as though belonging to
the healthy cohort, and an associated Z-score used as a measure of the
deviation from the healthy norm.
RESULTS
Resting energy expenditure
To establish the appropriate variables to include in the prediction
of REE, we examined the literature and subsequently explored
correlations of REE with age, gender, height2, bone mass,
FFM and FM.
Analysis of variance was carried out to test the effect of
ethnicity (white, black and Asian) on REE and LM, and showed that
in this group of volunteers there was no effect of ethnicity on REE
or LM (REE, F¼ 0.286, LM, F¼ 0.921). Stepwise multiple regression
analysis was carried out to establish which correlates contributed
signiﬁcantly to the prediction of REE and LM. Those that did not
contribute were excluded (Table 3).
The variables that contributed the least to the prediction of
REE were gender (R2¼ 0.004), height2 (R2¼ 0.005) and bone
mass (R2¼ 0.002). With these removed, age continued to
contribute to the overall prediction leaving FM (R2¼ 0.043),
FFM (R2¼ 0.660) and age (R2¼ 0.018) in the regression
(R2¼ 0.732). The resulting expression derived from the 135
healthy participants is
REE kJ=minð Þ ¼  0:010 ageð Þþ 0:016 FMðkgÞð Þ
þ 0:054 FFMðkgÞð Þþ 1:736
REE regression validation
The regression expression for REE above has been subject to
K-fold validation. The source data was randomised into
eight groups and regressions repeatedly derived from 7 17
and 1 16 subjects and tested in the remaining group.
The coefﬁcients of variation for the resulting eight estimates
of each regression coefﬁcient were: age 7.3%, FM 12.1%,
FFM 2.9% and constant 4.9%. The standard deviation of
residuals in the test group for the eight regressions ranged
from 0.27 to 0.49 kJ/min compared with 0.36 kJ/min for the
whole data set.
Lean mass
The least signiﬁcant coefﬁcient, age (P40.05), was taken out of
the analysis ﬁrst. Once this had been removed fat and height2
were highly signiﬁcant contributors in female subjects but height2
alone was signiﬁcant in male subjects. Bone mass was a signiﬁcant
contributor to LM in male subjects when it replaced FM but this
was not the case in female subjects. Therefore, the two gender-
speciﬁc regression equations for the prediction of LM are as
follows:
Male LM (kg) (n¼ 47)¼ 5.30bone mass (kg)þ 10.66
 height2 (m)þ 6.40
Female LM (kg) (n¼ 88)¼ 0.20 fat (kg)þ 14.08 height2 (m)
 2.94
The standard deviations of residuals for these two regressions
are, respectively, 3.90 and 3.85 kg.
Lean mass regression validation
As with the REE validation process, the male and female lean mass
regressions have undergone K-fold validation, randomised into
ﬁve groups and the analysis repeated ﬁve times. The female
results indicated that the standard deviation of residuals ranged
from 3.0 to 4.26 kg compared with 3.85 kg from the whole data
set. The male results indicated a range of 2.38–4.83 kg compared
with 3.90 kg from the whole data set. The data were also tested in
independent male and female data sets drawn from the entire
control group of another study and its ongoing successor (n¼ 18
males and 19 females). For the male group, the mean residual in
the test group is  1.49 kg with s.d. 3.91 kg. The offset of the male
mean from zero is predominantly due to a single outlier whose
residual was double that of any other subject, yet is not
signiﬁcantly different from zero. For the female group, the mean
residual is 0.15 kg (NS) with s.d. 2.2 kg.
Representation of data: Z-scores
Resting energy expenditure. To represent the normative data, the
residuals of measured REEpredicted REE were plotted with
corresponding Z-scores (Figure 1). LM, the strongest predictive
variable, is used to separate the data points. To assess the utility of
this approach in disorder states known to be associated with
altered body composition and resting metabolic rate, we
characterised patients with RTH, thyrotoxicosis and LD.1,27 When
data from patients with metabolic disorders is represented
alongside the healthy volunteer data, clear differences between
health and the disorder states emerge (Figure 2). As expected, all
the metabolic disease groups manifest elevated REE (mean Z RTH:
1.77; LD: 2.97) with the thyrotoxicosis group having the highest
REE values with a mean Z-score of 5.8 and a range from 1.5 to 9.6.
Lean mass. Supplementary Figure 1 shows the variability in LM
within the metabolically healthy male and female subjects.
The residuals of the difference between measured and predicted
Table 3. Multiple correlations of measured REE (kJ/min) and LM (kg), with demographic measurements
Variable Age (years) Gender Height2 FM FFM Bone
REE Coefficient  0.133  0.620 0.675 0.207 0.813 0.740
kJ/min Sig 0.123 0.000 0.000 0.016 0.000 0.000
LM Coefficient 0.004  0.819 0.845  0.012 1.000 0.805
kg Sig 0.961 0.000 0.000 0.890 0.000 0.000
Abbreviations: FFM, fat-free mass; FM, fat mass; LM, lean mass; REE, resting energy expenditure. N¼ 135, males¼ 47 and females¼ 88.
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LM are again presented together with Z-scores. Height was used
to separate the points. Figure 2 also demonstrates how metabolic
disorders may be characterised by comparison with healthy
subject data. The differences between LM in thyrotoxicosis and
RTH can be compared with that of the healthy cohort (mean Z
thyrotoxic:  1.23; RTH:  0.17). The LD data (mean Z: 4.20)
illustrates the substantial excess of lean tissue present in this
disorder.
LM and REE Z-scores may be plotted orthogonally, where they
combine to offer a succinct insight into the phenotypes of
metabolic disorders. Figure 3 illustrates the relationship between
changes in REE and LM in metabolic disorders compared with the
healthy group. The lipodystrophic group are characterised by
elevated LM and elevated REE with Z-scores ranging from 2.2 to
7.3 Z for LM and 1.4 to 4.8 Z for REE. The thyrotoxicosis group also
manifest elevated REE (1.5–9.6 Z) but, in contrast to the LD group,
have reduced LM (mean Z¼  1.2).
DISCUSSION
The aim of this work was to develop approaches to the description
of metabolic phenotypes in terms of the distribution of REE and
LM in metabolically healthy people. The novelty of our approach
lies in the way in which metabolic and body composition data is
represented. Subtracting a predicted value from measured values
produces a residual; and dividing this by the standard deviation of
residuals in a healthy cohort, we can assign a Z-score. Z-scores are
commonly used in the analysis of bone densitometry28 and on
growth charts to highlight individuals whose results deviate from
the population average.29 Here, we commend the use of Z-scores
to highlight individuals and groups of patients with abnormal
metabolic rates and/or abnormal LM.
Body composition measurements
The body composition measurements on which this paper relies
were undertaken by DXA. This is a widely available technique that
is able to provide quick and well-tolerated estimates of body
composition supported by reports of good accuracy and
precision.7 However, it is important to consider whether any
disorder to which our proposed methodology is applied might
generate a bias in the DXA measurements relative to the healthy
population. The work of Williams et al.30 offers valuable context for
this consideration. In the case of our example disorder groups, we
do not believe bias in DXA estimates to have been a concern.
Body composition data in our most extreme phenotype, LD, was
corroborated by air displacement plethysmography measurements.31
Resting energy expenditure
The results from the REE multiple regression analysis in this study
demonstrate a model that predicts REE accurately and with good
precision in healthy individuals. The variables that contribute to
0 20 40 60 80
-2
-1
0
1
2
1 SD = 0.36 kJ/min
2 SD = 0.72 kJ/min
1
2
-1
-2
0
3
-3
4
-4
Lean Mass (kg)
M
ea
su
re
d 
- P
re
di
ct
ed
 R
EE
kJ
/m
in
± 
1 
an
d 
2 
SD
Z 
Sc
or
es
Figure 1. Measuredpredicted REE (kJ/min) in healthy controls
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Figure 2. Differences between measured and predicted REE and LM in metabolic disorders and the healthy cohort.
Figure 3. Combination of LM and REE Z-scores to illustrate the
contribution to metabolic disorders. The circle indicates a Z-score of
±2 for REE and LM.
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our predictive equation are FFM, FM and age. These have
previously been documented as appropriate covariates.6,32–34
FFM is recognised as the main predictor of the interindividual
variability in resting energy expenditure. The relationship between
FFM and REE differs between men and women when constrained
through the origin, as is implicit when REE is expressed per unit
FFM. However, in preparing this work, we have conﬁrmed that
when an intercept is allowed, men and women tend to fall on the
same regression line. Moreover, the relationship between REE and
FFM is strengthened and therefore allows one regression equation
for both genders. There is, however, conﬂicting literature
regarding the contribution of FM to energy expenditure. In a
review, Cunningham6 suggested that FM contributes to energy
expenditure in women, but mostly in obese women. Our study
found that FM explained 4.0% of the variance in energy
expenditure and when the analysis was broken down by gender
there was no signiﬁcant difference in the variance explained by
FM between male and female subjects, even though we had a
greater number of female subjects in the cohort. The most
commonly used predictive equations for estimating energy
expenditure in a clinical setting are Schoﬁeld and Henry.3,5 They
include simple measurements such as height and weight, age and
gender, regardless of literature that disputes their accuracy and
precision, especially when applied to individuals outside the
original data sets.35,36 Weijs et al.37 performed a meta-analysis of
common REE prediction equations on 48 outpatients and 45 in-
patients with conditions including anorexia, overweight, thyroid
disease and inﬂammatory bowel disease, all of which have body
compositions and energy expenditures differing from healthy
controls.38–42 They saw errors ranging from 975 to 1782 kJ per day,
with at most only 40% of in-patients having an accurately
predicted REE when compared with measured REE. Johnstone
et al.43 demonstrated an average increase in accuracy of 32.9%
(240 kJ per day) when including body composition (FFM and FM)
and anthropometric measurements (skinfold thickness and
circumference) compared with the Schoﬁeld equation.3
FFM and FM may explain between 60 and 85% of the variance
in REE,6 leaving at least 15% unaccounted for. Our results
demonstrated that FFM and FM combined account for 70%,
leaving 30% unexplained. Age, gender, ethnicity and physical
activity have been reported to contribute to this variance.33 In our
study, we found a signiﬁcant but small contribution of age to the
prediction of REE (2%). Nielsen et al.32 investigated whether
adjusting FFM for extracellular ﬂuid would improve the prediction
of REE, but found that this was not the case. Johnstone et al.44
investigated the inﬂuence of FFM, FM, age, T4, T3 and leptin levels
on REE. They concluded that REE was not inﬂuenced by age,
gender, leptin or T3, although in men 25% of the variance was
associated with circulating T4 levels.
Lean mass
Predictions of FFM or LM are less frequently documented.
Previous publications predicting LM have used bioelectrical
impedance and skinfold thickness with DXA acting as the
reference measurement.45 The variables chosen for the LM
prediction equation in the current study were height2 and FM
for the female group and height2 and bone mass for the male
group. The presence of height2 in the equation reﬂects the fat and
FFM index concept,46,47 which recognises a relationship between
body composition and in body size and offers the prospect of
discrimination between health and individuals with abnormal fat
or FFM for their size.
Cross-validation
To test our prediction equations, we performed an observational
analysis of the coefﬁcients from published studies that have also
used FM, FFM and age as variables for prediction of REE
(Supplementary Table 2). Supplementary Table 2 suggests that
our coefﬁcients for FFM, FM and age are similar to those published
previously.6,32,48–50 Of this published work, only Nielson’s32 used
DXA for composition measurement; Horrie used bioimpedance,49
whereas Nelson et al.’s48 and Cunningham’s6 papers were based
on data previously published by others. When applied to the
current data set, the Nielsen equations produced a residual
standard deviation of 0.37 compared with 0.36 produced by our
equation. In the light of this sparsity of robust comparative data,
we performed a K-fold cross-validation analysis on REE and LM
models to test their reliability. Comparison of means and standard
deviations of residuals in these test groups with those of the
training groups suggests that the regressions may be applied
beyond the training group with some conﬁdence, although we
accept that testing in a larger group would increase this
conﬁdence. We would encourage readers who would like to
apply our approaches to derive and publish prediction regressions
from their own reference cohorts until such time as the published
coefﬁcients have converged to a closer consensus than we have
presented in Supplementary Table 2—perhaps when published
predictions agree to within 1 pooled standard deviation of their
residuals.
Application examples
Thyroid disorders. Thyroid conditions such as thyrotoxicosis and
RTH result in altered body composition and a raised energy
expenditure. Mitchell et al.40 showed that REE is raised in RTH and
markedly elevated in thyrotoxic patients. In both conditions there
was a higher fat-to-lean mass ratio compared with the healthy
controls, although the data suggest that in thyroid disorders the
dominant abnormality lies in REE rather than body composition.
Our results from the lean mass regression equation suggest that
the thyrotoxic group have reduced LM (Z¼  1.23), whereas the
RTH group have normal LM (Z¼  0.17) despite the increased REE.
Our results conﬁrm that REE is higher in a cohort of RTH subjects
compared with healthy controls; however, in patients with
thyrotoxicosis, the magnitude of elevation in REE is more
substantial. In RTH, predominant expression of defective thyroid
receptor-b in the hypothalamus and pituitary mediates resistance to
hormone action within the pituitary–thyroid feedback axis, resulting
in elevated levels of circulating free T4 and T3 with normal or
increased levels of TSH.51 Energy expenditure is raised as some
peripheral tissues (e.g. myocardium, skeletal muscle) that express
normal thyroid receptor-a retain sensitivity to elevated levels of
TH.40 In contrast, both b- and a-receptor-mediated signalling is
intact in conventional thyrotoxicosis, with preserved responsiveness
of tissues to elevated TH, resulting in markedly increased energy
expenditure, despite a reduction in LM.52
Lipodystrophy. Lipodystrophic subjects are characterised by an
elevated REE and LM.24 Importantly, this is not simply a result of a
relative reduction in fat mass, which is present in all of these
patients, but appears to be a true increase in lean mass. Although
organomegaly and pseudoacromegaly are features of LD
(particularly the generalised form),22 the increased lean mass
probably reﬂects contributions from several tissues. Organ tissue
will have some contribution to the estimation of lean mass,
although it has a relatively small mass of approximately 4.4 kg,34
whereas skeletal muscle mass is almost certainly the largest
contributing tissue. We show a mean residual increase of lean
mass of 16 kg (Z-score44) relative to our healthy cohort,
suggesting an increase in lean mass over an above that
expected through organ contribution. Savage et al.24
investigated the increase in REE in the lipodystrophic
participants and concluded that the increase in lean mass in LD
patients accounted for their elevated REE. When REE was
presented per kg of LM, there was no signiﬁcant difference
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between REE in lipodystrophics and healthy matched controls.
However, this picture changes when the relationship between REE
and LM is allowed an intercept, and changes further when fat
mass contributes to the model. We have found an elevation in REE
with a Z-score averaging 2 (range 1.4–4.8 kJ/min) relative to our
healthy controls (Figure 2). As our prediction of REE takes into
account the inﬂuence of measured FFM, our approach arguably
removes any coupling between departures from the norm in REE
and FFM, so our Z-scores are effectively independent. In doing so,
it suggests that there may be a component of the elevation in REE
in LD beyond that which is associated with FFM alone.
As mentioned in the methods, the lipodystrophic participants
had REE measured by room calorimetry rather than the ventilated
canopy measurement. In the light of this, we investigated the
difference between measurements made using the canopy
compared with room calorimetry, on a separate cohort. The
results indicated a difference of 0.20 kJ/min between the two
methods, suggesting that even after accounting for this difference
in measurement the lipodystrophic participants would still display
an REE Z-score 42 (mean Z: 2.98 kJ/min).
In summary, we offer expressions for REE and LM in health
based on FM, FFM, BMC, age and height2 measurements.
Measurements from individuals with uncommon metabolic
disorders were examined in the context of data from healthy
subjects and differences to be expressed as a Z-score. This
facilitates the representation and differentiation of disease
phenotypes. This approach may also aid in the characterisation
and potentially evaluation of the treatment in such individuals.
Further validation of our regressions on a separate cohort of
healthy individuals is desirable, but we believe the Z-score
approach to metabolic phenotype description will prove valuable
and illuminating in these and other metabolic disorders.
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Abstract
We describe a study to assess the precision of the GE Lunar iDXA and the agreement between the iDXA
and GE Lunar Prodigy densitometers for the measurement of regional- and total-body bone and body com-
position in normal to obese healthy adults. We compare the whole-body fat mass by dual-energy X-ray
absorptiometry (DXA) to measurements by a 4-component (4-C) model. Sixty-nine participants, aged 37 ± 12 yr,
with a body mass index of 26.2 ± 5.1 kg/cm2, were measured once on the Prodigy and twice on the iDXA.
The 4-C model estimated fat mass from body mass, total body water by deuterium dilution, body volume by
air displacement plethysmography, and bone mass by DXA. Agreements between measurements made on
the 2 instruments and by the 4-C model were analyzed by Bland-Altman and linear regression analyses.Where
appropriate, translational cross-calibration equations were derived. Differences between DXA software ver-
sions were investigated. iDXA precision was less than 2% of the measured value for all regional- and whole-
body bone and body composition measurements with the exception of arm fat mass (2.28%).We found significant
differences between iDXA and Prodigy (p < 0.05) whole-body and regional bone, fat mass (FM), and lean
mass, with the exception of hip bone mass, area and density, and spine area. Compared to iDXA, Prodigy
overestimated FM and underestimated lean mass. However, compared to 4-C, iDXA showed a smaller bias
and narrower limits of agreement than Prodigy. No significant differences between software versions in FM
estimations existed. Our results demonstrate excellent iDXA precision. However, significant differences exist
between the 2 GE Lunar instruments, Prodigy and iDXA measurement values. A divergence from the ref-
erence 4-C observations remains in FM estimations made by DXA even following the recent advances in
technology. Further studies are particularly warranted in individuals with large FM contents.
Key Words: Accuracy; DXA; fat mass; 4-component model; total body water.
Introduction
Dual-energy X-ray absorptiometry (DXA) is widely used
for bone density measurements within the clinical envi-
ronment.Within the research community, there is perhaps
more emphasis on body composition measurement, driven
by the increasing prevalence of obesity. In both contexts,
the ability to detect changes in measurements is arguably
of more interest than the absolute value of the measure-
ment so that an apparent change in bone or fat mass (FM)
should not be generated and interpreted falsely.
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DXA instruments have improved over time, most evi-
dently in reduced scan times.As the technology has matured,
the focus of development has shifted to image quality,which
has improved through advances in detector design, yielding
a higher pixel density.The major benefits of this technology
are better discrimination of bone edges and better imaging
of soft tissue, particularly in the thoracic region (1). Both
translate to improved repeated measures precision (2,3).
These benefits come at the cost of a new instrument, com-
pounded by the complexities of managing themigration from
old to new, which involves performing cross-calibration as-
sessments to identify any differences between instruments
and to account for them using translational regression equa-
tions (4).
The iDXA is the latest densitometer to come from GE
Lunar, a development of the GELunar Prodigy and Prodigy
Advance.A new detector and X-ray filter (producing dif-
ferent energy spectra) provide improved resolution and
image quality by better bone edge detection (1). This also
suggests there may be improved soft tissue algorithms within
the software compared to previous instruments. Re-
peated measures precision describes the variability between
2 measurements caused by the instrument itself, by repo-
sitioning and by operator error, and so sets the threshold
for discriminating the biological change between the 2 mea-
surements (5). Several authors have documented the
iDXA’s enhanced precision for repeated measures com-
pared with previous models (2,3,6).
Here we report an investigation that extends the pre-
viously reported work.The primary purpose of the present
study was to evaluate the precision and accuracy of the
iDXA. Secondly, we aim to produce translational regres-
sion equations for relating scans between the Lunar Prodigy
and the iDXA. Further, we have determined the accu-
racy of iDXA-measured FM measurement by comparison
with a 4-component model (4-C) (7). The 4-C model is
widely accepted as a reference against which the accu-
racy of other body composition methodologies is evaluated.
Materials and Methods
Participants
Sixty-nine healthy men (n = 33) and women (n = 36) were
recruited for the purposes of the present study. Two par-
ticipants were excluded from the hip analysis, one for poor
positioning and one for an artificial joint. One participant
was excluded from the total body water (TBW) analysis
because of an insufficient sample volume. The demo-
graphic data of the cohort are presented in Table 1.All par-
ticipants were made aware of the risks associated with the
measurements and provided informed consent in writing.
The participants were healthy, free from disease, and non-
smoking; they were excluded if they were pregnant or re-
ceiving any metabolism-influencing medications. The
study was approved by the Cambridge Central Ethics
Committee.
Each participant arrived at NIHR/Wellcome Trust
Clinical Research Facility, Addenbrooke’s biomedical
campus, Cambridge, at noon on the day of their visit to un-
dertake 3 procedures: total-body water determination using
deuterium dilution, DXA, and body volume determina-
tion using air displacement plethysmography (ADP).The
participants wore light, metal-free clothing and refrained
from food and drink for 30 min before and during the
measurements.
Protocol
Deuterium Dilution
A baseline saliva sample was obtained from the par-
ticipants shortly after arrival. Height and weight were then
measured. Height was measured on a stadiometer and re-
corded to the nearest millimeter (SECA 242 digital
stadiometer; Seca, Hamburg, Germany).Weight was mea-
sured on electronic scales to the nearest gram (Kern & Sohn
GmbH, Balingen, Germany). The participant then con-
sumed a dose of 70 mg/kg body mass of 2H2O (99.8%; CK
Table 1
Descriptive Data of the Participants
Males (n = 33) Females (n = 36)
Mean ± SD Range Mean ± SD Range
Age (yr) 38.0 ± 12.0 19.9–65.1 37.8 ± 12.7 19.2–57.9
Height (m) 1.80 ± 0.08 1.62–2.01 1.66 ± 6.7 1.53–1.83
Mass (kg)a 81.0 ± 12.0 54.1–106.9 73.9 ± 18.1 49.1–129.6
BMI (kg/m2) 25.3 ± 3.2 20.2–34.2 27.0 ± 6.3 18.4–47.5
Fat mass (kg) (4-C) 16.8 ± 8.1 4.1–33.4 28.0 ± 14.4 9.57–71.5
% Fat (4-C) 20.1 ± 8.0 5.3–34.4 36.0 ± 9.5 18.5–55.1
Note: 4-C model: n = 68; hip analysis: n = 67; scan mode: standard, n = 65, thick, n = 4.
Abbr: 4-C, 4-component; BMI, body mass index; SD, standard deviation.
aAir displacement plethysmography mass.
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Isotopes Ltd., Ibstock, Leicestershire,UK) (8). Further 1 ml
saliva samples were collected at 3, 4, and 5 h post dose. Food
and drink were withheld for 30 min before the collection
of each saliva sample. The saliva samples were frozen at
−20°C until later analysis using dual inlet isotope ratio mass
spectrometry (Isoprime, GV Instruments, Wythenshawe,
UK).
DXA
Each participant was scanned twice on the iDXA (EnCore
software version 16 [enhanced analysis]; GE Healthcare
Lunar,Maddison,WI), with repositioning in between scans,
and once on theGELunar Prodigy (EnCore software version
12.3).The Prodigy data (basic analysis) were reanalyzed on
the iDXA using software version 16 to provide enhanced
Prodigy analysis. All 3 scans were performed on the same
day by the same operator. The sites scanned were the hip
(left femur) and the lumbar spine (L2–L4) for bone mass,
area and density, and whole body for both whole-body bone
mass, area and density, and body composition. Calibration
block quality assurance and encapsulated spine phantom
quality control scans were performed on each instrument at
the start of each scanning day.
The scans were performed by 3 trained operators who
performed scans according to the manufacturer position-
ing and scanning protocols (precision for each operator,
represented by the percent coefficient of variance (% CV)
of repeated scans, ranged from 0.7% to 1.5% for the lumbar
spine and from 0.5% to 1.0% for the total hip, below the
recommended 1.9% for the lumbar spine and 1.8% for the
total hip by the International Society of Clinical Densi-
tometry (ISCD) (4)). Subsequent analysis of all scans was
carried out by a single operator to ensure consistency
throughout the study.
ADP
The participants were asked to pass urine before the
ADP procedure (BODPOD®; Cosmed Srl, Rome,
Italy). Tight-fitting swim wear and a swimming cap were
worn to minimize air trapped in clothing and hair. Lung
volume was estimated by the BODPOD software to provide
a net body volume estimate. The weight obtained during
the ADP procedure was used as the body mass value for
the 4-C analysis.
Analysis and Calculations
TBW Plateau Method. TBW was calculated according to
the method of the InternationalAtomic EnergyAgency (8).
In brief, aliquots of 0.2 ml, drawn from the saliva samples,
were placed in 3.7-ml glass bottles with rubber septa
(nonevacuated vials; Labco Ltd, Lampeter,UK) and equili-
brated with hydrogen in the presence of a platinum cata-
lyst.Data were drift corrected offline and all measurements
were made relative to the Vienna standard mean ocean
water using laboratory standards traceable to the interna-
tional standard.
2H2O dilution space was determined using the follow-
ing equation (9):
2
2 1000H O kg
D T Ed Et
d Es Ep
)( ) = × × −( )
× −( )
⎡
⎣⎢
⎤
⎦⎥
whereD is the amount of oral dosing solution, in gram, ad-
ministered to the subject;T is the amount of deionized tap
water used to dilute the enriched isotope dose, in gram; and
d is the amount of enriched isotope dose in gram.
Ed is enrichment of the diluted dose d in T;Et is the en-
richment of the tap water diluent; Es is the mean enrich-
ment of saliva samples at 3, 4, and 5 h; and Ep is the
enrichment of the pre dose sample.
TBW (in kilogram) was then calculated by reducing 2H2O
dilution space values by 4% to account for the exchange
of deuterium with nonaqueous hydrogen (10).
4-Component (4-C) Model. FM (in kilogram) using the 4-C
model was calculated using the following equation of Fuller
et al (7):
FM BV TBW
BMC BW
= × − ×
− × − ×
2 747 0 710
1 460 2 050
. .
. .
where BV is body volume, determined using ADP; TBW
is total body water, determined using deuterium dilution;
bone mineral content (BMC) is whole-body BMC, deter-
mined using DXA; and BW is the body weight, deter-
mined during the ADP procedure.
Statistical Analysis
Descriptive data are reported as mean ± (standard de-
viation [SD]) unless otherwise stated.
Precision of the iDXA was expressed as the root mean
square standard deviation (RMS-SD) and % CV accord-
ing to ISCD recommendations.The least significant change
was calculated (2.77 × RMS-SD) to establish the smallest
change between repeated scans, which could be identified
with 95% confidence intervals as originating from the par-
ticipant rather than instrument and positioning variabil-
ity (5).
Paired sample t tests were performed to determine the
difference between instruments.
Bland-Altman analysis was performed to determine the
association and the agreement between the 2 instruments
and between each instrument and 4-C-derived FM.Where
appropriate, linear regression analysis was used to derive
cross-calibration equations between Prodigy data using en-
hanced analysis mode and iDXA data. It should be noted
that enhanced analysis mode is only available on Lunar
Prodigy Advanced and iDXA instruments running soft-
ware versions 15 and 16. If an earlier version of the Lunar
Prodigy instrument is being used, refer to supplementary
data where we have given whole-body and regional bone
and body composition cross-calibration regression equations
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to translate from Lunar Prodigy measurements analyzed
in basic mode to Lunar iDXA measurements.
Repeated measuresANOVA was applied to test for the
significance in fat measurements.Post hoc comparisons with
Bonferroni correction were applied to discover the signifi-
cance between methods (4-C, iDXA,Prodigy enhanced, and
Prodigy basic). iDXA values were calculated as the mean
of 2 iDXA measurements.
GraphPad Prism (Version 6.00 forWindows; GraphPad
Software, San Diego, CA) was used to generate Bland-
Altman analyses, and IBM SPSS (IBM SPSS Statistics for
Windows,Version 21.0; IBM Corp.,Armonk,NY) was used
for all other statistical analyses.
Significance was assumed for p < 0.05 for all statistical
tests.
Results
iDXA Precision
The precision error for repeated iDXA scans is shown
in Table 2. Precision error, when represented by% CV,was
less than 2% for all measures, with the exception of arm
FM (2.28%).A greater precision was demonstrated for lean
mass (LM) than for FM.
iDXA FM Accuracy
iDXA-measured FM and 4-C-derived FM are highly cor-
related (r2 = 0.99, p < 0.05) with a slope of 0.892 and an in-
tercept of 3.39. However, there is a significant difference
between iDXA-measured FM and 4-C-derived FM (mean
difference [SD], −0.936 [1.83], p < 0.05) with wide limits of
agreements (−4.53 to 2.65). It can be seen in Fig. 1 that there
is a significant positive proportional bias and systematic bias.
Furthermore, at an average FM of 32.12 kg, the iDXA
shifted from overmeasuring to undermeasuring FM com-
pared to 4-C-derived FM.
iDXA vs Prodigy
There were significant differences in whole-body mass
and spine bone mass between iDXA- and Prodigy enhanced
Table 2
Precision Variables of 2 iDXAWhole-Body and Regional Body Composition Measurements
Region Variables Mean ± SD Mean difference RMS-SD % CV LSC
Hip BMC (g) 36.0 ± 7.6 -0.1 0.5 1.1 1.3
Area (cm2) 33.2 ± 4.0 0.4 0.3 0.6 0.8
BMD (g/cm2) 1.08 ± 0.16 0.00 0.01 0.72 0.03
Spine BMC (g) 58.7 ± 12.1 -0.4 0.7 0.9 2.0
Area (cm2) 46.6 ± 0.3 0.0 0.4 0.5 1.2
BMD (g/cm2) 1.25 ± 0.01 -0.01 0.01 0.74 0.04
Whole body BMC (kg) 2.8 ± 0.6 0.0 0.0 0.4 0.0
Arms Fat mass (kg) 2.3 ± 1.1 0.0 0.0 2.3 0.2
Lean mass (kg) 5.6 ± 1.8 0.0 0.1 1.2 0.3
Legs Fat mass (kg) 8.4 ± 4.5 -0.1 0.2 1.3 0.5
Lean mass (kg) 18.2 ± 4.0 -0.1 0.2 0.7 0.5
Trunk Fat mass (kg) 6.1 ± 6.5 -0.0 0.3 1.6 0.7
Lean mass (kg) 24.0 ± 4.7 0.1 0.3 0.9 0.8
Whole body Fat mass (kg) 23.6 ± 11.5 -0.1 0.3 0.9 0.7
Lean mass (kg) 51.0 ± 10.4 0.1 0.3 0.4 0.8
Abbr:%CV, percent coefficient of variance; BMC, bone mineral content; BMD, bone mineral density; LSC, least significant change;
RMS-SD, root mean square standard deviation; SD, standard deviation.
Fig. 1. Bland-Altman plot of iDXA and 4-component
model-derived fat mass (n = 68).The solid black linear re-
gression line demonstrates systematic bias, the hashed gray
box corresponds to the 95% confidence interval of the
systematic bias, the dashed lines represent the limits of
agreements, and the vertical dotted lines present the cross-
over of over- to undermeasuring fat mass at 32.12 kg.
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measurements; these differences were not seen in any hip
measurements (Table 3).
The comparison of body composition measurements
between the instruments reveals significant differences in
FM and LM across all regions (Table 4).
Differences in whole-body and regional bone and body
composition measurements between Prodigy basic mode
and iDXA enhanced mode analyses are presented in
supplementary Table S1.The relevant cross-calibration re-
gression equations can be found in supplementary Tables S2
and S3.
Figure 2 illustrates the agreement between instru-
ments in FM and LM by Bland-Altman analysis. Com-
pared to iDXA,Prodigy overestimates FM (mean difference
−1.29 kg) and underestimates LM (mean difference 1.18
kg).
Because of the observed differences between instru-
ments (Tables 3 and 4), linear regression cross-calibration
equations were derived where appropriate and can be seen
in Table 5.
Prodigy Accuracy
Prodigy enhanced FM and 4-C-derived FM are highly
correlated (r2 = 0.993), with a slope of 0.883 and an inter-
cept of 4.80.As observed with the iDXA (Fig. 1), there is
a significant difference between Prodigy enhanced FM and
4-C FM (mean difference [SD] −2.16 [2.05] kg).There are
also wider limits of agreement (−6.17 to 1.86) and a more
negative systematic bias compared with the iDXA (Fig. 3B
and C).
Four Method Comparison
The measurement of FM was significantly affected by
method (F(3, 201) = 41.057, p < 0.05). There was a signifi-
cant difference between 4-C-derived FM and iDXA (mean
difference −0.936, p = 0.000), Prodigy enhanced (−2.157,
p = 0.000) and Prodigy basic (−1.720, p = 0.000) FM.
However, there was no significant difference between
Prodigy basic and Prodigy enhanced FM measurements
(0.437, p = 0.275).
Table 3
Whole-Body and Regional iDXA and Prodigy Enhanced Bone Density Measurements
Region Variables iDXA Prodigy enhanced Bias LOA
Whole body BMC (kg) 2.8 ± 0.6 2.8 ± 0.6 0.0 ± 0.0* −0.1 to 0.1
Area (cm2) 2255.1 ± 234.3 2219.4 ± 236.9 35.8 ± 51.0* −64.2 to 135.7
BMD (g/cm2) 1.24 ± 0.15 1.25 ± 0.16 −0.01 ± 0.02* −0.06 to 0.04
Hip BMC (g) 36.0 ± 7.6 36.1 ± 7.6 −0.1 ± 1.2 −2.3 to 2.2
Area (cm2) 33.2 ± 4.0 33.2 ± 3.9 0.1 ± 0.9 −1.6 to 1.8
BMD (g/cm2) 1.08 ± 0.16 1.08 ± 0.15 0.00 ± 0.02 −0.04 to 0.04
Spine BMC (g) 58.7 ± 12.1 59.2 ± 12.3 −0.4 ± 1.2* −2.8 to 1.9
Area (cm2) 46.6 ± 5.6 46.6 ± 5.6 0.0 ± 0.8 −1.5 to 1.5
BMD (g/cm2) 1.25 ± 0.15 1.26 ± 0.15 −0.01 ± 0.02* −0.05 to 0.04
Note: Mean ± standard deviation.
Abbr: BMC, bone mineral content; BMD, bone mineral density; LOA, limits of agreement.
*p < 0.05.
Table 4
Whole-Body and Regional iDXA and Prodigy Enhanced Body Composition Measurements
Region Variables iDXA Prodigy enhanced Bias LOA
Whole body Fat mass (kg) 23.6 ± 11.6 24.9 ± 11.7 −1.3 ± 0.6* −2.5 to 0.1
Lean mass (kg) 51.0 ± 10.4 49.9 ± 10.1 1.1 ± 0.6* 0.0–2.2
Arm Fat mass (kg) 2.3 ± 1.1 2.5 ± 1.2 −0.3 ± 0.2* −0.6 to 0.1
Lean mass (kg) 5.6 ± 1.8 5.4 ± 1.8 0.2 ± 0.3* −0.5 to 0.9
Leg Fat mass (kg) 8.4 ± 4.5 8.9 ± 4.5 −0.5 ± 0.3* −1.1 to 0.1
Lean mass (kg) 18.2 ± 4.0 17.8 ± 3.9 0.5 ± 0.6* −0.8 to 1.7
Trunk Fat mass (kg) 12.1 ± 6.5 12.6 ± 6.4 −0.5 ± 0.4 −1.3 to 0.4
Lean mass (kg) 24.0 ± 4.7 23.6 ± 4.4 0.4 ± 0.7* −1.0 to 1.8
Note: Mean ± standard deviation.
Abbr: LOA, limits of agreement.
*p < 0.05.
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Figure 3 does show that iDXA limits of agreement with
4-C (−4.78 to 2.63) are narrower compared with Prodigy
in basic mode (−5.56 to 2.12), which in turn are narrower
than the Prodigy enhanced mode (−6.17 to 1.86).
Discussion
The aim of the present study was 2-fold: firstly, to de-
termine the precision and accuracy of the GE Lunar iDXA,
and secondly, to determine if cross-calibration equations
are necessary to relate data from the GE Lunar Prodigy
to the iDXA densitometers.The differences between soft-
ware versions for the Prodigy were also investigated.
When introducing a newDXA instrument, the ISCD rec-
ommend that a cross-calibration of at least 30 participants,
representative of the facility’s patient population, should
be performed. Participants should be scanned twice on the
new system and once on the old, on those anatomical sites
most commonly measured (4).We compared the iDXA and
Prodigy densitometers for regional and whole-body bone
mineral densities, BMCs, and bone areas, and, reflecting our
interest in body composition, for LM and FM.Where cross-
calibration equations were deemed necessary, they were
derived using linear regression.
iDXA Precision
Precision of the iDXA was assessed by % CV of re-
peated bone and body composition measurements. We
found excellent precision in whole-body and regional bone
Fig. 2. Bland-Altman analysis of the agreement between iDXA- and Prodigy-measured whole-body fat mass (A) and
lean mass (B).The solid black line corresponds to the systematic bias, the hashed gray box corresponds to the 95% con-
fidence interval of the systematic bias, and the vertical dotted lines represent the limits of agreements.
Table 5
Cross-Calibration Equations (Prodigy Enhanced to iDXA)
Variable Slope 95% CI Intercept 95% CI r2
Whole body BMC (g) 1.003* 0.983–1.023 0.017 −0.041 to 0.074 0.993
BA (cm2) 0.966* 0.914–1.017 112.0 −3.543 to 227.6 0.953
BMD (g/cm2) 0.965* 0.928–1.001 0.035 −0.011 to 0.081 0.976
Fat mass (kg) 0.991* 0.978–1.005 −1.016* −1.393 to −0.639 0.997
Lean mass (kg) 1.029 1.013–1.045 −0.262 −1.058 to 0.535 0.996
Spine BMC (g) 0.978* 0.954–1.001 0.877 −0.537 to 2.290 0.990
BA (cm2) 0.990* 0.956–1.023 0.505 −1.045 to 2.055 0.981
BMD (g/cm2) 0.986 0.950–1.022 0.008 −0.038 to 0.054 0.978
Regional Arm fat mass (kg) 0.962* 0.923–1.001 −0.155* −0.262 to − 0.048 0.973
Arm lean mass (kg) 0.972* 0.927–1.016 0.350* 0.097–0.603 0.966
Leg fat mass (kg) 0.989* 0.973–1.005 −0.444* −0.604 to −0.284 0.996
Leg lean mass (kg) 1.024* 0.985–1.063 0.036 −0.673–0.746 0.976
Trunk fat mass (kg) 1.010* 0.995–1.026 −0.591* −0.811– − 0.372 0.996
Trunk lean mass (kg) 1.042* 1.003–1.080 −0.576 −1.494–0.341 0.978
Note:Adjusted r2 indicates model variance.
Abbr: BA, bone area; BMC, bone mineral content; BMD, bone mineral density; CI, confidence interval.
*p < 0.05.
DXA Precision and Accuracy 503
Journal of Clinical Densitometry: Assessment & Management of Musculoskeletal Health Volume 20, 2017
density with all values below 2%. This was also observed
for whole-body and regional body composition measure-
ments with the exception of arm FM, which had a lower
precision of 2.28%.
Our findings support previously published literature,which
has reported similar precision data for whole-body and re-
gional bone density and body composition using iDXA
(2,3,11,12). Additionally, both Rothney et al (11) and
Kaminsky et al (12) support our findings of a lower preci-
sion in arm FM (2.8% and 4.2%, Rothney et al and
Kaminsky et al, respectively).The larger precision error may
be due to the repositioning of the participants or the inclu-
sion of breast tissue in the arm region of interest in some
rescans, therefore offering the potential for larger errors (13).
Compared to the iDXA, previously published reports
from its predecessor, the Prodigy has demonstrated a similar
precision for bone density with precisions reported below
2% by Oldroyd et al (14) and Krueger et al (15). However,
when exploring body composition, both Oldroyd et al and
Bilsborough et al (16) reported whole-body FM preci-
sion values of 2.5% for Prodigy.This is a much lower pre-
cision than that of 0.9% for the iDXA in the current study.
These comparisons suggest that the precision of iDXA
whenmeasuring bone density remains similar to the Prodigy.
However, there appears to be a worthwhile improvement
in precision in whole-body and regional FM.This may be
due to the improvement in soft tissue assessment as a result
of enhanced bone edge detection technology (17).
iDXA vs Prodigy
When scan analysis was carried out using the same soft-
ware version, significant differences between iDXA and
Prodigy were identified in all regions of bone mass, area, and
density except for the femoral hip BMD and lumbar spine
(L2–L4) bone area,with Prodigy over-reading all values with
the exception of hip area.This finding has been similarly ob-
served in other studies (18–20) with Hull et al (19) report-
ing significantly highermeanBMC values in the Prodigy than
in the iDXA in both males and females (males: 3.11 kg vs
3.06 kg, Prodigy vs iDXA, respectively, and females: 2.37 kg
vs 2.31 kg, Prodigy vs iDXA, respectively).Rhodes et al (20)
also found Prodigy BMC values were significantly higher
compared with the iDXA in all regions of bone mass (BMC,
2842 g vs 2651 g, Prodigy vs iDXA, respectively). Further-
more, Morrison et al (21) compared iDXA to Prodigy and
found significant differences in whole-body and regional bone
density (mean whole-body; 1.25 g/cm2 vs 1.22 g/cm2, Prodigy
vs iDXA, respectively)
When investigating body composition, we also ob-
served significant differences between iDXA and Prodigy,
with Prodigy tending to over-read FM and to under-read
LM relative to iDXA.The only study we found in the lit-
erature to make a similar comparison was that of Morri-
son et al (21), who reported that only leg LM and arm soft
tissue measurements were significantly different between
instruments (leg LM mean difference [in kilogram]: 0.586,
arm FM: −0.109, arm LM: −0.228).
The significant differences observed between the 2 DXA
instruments warranted the development of cross-calibration
regression equations. These differences and those ob-
served across the published literature highlight the impor-
tance of generating instrument-specific cross-calibration
equations when undergoing a system upgrade. It is also im-
portant that the cross-calibration equations are relevant to
the population under investigation as demonstrated by the
apparent outliers at the top end of the FM range.
DXA Accuracy
The accuracy of our DXA FMmeasurements was evalu-
ated by comparing FM estimated by DXA to that derived
from a 4-C model. The 4-C model, as well as whole-body
MRI, is a recognized standard in body composition mea-
surements as they account for interindividual variability in
TBW and bone mineral mass (22–24). Our results dem-
onstrated a good correlation between iDXA and 4-C-
derived FM (r = 0.994), but a systematic bias between the
Fig. 3. Demonstration of the difference and progression between the 4-component model and Prodigy basic analy-
sis (A), Prodigy Enhanced (B), and iDXA (C) with 95% limits of agreement. The solid black line corresponds to the
systematic bias, the hashed gray box corresponds to the 95% confidence interval of the systematic bias, and the vertical
dotted lines represent the limits of agreements with corresponding 95% confidence interval represented by gray boxes.
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2 FM estimates was evident.To our knowledge, there is no
literature that discusses the accuracy of either iDXA or
Prodigy FM measurement using the 4-C model. However,
previous literature has reported significant differences
between FM (percent) measured by various DXA models
(QDR2000, QDR2000W,DPX/L, and Lunar) and the 4-C
model (25).When comparing Prodigy and the 4-C model,
Williams et al (25) found significant differences in FM (1.35,
1.21, and 1.58 kg in nonobese men, women, and obese
women, respectively).Williams et al also reported that the
FM bias was positively associated with the body mass index.
Although it appears that the accuracy of DXA has im-
proved over the years, a systematic bias still remains
between the iDXA and the 4-C model.
The differences identified between the 2 methods could
have several origins.DXA assumes that the hydration value
for fat-free mass remains constant (26); however, this may
not be true for participants across a range of masses. Par-
ticipant mass itself may inflict a bias in soft tissue estima-
tion because of the influence of tissue depth on bone edge
detection by DXA; therefore, as subject mass increases, so
may the error in detecting soft tissue.
Comparisons between GE software versions (basic and
enhanced) for Prodigy and a 4-C model have not been in-
vestigated before. There are many publications that dem-
onstrate the transitions between instruments but few that
detail the differences when upgrading software versions.
In the final part of the present study, we investigated the
differences in whole-body FMmeasurements between basic
and enhanced software versions on the Prodigy and com-
pared these to the iDXA and 4-C model.
Prodigy basic analysis mode compared to 4-C demon-
strated a good agreement over a wide range of FMs.
However, in the highest FMs, the agreement was less good,
consistent with previous studies (25,27,28).As referred to
earlier,Williams et al (25) reported the largest difference
between 4-C and Prodigy (Encore 2002) in obese women
(mean bias 1.58 kg), andWells et al (27) (Software version
not stated) reported that Prodigy significantly overesti-
mated FM compared to 4-C by 0.9 kg with the greatest vari-
ability being observed at the highest FMs.
In summary, the latest DXA instrument from GE, the
iDXA, comes with new hardware in the form of a more
powerful X-ray tube, enhanced image resolution, and there-
fore better bone edge detection. Furthermore, the latest soft-
ware, Encore version 15 and 16, comes with developed soft
tissue algorithms.This enhancement in technology has led
to an improvement in both the accuracy and the preci-
sion of the new instrument. However, this finding means
that differences exist between the iDXA and the Prodigy
instruments, and therefore cross-calibration equations are
essential if comparisons between instruments are unavoid-
able.Even with these improvements, accuracy issues remain
at the highest FMs, reinforcing the importance of deriv-
ing cross-calibration equations that are relevant to the popu-
lation under investigation, and also, further comparative
studies are warranted in an obese population.
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